{ "version": "2.2", "instance": { "iva-20230630x6k.htm iva-20230630xex99d1.htm": { "nsprefix": "iva", "nsuri": "http://www.inventivapharma.com/20230630", "dts": { "schema": { "local": [ "iva-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] }, "calculationLink": { "local": [ "iva-20230630_cal.xml" ] }, "definitionLink": { "local": [ "iva-20230630_def.xml" ] }, "labelLink": { "local": [ "iva-20230630_lab.xml" ] }, "presentationLink": { "local": [ "iva-20230630_pre.xml" ] }, "inline": { "local": [ "iva-20230630x6k.htm", "iva-20230630xex99d1.htm" ] } }, "keyStandard": 173, "keyCustom": 171, "axisStandard": 23, "axisCustom": 2, "memberStandard": 35, "memberCustom": 69, "hidden": { "total": 8, "http://www.inventivapharma.com/20230630": 1, "http://xbrl.sec.gov/dei/2022": 6, "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full": 1 }, "contextCount": 305, "entityCount": 1, "segmentCount": 108, "elementCount": 820, "unitCount": 15, "baseTaxonomies": { "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full": 679, "http://xbrl.sec.gov/dei/2022": 8 }, "report": { "R1": { "role": "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation", "longName": "00090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630x6k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630x6k.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition", "longName": "00100 - Statement - Unaudited interim condensed consolidated statement of financial position", "shortName": "Unaudited interim condensed consolidated statement of financial position", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_6_30_2023_LG9rgGgpJEuZywlLG8ReWA", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2023_LG9rgGgpJEuZywlLG8ReWA", "name": "ifrs-full:NoncurrentAssets", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R3": { "role": "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss", "longName": "00200 - Statement - Unaudited interim condensed consolidated statement of (income) loss", "shortName": "Unaudited interim condensed consolidated statement of (income) loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "ifrs-full:Revenue", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "ifrs-full:ResearchAndDevelopmentExpense", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R4": { "role": "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss", "longName": "00300 - Statement - Unaudited interim condensed consolidated statement of comprehensive (income) loss", "shortName": "Unaudited interim condensed consolidated statement of comprehensive (income) loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "ifrs-full:ProfitLoss", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R5": { "role": "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity", "longName": "00400 - Statement - Unaudited interim condensed consolidated statement of changes in shareholders' equity", "shortName": "Unaudited interim condensed consolidated statement of changes in shareholders' equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_hrBOVes2Lk68SwTwqE8eHQ", "name": "ifrs-full:Equity", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_ky2eJnQchE6mT9oqJjmT0w", "name": "ifrs-full:Equity", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R6": { "role": "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows", "longName": "00500 - Statement - Unaudited interim condensed consolidated statement of cash flows", "shortName": "Unaudited interim condensed consolidated statement of cash flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "ifrs-full:ProfitLoss", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "iva:AdjustmentsForDepreciationAmortisationAndProvisions", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R7": { "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformation", "longName": "10101 - Disclosure - Company information", "shortName": "Company information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "iva:CompanyInformationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "iva:CompanyInformationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfCompliance", "longName": "10201 - Disclosure - Basis of preparation and statement of compliance", "shortName": "Basis of preparation and statement of compliance", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "ifrs-full:StatementOfIFRSCompliance", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "ifrs-full:StatementOfIFRSCompliance", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciples", "longName": "10301 - Disclosure - Accounting Principles", "shortName": "Accounting Principles", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheet", "longName": "10401 - Disclosure - Notes to the consolidated balance sheet", "shortName": "Notes to the consolidated balance sheet", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "iva:DisclosureOfNotesToConsolidatedBalanceSheetTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "iva:DisclosureOfNotesToConsolidatedBalanceSheetTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatement", "longName": "10501 - Disclosure - Notes to the income statement", "shortName": "Notes to the income statement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "iva:DisclosureOfComponentsOfIncomeStatementTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "iva:DisclosureOfComponentsOfIncomeStatementTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformation", "longName": "10601 - Disclosure - Other financial information", "shortName": "Other financial information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "iva:DisclosureOfOtherFinancialInformationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "iva:DisclosureOfOtherFinancialInformationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies", "longName": "20302 - Disclosure - Accounting Principles (Policies)", "shortName": "Accounting Principles (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceTables", "longName": "30203 - Disclosure - Basis of preparation and statement of compliance (Tables)", "shortName": "Basis of preparation and statement of compliance (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesTables", "longName": "30303 - Disclosure - Accounting Principles (Tables)", "shortName": "Accounting Principles (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory", "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory", "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables", "longName": "30403 - Disclosure - Notes to the consolidated balance sheet (Tables)", "shortName": "Notes to the consolidated balance sheet (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "iva:DisclosureOfNotesToConsolidatedBalanceSheetTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "iva:DisclosureOfNotesToConsolidatedBalanceSheetTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementTables", "longName": "30503 - Disclosure - Notes to the income statement (Tables)", "shortName": "Notes to the income statement (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "17", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "iva:RevenueAndOtherIncomeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "iva:DisclosureOfComponentsOfIncomeStatementTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "iva:RevenueAndOtherIncomeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "iva:DisclosureOfComponentsOfIncomeStatementTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationTables", "longName": "30630 - Disclosure - Other financial information (Tables)", "shortName": "Other financial information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "18", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "ifrs-full:DisclosureOfContingentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "iva:DisclosureOfOtherFinancialInformationTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "ifrs-full:DisclosureOfContingentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "iva:DisclosureOfOtherFinancialInformationTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "longName": "40101 - Disclosure - Company information - Amendments to Contract CRO with Pharmaceutical Research Associates B.V. & Service Agreement with Summit Clinical Research LLC (Details)", "shortName": "Company information - Amendments to Contract CRO with Pharmaceutical Research Associates B.V. & Service Agreement with Summit Clinical Research LLC (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "19", "firstAnchor": { "contextRef": "As_Of_6_30_2023_LG9rgGgpJEuZywlLG8ReWA", "name": "iva:NumberOfActiveClinicalSitesInNativ3Trial", "unitRef": "Unit_Standard_pure_kN5DT9wF0kqiLJmLvKbIcg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "iva:CompanyInformationTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2023_LG9rgGgpJEuZywlLG8ReWA", "name": "iva:NumberOfActiveClinicalSitesInNativ3Trial", "unitRef": "Unit_Standard_pure_kN5DT9wF0kqiLJmLvKbIcg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "iva:CompanyInformationTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqDetails", "longName": "40102 - Disclosure - Company information - CTTQ (Details)", "shortName": "Company information - CTTQ (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "20", "firstAnchor": { "contextRef": "Duration_5_22_2023_To_5_22_2023_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_mSkIG2d2EUmVus-mMW57Cg", "name": "iva:AmountInvoicedToCounterparty", "unitRef": "Unit_Standard_USD_4yszRoOXRUetO1GTcQp8BQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "iva:DisclosureOfComponentsOfIncomeStatementTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_26_2023_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_ContractCroWithPharmaceuticalResearchAssociatesB.vMember_LRajRshMTUS4Ly340zs3jA", "name": "iva:CommitmentsAmountPayableForServicesReceivedUnderContractMaximumBonusOrMalusAmount", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R21": { "role": "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails", "longName": "40201 - Disclosure - Basis of preparation and statement of compliance - Significant Investments In Subsidiaries (Details)", "shortName": "Basis of preparation and statement of compliance - Significant Investments In Subsidiaries (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "21", "firstAnchor": { "contextRef": "As_Of_6_30_2023_LG9rgGgpJEuZywlLG8ReWA", "name": "iva:NumberOfEntitiesBeingConsolidated", "unitRef": "Unit_Standard_entity_iqebbeIkhUKvj3iRrSixOg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2023_LG9rgGgpJEuZywlLG8ReWA", "name": "iva:NumberOfEntitiesBeingConsolidated", "unitRef": "Unit_Standard_entity_iqebbeIkhUKvj3iRrSixOg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceForeignExchangeRatesDetails", "longName": "40202 - Disclosure - Basis of preparation and statement of compliance - Foreign Exchange Rates (Details)", "shortName": "Basis of preparation and statement of compliance - Foreign Exchange Rates (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "22", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "ifrs-full:AverageForeignExchangeRate", "unitRef": "Unit_Divide_USD_EUR_AHMsL8InE0Sg26KqjssHEQ", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "ifrs-full:AverageForeignExchangeRate", "unitRef": "Unit_Divide_USD_EUR_AHMsL8InE0Sg26KqjssHEQ", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "longName": "40301 - Disclosure - Accounting Principles - Fair value measurement (Details)", "shortName": "Accounting Principles - Fair value measurement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "As_Of_6_30_2023_LG9rgGgpJEuZywlLG8ReWA", "name": "ifrs-full:FinancialLiabilities", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_1AzfIcdZ-0Oac47NluEydQ", "name": "ifrs-full:FinancialLiabilities", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory", "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R24": { "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "longName": "40302 - Disclosure - Accounting principles - Going concern (Details)", "shortName": "Accounting principles - Going concern (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "As_Of_6_30_2023_LG9rgGgpJEuZywlLG8ReWA", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2023_LG9rgGgpJEuZywlLG8ReWA", "name": "ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "span", "td", "tr", "table", "ifrs-full:DisclosureOfGoingConcernExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R25": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetIntangibleAssetsDetails", "longName": "40401 - Disclosure - Notes to the consolidated balance sheet - Intangible assets (Details)", "shortName": "Notes to the consolidated balance sheet - Intangible assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "As_Of_12_31_2022_tJzaIiLeeUy7E26XcEy5BA", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_w2Ao0jmM-Ua_fq4tgguU_Q", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "iva:DisclosureOfNotesToConsolidatedBalanceSheetTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R26": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentDetails", "longName": "40402 - Disclosure - Notes to the consolidated balance sheet - Property, Plant and Equipment (Details)", "shortName": "Notes to the consolidated balance sheet - Property, Plant and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "As_Of_6_30_2023_LG9rgGgpJEuZywlLG8ReWA", "name": "ifrs-full:PropertyPlantAndEquipment", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_5FxB7jk9KEqbiHTLLlCxEA", "name": "ifrs-full:PropertyPlantAndEquipment", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R27": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentAdditionalInformationDetails", "longName": "40403 - Disclosure - Notes to the consolidated balance sheet - Property, Plant and Equipment - Additional Information (Details)", "shortName": "Notes to the consolidated balance sheet - Property, Plant and Equipment - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "ifrs-full:ChangesInPropertyPlantAndEquipment", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "ifrs-full:ChangesInPropertyPlantAndEquipment", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsDetails", "longName": "40404 - Disclosure - Notes to the consolidated balance sheet - Other Non-Current Assets (Details)", "shortName": "Notes to the consolidated balance sheet - Other Non-Current Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "As_Of_6_30_2023_LG9rgGgpJEuZywlLG8ReWA", "name": "iva:NonCurrentLongTermDepositsFromCustomers", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfOtherNoncurrentAssetsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2023_LG9rgGgpJEuZywlLG8ReWA", "name": "iva:NonCurrentLongTermDepositsFromCustomers", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfOtherNoncurrentAssetsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsAdditionalInformationDetails", "longName": "40405 - Disclosure - Notes to the consolidated balance sheet - Other Non-Current Assets - Additional Information (Details)", "shortName": "Notes to the consolidated balance sheet - Other Non-Current Assets - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "iva:IncreaseDecreaseInLongTermDepositAccounts", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "iva:IncreaseDecreaseInLongTermDepositAccounts", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDeferredTaxAssetDetails", "longName": "40406 - Disclosure - Notes to the consolidated balance sheet -Deferred tax asset (Details)", "shortName": "Notes to the consolidated balance sheet -Deferred tax asset (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "As_Of_6_30_2023_LG9rgGgpJEuZywlLG8ReWA", "name": "ifrs-full:DeferredTaxAssets", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2023_LG9rgGgpJEuZywlLG8ReWA", "name": "ifrs-full:DeferredTaxAssets", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetInventoriesDetails", "longName": "40407 - Disclosure - Notes to the consolidated balance sheet - Inventories (Details)", "shortName": "Notes to the consolidated balance sheet - Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "As_Of_6_30_2023_LG9rgGgpJEuZywlLG8ReWA", "name": "ifrs-full:Inventories", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2023_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ZdUJnUOgSUqMpw531nWAkg", "name": "ifrs-full:Inventories", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:IfrsScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R32": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails", "longName": "40408 - Disclosure - Notes to the consolidated balance sheet - Trade Receivables and Other Current Assets and Receivables - Trade Receivables (Details)", "shortName": "Notes to the consolidated balance sheet - Trade Receivables and Other Current Assets and Receivables - Trade Receivables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "As_Of_6_30_2023_LG9rgGgpJEuZywlLG8ReWA", "name": "ifrs-full:CurrentTradeReceivables", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_C4rGjmXLsUyP7XH-tvFwyg", "name": "iva:LicensingAndCollaborationAgreementAmountInvoicedToCounterpartyNetOfWithholdingTaxes", "unitRef": "Unit_Standard_USD_4yszRoOXRUetO1GTcQp8BQ", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R33": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails", "longName": "40409 - Disclosure - Notes to the consolidated balance sheet - Trade Receivables and Other Current Assets and Receivables - Other Current Assets and Receivables (Details)", "shortName": "Notes to the consolidated balance sheet - Trade Receivables and Other Current Assets and Receivables - Other Current Assets and Receivables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "As_Of_6_30_2023_LG9rgGgpJEuZywlLG8ReWA", "name": "iva:CirAndOtherResearchTaxCreditsReceivable", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2023_LG9rgGgpJEuZywlLG8ReWA", "name": "iva:OtherCurrentTaxReceivables", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R34": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails", "longName": "40410 - Disclosure - Notes to the consolidated balance sheet - Trade Receivables and Other Current Assets and Receivables - Additional Information (Details)", "shortName": "Notes to the consolidated balance sheet - Trade Receivables and Other Current Assets and Receivables - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "As_Of_6_30_2023_LG9rgGgpJEuZywlLG8ReWA", "name": "iva:CirAndOtherResearchTaxCreditsReceivable", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_iva_InventivaIncMember_Y_YLEPrTK0SRvFOTO1RHYw", "name": "iva:CirAndOtherResearchTaxCreditsReceived", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R35": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCashAndCashEquivalentsDetails", "longName": "40411 - Disclosure - Notes to the consolidated balance sheet - Cash and Cash Equivalents (Details)", "shortName": "Notes to the consolidated balance sheet - Cash and Cash Equivalents (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "As_Of_6_30_2023_LG9rgGgpJEuZywlLG8ReWA", "name": "ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfCashAndCashEquivalentsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2023_LG9rgGgpJEuZywlLG8ReWA", "name": "ifrs-full:Cash", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfCashAndCashEquivalentsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R36": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareCapitalDetails", "longName": "40412 - Disclosure - Notes to the consolidated balance sheet - Shareholders' equity - Share capital (Details)", "shortName": "Notes to the consolidated balance sheet - Shareholders' equity - Share capital (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "Duration_1_1_2022_To_6_30_2022_GJ4ZqEvxXkWhr1WcD7UtjQ", "name": "ifrs-full:IssueOfEquity", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2022_Bu7ktUw0WUWlXc0BOf722Q", "name": "ifrs-full:NumberOfSharesOutstanding", "unitRef": "Unit_Standard_shares_zrF2ogaTOEqDnTi45iVRxg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R37": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareWarrantsPlansDetails", "longName": "40413 - Disclosure - Notes to the consolidated balance sheet Shareholders' Equity - Share warrants plans (Details)", "shortName": "Notes to the consolidated balance sheet Shareholders' Equity - Share warrants plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "Duration_5_25_2023_To_5_25_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaShareWarrantsMember_uLJLnv8MV0KF503gay_3WQ", "name": "ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019", "unitRef": "Unit_Divide_EUR_shares_G5wkzWmNXkeuI0Yn4hLHOQ", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_5_25_2023_To_5_25_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaShareWarrantsMember_uLJLnv8MV0KF503gay_3WQ", "name": "ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019", "unitRef": "Unit_Divide_EUR_shares_G5wkzWmNXkeuI0Yn4hLHOQ", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails", "longName": "40414 - Disclosure - Notes to the consolidated balance sheet Shareholders' Equity - Characteristics of BSA share warrant plans (Details)", "shortName": "Notes to the consolidated balance sheet Shareholders' Equity - Characteristics of BSA share warrant plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "As_Of_5_25_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa20231ShareWarrantPlanMember_F4Rjl5NQCU6mii41E8HiOA", "name": "iva:WarrantsSubscriptionPrice", "unitRef": "Unit_Divide_EUR_shares_G5wkzWmNXkeuI0Yn4hLHOQ", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_5_25_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa20231ShareWarrantPlanMember_F4Rjl5NQCU6mii41E8HiOA", "name": "iva:WarrantsSubscriptionPrice", "unitRef": "Unit_Divide_EUR_shares_G5wkzWmNXkeuI0Yn4hLHOQ", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails", "longName": "40415 - Disclosure - Notes to the consolidated balance sheet Shareholders' Equity - Movements in BSPCE and BSA share warrants (in number of shares issuable upon exercise) (Details)", "shortName": "Notes to the consolidated balance sheet Shareholders' Equity - Movements in BSPCE and BSA share warrants (in number of shares issuable upon exercise) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "As_Of_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BspceAndBsaShareWarrantsMember_3QaXGMbWykazdpaesZ12AA", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "Unit_Standard_pure_kN5DT9wF0kqiLJmLvKbIcg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BspceAndBsaShareWarrantsMember_3QaXGMbWykazdpaesZ12AA", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "Unit_Standard_pure_kN5DT9wF0kqiLJmLvKbIcg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails", "longName": "40416 - Disclosure - Notes to the consolidated balance sheet - Free share awards (Details)", "shortName": "Notes to the consolidated balance sheet - Free share awards (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtDetails", "longName": "40417 - Disclosure - Notes to the consolidated balance sheet - Financial debt (Details)", "shortName": "Notes to the consolidated balance sheet - Financial debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "As_Of_6_30_2023_LG9rgGgpJEuZywlLG8ReWA", "name": "ifrs-full:LoansReceived", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": null }, "R42": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtMovementsInPeriodBreakDownDetails", "longName": "40418 - Disclosure - Notes to the consolidated balance sheet - Financial debt - Movements in the period break down (Details)", "shortName": "Notes to the consolidated balance sheet - Financial debt - Movements in the period break down (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "As_Of_12_31_2022_tJzaIiLeeUy7E26XcEy5BA", "name": "ifrs-full:Borrowings", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "iva:DisclosureOfChangesInBorrowingsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "iva:SubscriptionOfLeaseLiabilities", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfChangesInBorrowingsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R43": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "longName": "40419 - Disclosure - Notes to the consolidated balance sheet - French state-guaranteed loan (\"PGE\") and equity recovery loans (\"PPR\") (Details)", "shortName": "Notes to the consolidated balance sheet - French state-guaranteed loan (\"PGE\") and equity recovery loans (\"PPR\") (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "Duration_1_1_2022_To_6_30_2022_GJ4ZqEvxXkWhr1WcD7UtjQ", "name": "ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_6_1_2022_To_6_30_2022_ifrs-full_BorrowingsByNameAxis_iva_LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember_lxSsOBC4HUGRL6vVkl9kig", "name": "iva:NumberOfLoanAgreements", "unitRef": "Unit_Standard_loan_wPb2W1F7QUK_wrXkA6140g", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R44": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "longName": "40420 - Disclosure - Notes to the consolidated balance sheet - Credit facility agreement with the European Investment Bank (Details)", "shortName": "Notes to the consolidated balance sheet - Credit facility agreement with the European Investment Bank (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "ifrs-full:ProceedsFromIssuingShares", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_5_16_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankMember_oj44hMFjIk67wVodTGnaXQ", "name": "ifrs-full:NotionalAmount", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R45": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails", "longName": "40421 - Disclosure - Notes to the consolidated balance sheet - Derivatives (Details)", "shortName": "Notes to the consolidated balance sheet - Derivatives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2022Member_a8PZfUjnO0uCNaXOwNJtww", "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted", "unitRef": "Unit_Standard_pure_kN5DT9wF0kqiLJmLvKbIcg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfValuationApproachForBsaShareBasedPaymentArrangementTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2022Member_a8PZfUjnO0uCNaXOwNJtww", "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted", "unitRef": "Unit_Standard_pure_kN5DT9wF0kqiLJmLvKbIcg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfValuationApproachForBsaShareBasedPaymentArrangementTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails", "longName": "40422 - Disclosure - Notes to the consolidated balance sheet - Lease liabilities (Details)", "shortName": "Notes to the consolidated balance sheet - Lease liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "As_Of_6_30_2023_LG9rgGgpJEuZywlLG8ReWA", "name": "ifrs-full:LoansReceived", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2023_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_HZyNzq_7zE2BwY_th7kQ0Q", "name": "ifrs-full:LoansReceived", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R47": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetNetProvisionDetails", "longName": "40423 - Disclosure - Notes to the consolidated balance sheet - Net provision (Details)", "shortName": "Notes to the consolidated balance sheet - Net provision (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "As_Of_6_30_2023_LG9rgGgpJEuZywlLG8ReWA", "name": "ifrs-full:DefinedBenefitObligationAtPresentValue", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2023_LG9rgGgpJEuZywlLG8ReWA", "name": "ifrs-full:DefinedBenefitObligationAtPresentValue", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetChangeInNetProvisionDetails", "longName": "40424 - Disclosure - Notes to the consolidated balance sheet - Change in net provision (Details)", "shortName": "Notes to the consolidated balance sheet - Change in net provision (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "As_Of_12_31_2022_tJzaIiLeeUy7E26XcEy5BA", "name": "ifrs-full:LiabilityAssetOfDefinedBenefitPlans", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "iva:DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R49": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetBreakdownOfExpenseRecognizedForPeriodDetails", "longName": "40425 - Disclosure - Notes to the consolidated balance sheet - Breakdown of expense recognized for the period (Details)", "shortName": "Notes to the consolidated balance sheet - Breakdown of expense recognized for the period (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "ifrs-full:CurrentServiceCostDefinedBenefitPlans", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "ifrs-full:CurrentServiceCostDefinedBenefitPlans", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradePayablesAndOtherCurrentLiabilitiesDetails", "longName": "40426 - Disclosure - Notes to the consolidated balance sheet - Trade payables and other current liabilities (Details)", "shortName": "Notes to the consolidated balance sheet - Trade payables and other current liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "As_Of_6_30_2023_LG9rgGgpJEuZywlLG8ReWA", "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2023_LG9rgGgpJEuZywlLG8ReWA", "name": "iva:TradePayablesAndOtherCurrentLiabilities", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "iva:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R51": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradePayablesDetails", "longName": "40427 - Disclosure - Notes to the consolidated balance sheet - Trade payables (Details)", "shortName": "Notes to the consolidated balance sheet - Trade payables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "As_Of_6_30_2023_LG9rgGgpJEuZywlLG8ReWA", "name": "ifrs-full:TradeAndOtherCurrentPayables", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2023_LG9rgGgpJEuZywlLG8ReWA", "name": "ifrs-full:TradeAndOtherCurrentPayables", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherCurrentLiabilitiesDetails", "longName": "40428 - Disclosure - Notes to the consolidated balance sheet - Other current liabilities (Details)", "shortName": "Notes to the consolidated balance sheet - Other current liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "As_Of_6_30_2023_LG9rgGgpJEuZywlLG8ReWA", "name": "iva:EmployeeRelatedPayables", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2023_LG9rgGgpJEuZywlLG8ReWA", "name": "iva:EmployeeRelatedPayables", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails", "longName": "40429 - Disclosure - Notes to the consolidated balance sheet - Financial assets and liabilities (Details)", "shortName": "Notes to the consolidated balance sheet - Financial assets and liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "As_Of_6_30_2023_LG9rgGgpJEuZywlLG8ReWA", "name": "ifrs-full:FinancialAssets", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2023_LG9rgGgpJEuZywlLG8ReWA", "name": "ifrs-full:FinancialAssetsAtFairValue", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R54": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementRevenuesAndOtherIncomeDetails", "longName": "40501 - Disclosure - Notes to the income statement - Revenues and other income (Details)", "shortName": "Notes to the income statement - Revenues and other income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:RevenueAndOtherIncomeTableTextBlock", "iva:DisclosureOfComponentsOfIncomeStatementTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:RevenueAndOtherIncomeTableTextBlock", "iva:DisclosureOfComponentsOfIncomeStatementTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementNarrativesDetails", "longName": "40502 - Disclosure - Notes to the income statement - Narratives (Details)", "shortName": "Notes to the income statement - Narratives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "As_Of_6_30_2023_LG9rgGgpJEuZywlLG8ReWA", "name": "iva:CurrentTaxCreditResearchCurrentYear", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2023_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_equasCUl3k2F9b-SgX_SxQ", "name": "iva:OtherIncomeRelatingToReinvoicingOfShareOfCostsUnderLicensingAndCollaborationAgreement", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R56": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails", "longName": "40503 - Disclosure - Notes to the income statement - Operating expenses (Details)", "shortName": "Notes to the income statement - Operating expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "iva:Disposables", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "iva:ResearchAndDevelopmentMarketingTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "iva:Disposables", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "iva:ResearchAndDevelopmentMarketingTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails", "longName": "40504 - Disclosure - Notes to the income statement - Personnel costs and headcount (Details)", "shortName": "Notes to the income statement - Personnel costs and headcount (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "As_Of_6_30_2023_LG9rgGgpJEuZywlLG8ReWA", "name": "ifrs-full:NumberOfEmployees", "unitRef": "Unit_Standard_employee_71PphzI8JESrGyz_gsFnJw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2023_LG9rgGgpJEuZywlLG8ReWA", "name": "ifrs-full:NumberOfEmployees", "unitRef": "Unit_Standard_employee_71PphzI8JESrGyz_gsFnJw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOtherOperatingIncomeAndExpensesDetails", "longName": "40505 - Disclosure - Notes to the income statement - Other operating income and expenses - (Details)", "shortName": "Notes to the income statement - Other operating income and expenses - (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "Duration_1_1_2022_To_6_30_2022_GJ4ZqEvxXkWhr1WcD7UtjQ", "name": "ifrs-full:MiscellaneousOtherOperatingIncome", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "iva:DisclosureOfOtherOperatingIncomeExpenseTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2022_To_6_30_2022_GJ4ZqEvxXkWhr1WcD7UtjQ", "name": "ifrs-full:MiscellaneousOtherOperatingIncome", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "iva:DisclosureOfOtherOperatingIncomeExpenseTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementFinancialIncomeAndExpensesDetails", "longName": "40506 - Disclosure - Notes to the income statement - Financial income and expenses (Details)", "shortName": "Notes to the income statement - Financial income and expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "ifrs-full:InterestIncomeOnCashAndCashEquivalents", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:FinancialIncomeAndExpensesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "ifrs-full:InterestIncomeOnCashAndCashEquivalents", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:FinancialIncomeAndExpensesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementIncomeTaxDetails", "longName": "40507 - Disclosure - Notes to the income statement - Income tax (Details)", "shortName": "Notes to the income statement - Income tax (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_Fx9_V29d5U-CqHNdg5Dq4g", "name": "ifrs-full:TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods", "unitRef": "Unit_Standard_pure_kN5DT9wF0kqiLJmLvKbIcg", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_Fx9_V29d5U-CqHNdg5Dq4g", "name": "ifrs-full:TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods", "unitRef": "Unit_Standard_pure_kN5DT9wF0kqiLJmLvKbIcg", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementBasicAndDilutedLossPerShareDetails", "longName": "40508 - Disclosure - Notes to the income statement - Basic and diluted loss per share (Details)", "shortName": "Notes to the income statement - Basic and diluted loss per share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_JVm7FL9ME0-fdl3v5gBCgw", "name": "ifrs-full:ProfitLoss", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": null }, "R62": { "role": "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails", "longName": "40601 - Disclosure - Other financial information (Details)", "shortName": "Other financial information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "As_Of_6_30_2023_LG9rgGgpJEuZywlLG8ReWA", "name": "ifrs-full:ContractualCapitalCommitments", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfContingentLiabilitiesExplanatory", "iva:DisclosureOfOtherFinancialInformationTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2023_LG9rgGgpJEuZywlLG8ReWA", "name": "ifrs-full:ContractualCapitalCommitments", "unitRef": "Unit_Standard_EUR_mofYwYloR0Ks3omWcvCRlg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfContingentLiabilitiesExplanatory", "iva:DisclosureOfOtherFinancialInformationTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationRelatedPartyTransactionsDetails", "longName": "40602 - Disclosure - Other financial information - Related-party transactions (Details)", "shortName": "Other financial information - Related-party transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "Duration_5_25_2023_To_5_25_2023_BNXnQj6Ydk26pj4pn9etAA", "name": "iva:PercentageOfSeverancePaymentSubjectToPerformanceCondition", "unitRef": "Unit_Standard_pure_kN5DT9wF0kqiLJmLvKbIcg", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_5_25_2023_To_5_25_2023_BNXnQj6Ydk26pj4pn9etAA", "name": "iva:PercentageOfSeverancePaymentSubjectToPerformanceCondition", "unitRef": "Unit_Standard_pure_kN5DT9wF0kqiLJmLvKbIcg", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails", "longName": "40603 - Disclosure - Other financial information - Events after the reporting date (Details)", "shortName": "Other financial information - Events after the reporting date (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "As_Of_6_30_2022_Bu7ktUw0WUWlXc0BOf722Q", "name": "ifrs-full:ParValuePerShare", "unitRef": "Unit_Divide_EUR_shares_G5wkzWmNXkeuI0Yn4hLHOQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_8_30_2023_To_8_30_2023_OPyqGqnKr0C1mUMB7v7C7g", "name": "iva:SubscriptionPricePerShare", "unitRef": "Unit_Divide_EUR_shares_G5wkzWmNXkeuI0Yn4hLHOQ", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R65": { "role": "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails", "longName": "40604 - Disclosure - Other financial information - Licensing agreement with Hepalys (Details)", "shortName": "Other financial information - Licensing agreement with Hepalys (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "As_Of_9_20_2023_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_LicensingAgreementWithHepalysMember_sr6k0YgJ9EeiVX51vf31Sg", "name": "iva:LicenseAndCollaborationAgreementUpfrontFeeReceivable", "unitRef": "Unit_Standard_USD_4yszRoOXRUetO1GTcQp8BQ", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_20_2023_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_LicensingAgreementWithHepalysMember_srt_StatementGeographicalAxis_country_KR_RDxlweRvt0iDOMbWnOQynA", "name": "iva:PercentageOfPatientsWithSignificantFibrosis", "unitRef": "Unit_Standard_pure_kN5DT9wF0kqiLJmLvKbIcg", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } } }, "tag": { "iva_AdvancesToSuppliersNonCurrentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "AdvancesToSuppliersNonCurrentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for advances to suppliers, non-current.", "label": "Advances to suppliers - non-current" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "StatementOfChangesInEquityTable", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } } }, "auth_ref": [ "r6" ] }, "ifrs-full_RightofuseAssetsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "RightofuseAssetsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Right of use" } }, "en": { "role": { "documentation": "This member stands for right-of-use assets. [Refer: Right-of-use assets]" } } }, "auth_ref": [ "r132" ] }, "iva_ResearchCollaborationWithAbbvieMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ResearchCollaborationWithAbbvieMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for research collaboration with AbbVie.", "label": "AbbVie [Member]", "terseLabel": "AbbVie" } } }, "auth_ref": [] }, "ifrs-full_LandMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "LandMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Land" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing land held by the entity for use in operations. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r202" ] }, "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementNarrativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of attribution of expenses by nature to their function [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to attribution of expenses by nature to analysis of expenses by function in the statement of profit or loss." } } }, "auth_ref": [ "r260", "r264" ] }, "iva_WarrantsFairValueAtGrantDate": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "WarrantsFairValueAtGrantDate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "The fair value at grant date per warrant.", "label": "Warrants, Fair Value at Grant Date", "verboseLabel": "Fair Value (k\u20ac)" } } }, "auth_ref": [] }, "iva_JpgHealthcareLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "JpgHealthcareLlcMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for JPG Healthcare LLC.", "label": "JPG Healthcare LLC" } } }, "auth_ref": [] }, "iva_WarrantsSubscriptionPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "WarrantsSubscriptionPrice", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareWarrantsPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "The subscription price per warrant.", "label": "Warrants, Subscription Price", "verboseLabel": "Subscription price per share" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseInBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IncreaseDecreaseInBorrowings", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of increase (decrease) in borrowings.", "label": "Increase Decrease In Borrowings", "terseLabel": "Increase (Decrease) in borrowings" } } }, "auth_ref": [] }, "iva_DisclosureOfChangesInBorrowingsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DisclosureOfChangesInBorrowingsTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of changes in borrowings.", "label": "Disclosure Of Changes In Borrowings [Table Text Block]", "verboseLabel": "Schedule of movements in the period break down" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) operating activities [abstract]", "terseLabel": "Cash flows used in operating activities" } } }, "auth_ref": [] }, "iva_AtMarketOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "AtMarketOfferingMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for at-the market offering (ATM).", "label": "At Market Offering [Member]", "terseLabel": "ATM" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to classes of share capital." } } }, "auth_ref": [ "r31" ] }, "iva_ClassOfWarrantOrRightGranted": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ClassOfWarrantOrRightGranted", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights granted.", "label": "Class of Warrant or Right, Granted", "verboseLabel": "Number of warrants issued" } } }, "auth_ref": [] }, "iva_DefinedBenefitPlanGainLossFromPlanCurtailmentsAndModifications": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DefinedBenefitPlanGainLossFromPlanCurtailmentsAndModifications", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetBreakdownOfExpenseRecognizedForPeriodDetails": { "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetBreakdownOfExpenseRecognizedForPeriodDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized for plan curtailments and modifications related to defined benefit plan.", "label": "Defined Benefit Plan, Gain (Loss) From Plan Curtailments And Modifications", "terseLabel": "Plan curtailments and modifications" } } }, "auth_ref": [] }, "ifrs-full_ComputerSoftwareMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ComputerSoftwareMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Software licenses" } }, "en": { "role": { "documentation": "This member stands for a class of intangible assets representing computer software. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r209" ] }, "iva_DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about provision recorded in respect of defined benefit schemes at the end of each reporting period.", "label": "Disclosure Of Provision Recorded In Respect Of Defined Benefit Schemes At End Of Each Reporting Period, Explanatory", "terseLabel": "Schedule of provision recorded in respect of defined benefit schemes at the end of each reporting period" } } }, "auth_ref": [] }, "iva_DisclosureOfOtherOperatingIncomeExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DisclosureOfOtherOperatingIncomeExpenseTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of other operating income (expense).", "label": "Disclosure Of Other Operating Income Expense [Table Text Block]", "terseLabel": "Schedule of other operating income and expenses" } } }, "auth_ref": [] }, "iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementNarrativesDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "IFRS Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of property, plant and equipment." } } }, "auth_ref": [ "r50" ] }, "iva_IfrsAdrMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsAdrMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Ifrs ADR Member\n.", "label": "Adr [Member]", "terseLabel": "ADS" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDefinedBenefitPlansTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfDefinedBenefitPlansTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetChangeInNetProvisionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetNetProvisionDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of defined benefit plans [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to defined benefit plans." } } }, "auth_ref": [ "r53" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for decrease (increase) in trade and other receivables", "terseLabel": "Decrease / (increase) in operating and other receivables" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]" } } }, "auth_ref": [ "r289" ] }, "iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "IFRS Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "auth_ref": [] }, "iva_FinancialIncomeAndExpensesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "FinancialIncomeAndExpensesTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information pertaining to disclosure of financial income and expenses.", "label": "Financial Income And Expenses [Table]" } } }, "auth_ref": [] }, "iva_CurrentTradeReceivablesAveragePaymentPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "CurrentTradeReceivablesAveragePaymentPeriod", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the average payment period for trade receivables.", "label": "Current Trade Receivables, Average Payment Period", "terseLabel": "Average payment period for trade receivables" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetChangeInNetProvisionDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in net defined benefit liability (asset) resulting from expense (income) in profit or loss", "negatedLabel": "Expense for the period" } }, "en": { "role": { "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from expense (income) included in profit or loss. [Refer: Net defined benefit liability (asset); Profit (loss)] [Contrast: Post-employment benefit expense in profit or loss, defined benefit plans]" } } }, "auth_ref": [ "r277" ] }, "iva_KarenAachFormerAdministratorMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "KarenAachFormerAdministratorMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Karen Aach (former administrator).", "label": "Karen Aach (former administrator)" } } }, "auth_ref": [] }, "iva_NumberOfSharesPerOtherEquityInstrumentGranted": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NumberOfSharesPerOtherEquityInstrumentGranted", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that each equity instruments other than share options granted in a share-based payment arrangement, entitles the holder.", "label": "Number Of Shares Per Other Equity Instrument Granted", "terseLabel": "Number of shares per AGA", "verboseLabel": "Number of shares entitled per warrant" } } }, "auth_ref": [] }, "iva_OtherCurrentTaxReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "OtherCurrentTaxReceivables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of other tax receivables, classified as current.", "label": "Other Current Tax Receivables", "terseLabel": "Other" } } }, "auth_ref": [] }, "iva_AccrualsClassifiedAsCurrentRelatingToScientificProjects": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "AccrualsClassifiedAsCurrentRelatingToScientificProjects", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradePayablesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of accruals classified as current relating to scientific projects", "label": "Accruals classified as current relating to scientific projects", "terseLabel": "Accrued liabilities relating to scientific projects" } } }, "auth_ref": [] }, "iva_FinancialIncomeAndExpensesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "FinancialIncomeAndExpensesTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of financial income and expense.", "label": "Financial Income and Expenses [Table Text Block]", "terseLabel": "Schedule of financial income and expenses" } } }, "auth_ref": [] }, "iva_EmployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "EmployeesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for employees.", "label": "Employees" } } }, "auth_ref": [] }, "iva_ClassOfWarrantOrRightMeasurementPeriodForSharePriceToDetermineNumberOfInstrumentsGranted": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ClassOfWarrantOrRightMeasurementPeriodForSharePriceToDetermineNumberOfInstrumentsGranted", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Class Of Warrant Or Right, Measurement period for share price to determine number of instruments granted", "label": "Class Of Warrant Or Right, Measurement period for share price to determine number of instruments granted", "terseLabel": "Measurement period for share price to determine number of instruments granted" } } }, "auth_ref": [] }, "iva_NetProceedsFromIssueOfOrdinaryShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NetProceedsFromIssueOfOrdinaryShares", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuing of ordinary shares after deducting transaction costs.", "label": "Net Proceeds From Issue Of Ordinary Shares", "terseLabel": "Net proceeds from issuance of shares" } } }, "auth_ref": [] }, "iva_CurrentTaxCreditResearchCurrentYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "CurrentTaxCreditResearchCurrentYear", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of tax credit research from current year, classified as current.", "label": "Current Tax Credit Research, Current Year", "terseLabel": "Receivable for current year", "verboseLabel": "Tax credits of current year" } } }, "auth_ref": [] }, "ifrs-full_InitiallyAppliedIFRSsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "InitiallyAppliedIFRSsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtMovementsInPeriodBreakDownDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Initially applied IFRSs [member]" } }, "en": { "role": { "documentation": "This member stands for IFRSs that have been initially applied by the entity. It also represents the standard value for the 'Initially applied IFRSs' axis if no other member is used. [Refer: IFRSs [member]]" } } }, "auth_ref": [ "r100" ] }, "iva_OtherCurrentAssetsAndReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "OtherCurrentAssetsAndReceivables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of other current assets and receivables as of balance sheet date.", "label": "Other Current Assets And Receivables", "totalLabel": "Other current assets and receivables" } } }, "auth_ref": [] }, "ifrs-full_InterestCostsCapitalised": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "InterestCostsCapitalised", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "label": "Interest costs capitalised", "terseLabel": "Capitalized interest amount" } }, "en": { "role": { "documentation": "The amount of interest costs that an entity incurs in connection with the borrowing of funds that are directly attributable to the acquisition, construction or production of a qualifying asset and which form part of the cost of that asset." } } }, "auth_ref": [ "r264" ] }, "iva_LanifibranorMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LanifibranorMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Lanifbranor", "label": "Lanifibranor [Member]", "terseLabel": "Lanifibranor" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of subsidiaries [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to subsidiaries." } } }, "auth_ref": [ "r67", "r69", "r120" ] }, "iva_PurchaseOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "PurchaseOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Purchase Of Property Plant And Equipment And Intangile Assets Classified As Investing Activities", "label": "Purchase Of Property Plant And Equipment And Intangible Assets Classified As Investing Activities", "negatedLabel": "Purchases of property, plant and equipment and intangible assets" } } }, "auth_ref": [] }, "ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "LaterThanSixMonthsAndNotLaterThanOneYearMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Between 6 and 12 months" } }, "en": { "role": { "documentation": "This member stands for a time band of later than six months and not later than one year." } } }, "auth_ref": [ "r228", "r231", "r237", "r240", "r244" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [text block]", "terseLabel": "Schedule of property, plant and equipment" } }, "en": { "role": { "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r50" ] }, "ifrs-full_FinancialAssetsCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "FinancialAssetsCategoryMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets, category [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated categories of financial assets. It also represents the standard value for the 'Categories of financial assets' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r166" ] }, "iva_FinancialIncomeAndExpensesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "FinancialIncomeAndExpensesLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.", "label": "Financial Income And Expenses [Line Items]", "verboseLabel": "Financial income and expenses" } } }, "auth_ref": [] }, "iva_CurrentTaxCreditResearchPriorPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "CurrentTaxCreditResearchPriorPeriod", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of tax credit research from prior period, classified as current.", "label": "Current Tax Credit Research, Prior Period", "terseLabel": "Receivables from previous years not yet received" } } }, "auth_ref": [] }, "iva_NumberOfSitesInStudy": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NumberOfSitesInStudy", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of sites involved in study", "label": "Number of sites in study" } } }, "auth_ref": [] }, "iva_CurrentTaxCreditResearchCorrectiveClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "CurrentTaxCreditResearchCorrectiveClaims", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of tax credit research for corrective claims, classified as current.", "label": "Current Tax Credit Research, Corrective Claims", "terseLabel": "Corrective claims" } } }, "auth_ref": [] }, "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "OperatingExpenseExcludingOtherOperatingIncomeExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to amount of all operating expenses.", "label": "Operating Expense Excluding Other Operating Income Expense", "negatedTotalLabel": "Total operating expenses" } } }, "auth_ref": [] }, "iva_ThresholdSalesValueForCalculationOfRoyaltyPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ThresholdSalesValueForCalculationOfRoyaltyPayments", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Threshold sales value for calculation of royalty payments", "label": "Threshold sales value for calculation of royalty payments" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementNarrativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of attribution of expenses by nature to their function [line items]", "terseLabel": "Operating expenses", "verboseLabel": "Notes to the income statement" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInAssociatesTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of associates [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to associates." } } }, "auth_ref": [ "r67", "r69", "r121" ] }, "iva_CurrentTaxCreditResearchPriorPeriodIncludingCorrectiveClaim": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "CurrentTaxCreditResearchPriorPeriodIncludingCorrectiveClaim", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of tax credit research from prior period including corrective claim, classified as current.", "label": "Current Tax Credit Research, Prior Period Including Corrective Claim", "terseLabel": "Receivables from previous years not yet received including corrective claim" } } }, "auth_ref": [] }, "iva_NumberOfLoansObtainedGuaranteedByFrenchState": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NumberOfLoansObtainedGuaranteedByFrenchState", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of loans obtained which are guaranteed by the french state.", "label": "Number Of Loans Obtained Guaranteed By The French State", "verboseLabel": "Number of loans obtained guaranteed by the french state" } } }, "auth_ref": [] }, "iva_TaxCreditReceivedPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "TaxCreditReceivedPercent", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of amount received for tax credit.", "label": "Tax Credit Received, Percent", "terseLabel": "Percentage of amount received for tax credit" } } }, "auth_ref": [] }, "ifrs-full_Cash": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "Cash", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCashAndCashEquivalentsDetails": { "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "Cash", "terseLabel": "Cash at bank and at hand" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]" } } }, "auth_ref": [ "r290" ] }, "iva_IfrsValueAddedTaxReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsValueAddedTaxReceivableCurrent", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.", "label": "IFRS Value Added Tax Receivable, Current", "terseLabel": "VAT receivables" } } }, "auth_ref": [] }, "iva_LongTermSecurityDepositsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LongTermSecurityDepositsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for long-term security deposits.", "label": "Long-term security deposits" } } }, "auth_ref": [] }, "ifrs-full_FinancialAssetsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "FinancialAssetsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets, class [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r159", "r160", "r181", "r186", "r187", "r188" ] }, "iva_CompanyInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "CompanyInformationAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Company information" } } }, "auth_ref": [] }, "iva_NumberOfCountriesInStudy": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NumberOfCountriesInStudy", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of countries involved in study", "label": "Number of countries in study" } } }, "auth_ref": [] }, "iva_DisclosureOfCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DisclosureOfCashAndCashEquivalentsTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of cash and cash equivalents.", "label": "Disclosure Of Cash And Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of cash and cash equivalents" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "IncreaseDecreaseThroughTransfersAndOtherChangesEquity", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through other changes, equity", "terseLabel": "Other" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Equity]" } } }, "auth_ref": [ "r5" ] }, "iva_InventivaIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "InventivaIncMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementNarrativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Inventiva Inc, U.S. affiliate.", "label": "Inventiva Inc [Member]", "terseLabel": "Inventiva Inc." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOtherProvisionsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfOtherProvisionsTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of other provisions [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to other provisions." } } }, "auth_ref": [ "r75" ] }, "ifrs-full_NotLaterThanOneMonthMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NotLaterThanOneMonthMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradePayablesDetails" ], "lang": { "en-us": { "role": { "label": "Due in 30 days" } }, "en": { "role": { "documentation": "This member stands for a time band of not later than one month." } } }, "auth_ref": [ "r227", "r229", "r237" ] }, "iva_ExercisePeriodForShareAcquisitionOptionFromEffectiveDateOfLicensingAgreement": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ExercisePeriodForShareAcquisitionOptionFromEffectiveDateOfLicensingAgreement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "documentation": "Exercise period for share acquisition option from effective date of licensing agreement", "label": "Exercise period for share acquisition option from effective date of licensing agreement" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfIntangibleAssetsTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of intangible assets." } } }, "auth_ref": [ "r82" ] }, "ifrs-full_OtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "OtherComprehensiveIncome", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income", "terseLabel": "Other comprehensive income (loss)" } }, "en": { "role": { "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]" } } }, "auth_ref": [ "r3", "r33", "r38", "r115" ] }, "iva_OptionToAcquireSharesInCompanyPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "OptionToAcquireSharesInCompanyPercentage", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "documentation": "Option to acquire shares in company, percentage", "label": "Option to acquire shares in company, percentage" } } }, "auth_ref": [] }, "iva_CompanyInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "CompanyInformationTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformation" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure on company information.", "label": "Company Information [Text Block]", "terseLabel": "Company information" } } }, "auth_ref": [] }, "iva_BonusShareAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "BonusShareAwardsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for bonus share awards.", "label": "AGA [Member]" } } }, "auth_ref": [] }, "iva_PercentageOfPopulationSufferingFromNash": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "PercentageOfPopulationSufferingFromNash", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of population suffering from NASH", "label": "Percentage of population suffering from NASH" } } }, "auth_ref": [] }, "iva_PercentageOfPatientsWithSignificantFibrosis": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "PercentageOfPatientsWithSignificantFibrosis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of patients with significant fibrosis", "label": "Percentage of patients with significant fibrosis" } } }, "auth_ref": [] }, "iva_IfrsSaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsSaleOfStockAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "IFRS Sale of Stock [Axis]" } } }, "auth_ref": [] }, "iva_NetCarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NetCarryingAmountMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetIntangibleAssetsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the net carrying amount", "label": "Net" } } }, "auth_ref": [] }, "iva_Bspce2021PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "Bspce2021PlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSPCE 2021 plan.", "label": "BSPCE 2021" } } }, "auth_ref": [] }, "iva_IfrsSaleOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsSaleOfStockDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "IFRS Sale of Stock [Domain]" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromIfricRevision": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromIfricRevision", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetChangeInNetProvisionDetails" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from IFRIC revision.", "label": "Increase (Decrease) in Net Defined Benefit Liability (Asset) Resulting From IFRIC Revision", "terseLabel": "IFRIC revision - IAS 19" } } }, "auth_ref": [] }, "iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementNarrativesDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "IFRS Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "auth_ref": [] }, "ifrs-full_CurrentProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CurrentProvisions", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current provisions", "terseLabel": "Short-term provisions" } }, "en": { "role": { "documentation": "The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]" } } }, "auth_ref": [ "r14" ] }, "ifrs-full_ForeignExchangeGain": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ForeignExchangeGain", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementFinancialIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Foreign exchange gain", "terseLabel": "Foreign exchange gains" } }, "en": { "role": { "documentation": "The gross gain arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]" } } }, "auth_ref": [ "r8", "r61" ] }, "iva_NewBsa2021ShareWarrantPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NewBsa2021ShareWarrantPlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for new BSA 2021 share warrant plan.", "label": "BSA 2021" } } }, "auth_ref": [] }, "iva_StockIssuedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "StockIssuedDuringPeriodShares", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued during the period.", "label": "Stock Issued During Period, Shares", "terseLabel": "Number of shares issued during the period" } } }, "auth_ref": [] }, "iva_NewBonusShareAwardPlanAga2021Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NewBonusShareAwardPlanAga2021Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2021)", "label": "AGA 2021 [Member]" } } }, "auth_ref": [] }, "iva_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure for trade payables and other current liabilities.", "label": "Disclosure Of Trade Payables and Other Current Liabilities [Table Text Block]", "terseLabel": "Schedule of trade payables and other current liabilities" } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "iva_TradePayablesAndOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "TradePayablesAndOtherCurrentLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradePayablesAndOtherCurrentLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradePayablesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of trade payables and other current liabilities.", "label": "Trade Payables And Other Current Liabilities.", "totalLabel": "Trade payables and other current liabilities" } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityFilerCategory", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r250" ] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AddressTypeDomain", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "iva_ResearchAndDevelopmentMarketingTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ResearchAndDevelopmentMarketingTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of Research and Development, Marketing.", "label": "Research and Development, Marketing [Table Text Block]", "terseLabel": "Schedule of research and development, marketing" } } }, "auth_ref": [] }, "ifrs-full_BorrowingsInterestRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "BorrowingsInterestRate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Borrowings, interest rate", "terseLabel": "Interest rate" } }, "en": { "role": { "documentation": "The interest rate on borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r294" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AuditorLocation", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r252", "r253", "r254" ] }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Additions other than through business combinations, property, plant and equipment", "terseLabel": "Acquisitions" } }, "en": { "role": { "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]" } } }, "auth_ref": [ "r46" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AuditorName", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r252", "r253", "r254" ] }, "iva_IfrsShareBasedPaymentArrangementTrancheThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsShareBasedPaymentArrangementTrancheThreeMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Tranche three" } } }, "auth_ref": [] }, "dei_BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "BusinessContactMember", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Business Contact [Member]", "documentation": "Business contact for the entity" } } }, "auth_ref": [ "r253", "r254" ] }, "iva_Bspce2015PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "Bspce2015PlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSPCE - 2015 plan.", "label": "BSPCE - 2015 Plan [Member]", "terseLabel": "BSPCE - 2015 Plan" } } }, "auth_ref": [] }, "iva_GrossProceedsFromIssuingShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "GrossProceedsFromIssuingShares", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of gross proceeds from issuing shares.", "label": "Gross Proceeds From Issuing Shares", "terseLabel": "Gross proceeds" } } }, "auth_ref": [] }, "iva_Bspce2013PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "Bspce2013PlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSPCE - 2013 plan.", "label": "BSPCE - 2013 Plan" } } }, "auth_ref": [] }, "iva_FinancingFromSyndicateOfFrenchBanksMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "FinancingFromSyndicateOfFrenchBanksMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for financing from a syndicate of French banks.", "label": "Financing from a syndicate of French banks" } } }, "auth_ref": [] }, "iva_NumberOfLoansGuaranteedByFrenchState": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NumberOfLoansGuaranteedByFrenchState", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of loans guaranteed by French State.", "label": "Number Of Loans Guaranteed By French State", "terseLabel": "Number of loans guaranteed by the French State" } } }, "auth_ref": [] }, "ifrs-full_ParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ParValuePerShare", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "label": "Par value per share", "verboseLabel": "Nominal value" } }, "en": { "role": { "documentation": "The nominal value per share." } } }, "auth_ref": [ "r29" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AuditorFirmId", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r252", "r253", "r254" ] }, "ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Other inflows (outflows) of cash, classified as operating activities", "verboseLabel": "Other" } }, "en": { "role": { "documentation": "Inflows (outflows) of cash, classified as operating activities, that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r91" ] }, "iva_NewBonusShareAwardPlan20181Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NewBonusShareAwardPlan20181Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2018-1).", "label": "AGA 2018-1" } } }, "auth_ref": [] }, "iva_IfrsForeignExchangeForwardMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsForeignExchangeForwardMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.", "label": "Foreign currency forwards", "terseLabel": "Foreign currency forwards" } } }, "auth_ref": [] }, "iva_NumberOfTranchesInShareBasedPaymentArrangement": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NumberOfTranchesInShareBasedPaymentArrangement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of tranches in share-based arrangement.", "label": "Number of Tranches in Share-based Payment Arrangement", "terseLabel": "Number of tranches" } } }, "auth_ref": [] }, "iva_BorrowingsMaximumExtensionTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "BorrowingsMaximumExtensionTerm", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "Period up to which the maturity term of the borrowings can be extended.", "label": "Borrowings, Maximum Extension Term", "verboseLabel": "Extension of term of debt" } } }, "auth_ref": [] }, "iva_IfrsShareBasedPaymentArrangementTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsShareBasedPaymentArrangementTrancheTwoMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Tranche two" } } }, "auth_ref": [] }, "ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "LaterThanThreeYearsAndNotLaterThanFiveYearsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Between 3 and 5 years" } }, "en": { "role": { "documentation": "This member stands for a time band of later than three years and not later than five years." } } }, "auth_ref": [ "r228", "r233", "r237" ] }, "iva_IfrsShareBasedPaymentArrangementTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsShareBasedPaymentArrangementTrancheOneMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Tranche one" } } }, "auth_ref": [] }, "iva_AgaBonusPlansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "AgaBonusPlansMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for AGA Bonus plan", "label": "AGA Bonus Plans" } } }, "auth_ref": [] }, "iva_LaterThanTwoMonthsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LaterThanTwoMonthsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradePayablesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for a time band of later than two months.", "label": "Due in more than 60 days" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseThroughAppropriationOfShareIssuancePremium": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IncreaseDecreaseThroughAppropriationOfShareIssuancePremium", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in equity resulting from the appropriation of a share issuance premium.", "label": "Increase (Decrease) Through Appropriation of Share Issuance Premium", "terseLabel": "Appropriation of the issue premium" } } }, "auth_ref": [] }, "ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "RepaymentsOfBorrowingsClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Repayments of borrowings, classified as financing activities", "negatedLabel": "Repayment of debt", "terseLabel": "Repayments of borrowings" } }, "en": { "role": { "documentation": "The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]" } } }, "auth_ref": [ "r213" ] }, "iva_ServiceProvidersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ServiceProvidersMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareWarrantsPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to service providers.", "label": "Service Providers" } } }, "auth_ref": [] }, "iva_ProvisionForFrenchResearchTaxCreditRelatedToTaxAuditForYearsEnded20132014And2015Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ProvisionForFrenchResearchTaxCreditRelatedToTaxAuditForYearsEnded20132014And2015Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for provision for French Research Tax Credit (CIR) related to tax audit for the years ended December 31, 2013, 2014 and 2015.", "label": "Provision For French Research Tax Credit elated To Tax Audit For Years Ended 2013 2014 And 2015 [Member]" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for share-based payment transactions [text block]", "terseLabel": "Share-based payments" } }, "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]\nEffective 2023-01-01: The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]" } } }, "auth_ref": [ "r295", "r296" ] }, "ifrs-full_CashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 5.0 }, "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCashAndCashEquivalentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCashAndCashEquivalentsDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalent", "periodEndLabel": "Net cash and cash equivalents at the end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and cash equivalents" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } } }, "auth_ref": [ "r12", "r97", "r116" ] }, "iva_OtherAccruedTaxesAndEmployeeRelatedExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "OtherAccruedTaxesAndEmployeeRelatedExpenses", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherCurrentLiabilitiesDetails": { "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of accrued taxes and employee related expenses.", "label": "Other Accrued taxes And Employee Related Expenses", "terseLabel": "Other accrued taxes and employeerelated expenses" } } }, "auth_ref": [] }, "iva_DirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DirectorsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareWarrantsPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Directors.", "label": "Directors" } } }, "auth_ref": [] }, "iva_RepaymentPeriodOfLoan": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "RepaymentPeriodOfLoan", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "The period for repayment of loan.", "label": "Repayment Period of Loan", "terseLabel": "Repayment period for loan" } } }, "auth_ref": [] }, "dei_ContactPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "ContactPersonnelName", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForSharebasedPayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "AdjustmentsForSharebasedPayments", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for share-based payments", "terseLabel": "Share-based compensation expense" } }, "en": { "role": { "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r288" ] }, "ifrs-full_OtherCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "OtherCurrentPayables", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherCurrentLiabilitiesDetails": { "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Other current payables", "terseLabel": "Other miscellaneous payables" } }, "en": { "role": { "documentation": "The amount of current payables that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r265" ] }, "iva_BspceAndBsaShareWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "BspceAndBsaShareWarrantsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSPCE and BSA share warrants.", "label": "BSPCE and BSA Share Warrants", "verboseLabel": "BSPCE share warrants and BSA share warrants" } } }, "auth_ref": [] }, "ifrs-full_AccrualsClassifiedAsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "AccrualsClassifiedAsCurrent", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradePayablesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Accruals classified as current", "terseLabel": "Accrued expenses" } }, "en": { "role": { "documentation": "The amount of accruals classified as current. [Refer: Accruals]" } } }, "auth_ref": [ "r268" ] }, "iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Ifrs Collaborative Arrangement And Arrangement Other Than Collaborative Line items", "verboseLabel": "Collaborative Arrangements" } } }, "auth_ref": [] }, "iva_ExternalAdvisorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ExternalAdvisorsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to external advisors.", "label": "External Advisors [Member]" } } }, "auth_ref": [] }, "ifrs-full_FinancialLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "FinancialLiabilitiesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities, class [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r159", "r160", "r181", "r187" ] }, "iva_NumberOfPersonsWhoForfeitedAwards": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NumberOfPersonsWhoForfeitedAwards", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of persons who forfeited awards.", "label": "Number Of Persons Who Forfeited Awards", "terseLabel": "Number of persons forfeiting awads" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForFairValueGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "AdjustmentsForFairValueGainsLosses", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for fair value losses (gains)", "terseLabel": "Fair value variation through profit and loss" } }, "en": { "role": { "documentation": "Adjustments for fair value losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r288" ] }, "ifrs-full_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 3.0 }, "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 9.0 }, "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementBasicAndDilutedLossPerShareDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Profit (loss)", "terseLabel": "Net loss for the period", "totalLabel": "Net loss for the period", "verboseLabel": "Net income (loss) for the period" } }, "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r2", "r32", "r92", "r102", "r104", "r172", "r174", "r218", "r238", "r239" ] }, "iva_BonusShareAwardPlansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "BonusShareAwardPlansMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for bonus share award plans.", "label": "Bonus Share Award Plans [Member]" } } }, "auth_ref": [] }, "iva_DerivativeAssetForeignCurrencyForwardsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DerivativeAssetForeignCurrencyForwardsCurrent", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the asset arising from a foreign currency forward contract classified as current.", "label": "Derivative Asset, Foreign Currency Forwards, Current", "terseLabel": "Foreign currency forwards" } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntitySmallBusiness", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r250" ] }, "ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current borrowings and current portion of non-current borrowings", "terseLabel": "Short-term debt" } }, "en": { "role": { "documentation": "The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r265" ] }, "iva_IfrsVestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsVestingDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Ifrs Vesting [Domain]" } } }, "auth_ref": [] }, "iva_PayrollTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "PayrollTaxes", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "documentation": "A class of employee benefits expense that represents payroll taxes.", "label": "Payroll taxes", "negatedLabel": "Payroll taxes" } } }, "auth_ref": [] }, "ifrs-full_AdjustedWeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "AdjustedWeightedAverageShares", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementBasicAndDilutedLossPerShareDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Adjusted weighted average number of ordinary shares outstanding", "terseLabel": "Weighted average number of shares outstanding used to calculate diluted loss per share" } }, "en": { "role": { "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r72" ] }, "iva_BsaShareWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "BsaShareWarrantsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareWarrantsPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA share warrants.", "label": "BSA share warrants" } } }, "auth_ref": [] }, "iva_NewBonusShareAwardPlan20171Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NewBonusShareAwardPlan20171Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2017-1).", "label": "AGA 2017-1" } } }, "auth_ref": [] }, "iva_IfrsIncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsIncreaseDecreaseInPrepaidExpense", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "IFRS Increase (Decrease) in Prepaid Expense", "terseLabel": "Increase in prepaid expense" } } }, "auth_ref": [] }, "iva_TaxCreditsReceivableResearchCreditsFromCurrentTaxYearCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "TaxCreditsReceivableResearchCreditsFromCurrentTaxYearCurrent", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of research tax credit receivables attributable to the current tax year, classified as current.", "label": "Tax Credits Receivable, Research Credits from Current Tax Year, Current", "terseLabel": "Research tax credits receivable from current tax year" } } }, "auth_ref": [] }, "ifrs-full_EquityMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "EquityMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareCapitalDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity [member]" } }, "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } } }, "auth_ref": [ "r6" ] }, "iva_TaxCreditsReceivableResearchCreditsFromPriorTaxYearsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "TaxCreditsReceivableResearchCreditsFromPriorTaxYearsCurrent", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of research tax credit receivables attributable to prior tax years, classified as current.", "label": "Tax Credits Receivable, Research Credits from Prior Tax Years, Current", "verboseLabel": "Corrective claims for additional reimbursements of CIR, prior years" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "iva_AdjustmentsForDecreaseIncreaseInShortTermDepositAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "AdjustmentsForDecreaseIncreaseInShortTermDepositAccounts", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Adjustments for decrease (increase) in short-term deposit accounts to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustments for Decrease (Increase) in Short-Term Deposit Accounts", "terseLabel": "Increase in short-term deposit accounts" } } }, "auth_ref": [] }, "iva_IfrsIpoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsIpoMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO" } } }, "auth_ref": [] }, "iva_BspcePlansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "BspcePlansMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSPCE plans.", "label": "BSPCE plans" } } }, "auth_ref": [] }, "iva_NewShareWarrantPlansBsa2019TerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NewShareWarrantPlansBsa2019TerMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for a new share warrant plan (\"BSA 2019 ter).", "label": "BSA 2019 ter" } } }, "auth_ref": [] }, "iva_IfrsVestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsVestingAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Ifrs Vesting [Axis]" } } }, "auth_ref": [] }, "iva_KeplerCheuvreuxMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "KeplerCheuvreuxMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Kepler Cheuvreux.", "label": "Kepler Cheuvreux" } } }, "auth_ref": [] }, "iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Ifrs Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "verboseLabel": "Number of shares per BSA" } } }, "auth_ref": [] }, "ifrs-full_DiscountedUnguaranteedResidualValueOfAssetsSubjectToFinanceLease": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DiscountedUnguaranteedResidualValueOfAssetsSubjectToFinanceLease", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Discounted unguaranteed residual value of assets subject to finance lease", "terseLabel": "Residual amount" } }, "en": { "role": { "documentation": "The amount of the discounted unguaranteed residual value of assets subject to finance leases. Unguaranteed residual value is the portion of the residual value of the underlying asset, the realisation of which by a lessor is not assured or is guaranteed solely by a party related to the lessor. Finance lease is a lease that transfers substantially all the risks and rewards incidental to ownership of an underlying asset." } } }, "auth_ref": [ "r137" ] }, "iva_IfrsClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsClassOfWarrantOrRightOutstanding", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "IFRS Class of Warrant or Right, Outstanding", "terseLabel": "Number of share warrants outstanding", "verboseLabel": "Number of BSA outstanding" } } }, "auth_ref": [] }, "iva_NewShareWarrantPlansBsa2019BisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NewShareWarrantPlansBsa2019BisMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for a new share warrant plan (\"BSA 2019 bis).", "label": "BSA 2019 bis" } } }, "auth_ref": [] }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments exercised or vested in share-based payment arrangement", "negatedLabel": "Exercised/Vesting" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement." } } }, "auth_ref": [ "r293" ] }, "ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DescriptionOfAccountingPolicyForBorrowingsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for borrowings [text block]", "terseLabel": "Loans and borrowings" } }, "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for borrowings. [Refer: Borrowings]\nEffective 2023-01-01: The description of the entity's material accounting policy information for borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r295", "r296" ] }, "iva_TaxEffectOfTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "TaxEffectOfTaxCredits", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to tax effect of tax credits.", "label": "Tax effect of tax credits", "verboseLabel": "Amount received for tax credit" } } }, "auth_ref": [] }, "iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "IFRS Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price of warrant" } } }, "auth_ref": [] }, "iva_CurrentResearchTaxCreditReceivablesToBeCollected": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "CurrentResearchTaxCreditReceivablesToBeCollected", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of current research tax credits to be collected during the current year.", "label": "Current Research Tax Credit, Receivables to be Collected", "terseLabel": "Amount of CIR requested to be repaid" } } }, "auth_ref": [] }, "ifrs-full_NumberOfEmployees": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NumberOfEmployees", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Number of employees", "verboseLabel": "Number of employees" } }, "en": { "role": { "documentation": "The number of personnel employed by the entity at a date." } } }, "auth_ref": [ "r264" ] }, "ifrs-full_ClassesOfFinancialLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ClassesOfFinancialLiabilitiesAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r159", "r160", "r181", "r187" ] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "terseLabel": "Document and Entity Information", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "LaterThanOneYearAndNotLaterThanThreeYearsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Between 1 and 3 years" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one year and not later than three years." } } }, "auth_ref": [ "r228", "r232", "r237" ] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]", "terseLabel": "Schedule of movements in BSPCE and BSA share warrants and Bonus shares" } }, "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)." } } }, "auth_ref": [ "r293" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentType", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "iva_DavidNikodemMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DavidNikodemMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareWarrantsPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for David Nikodem, a member of Sapidus Consulting Group LLC, a service provider to the Company.", "label": "David Nikodem" } } }, "auth_ref": [] }, "ifrs-full_CounterpartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CounterpartiesAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCashAndCashEquivalentsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "Counterparties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r168" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentAnnualReport", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r252", "r253", "r254" ] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "label": "Non-adjusting events after reporting period [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r40" ] }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CategoriesOfRelatedPartiesAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareWarrantsPlansDetails" ], "lang": { "en-us": { "role": { "label": "Categories of related parties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r64" ] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementNarrativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "ifrs-full_OtherBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "OtherBorrowings", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtDetails": { "parentTag": "ifrs-full_Borrowings", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Other borrowings", "terseLabel": "Other loans", "verboseLabel": "Other loans and similar borrowings" } }, "en": { "role": { "documentation": "The amount of borrowings that the entity does not separately disclose in the same statement or note. [Refer: Borrowings]" } } }, "auth_ref": [ "r264" ] }, "ifrs-full_BorrowingsByNameAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "BorrowingsByNameAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Borrowings by name [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r294" ] }, "ifrs-full_WagesAndSalaries": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "WagesAndSalaries", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Wages and salaries", "negatedLabel": "Wages, salaries and similar costs" } }, "en": { "role": { "documentation": "A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]" } } }, "auth_ref": [ "r280" ] }, "iva_AccruedIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "AccruedIncomeMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for accrued income.", "label": "Current accrued income" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "LegalEntityAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementNarrativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "ifrs-full_ClassesOfAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ClassesOfAssetsAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "Classes of assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r73", "r74", "r126", "r136" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentTransitionReport", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r255" ] }, "ifrs-full_ContractualCapitalCommitments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ContractualCapitalCommitments", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "Contractual capital commitments", "terseLabel": "Total commitments given" } }, "en": { "role": { "documentation": "The amount of capital commitments for which the entity has entered into a contract. [Refer: Capital commitments]" } } }, "auth_ref": [ "r264" ] }, "ifrs-full_OtherCurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "OtherCurrentReceivables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Other current receivables", "terseLabel": "Other receivables" } }, "en": { "role": { "documentation": "The amount of current other receivables. [Refer: Other receivables]" } } }, "auth_ref": [ "r198" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentShellCompanyReport", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r253" ] }, "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income that will not be reclassified to profit or loss, net of tax", "terseLabel": "Items not recycled to income" } }, "en": { "role": { "documentation": "The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r200", "r201" ] }, "ifrs-full_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Tax rate effect of adjustments for current tax of prior periods", "terseLabel": "Projected tax rate" } }, "en": { "role": { "documentation": "Tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from adjustments for the current tax of prior periods. [Refer: Average effective tax rate; Applicable tax rate; Adjustments for current tax of prior periods]" } } }, "auth_ref": [ "r272" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r256" ] }, "ifrs-full_AccumulatedImpairmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "AccumulatedImpairmentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetInventoriesDetails" ], "lang": { "en-us": { "role": { "label": "Inventories write-down" } }, "en": { "role": { "documentation": "This member stands for accumulated impairment. [Refer: Impairment loss]" } } }, "auth_ref": [ "r145", "r151", "r226", "r241", "r247", "r274", "r282", "r283", "r284" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentRegistrationStatement", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r248" ] }, "iva_IslsConsultingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IslsConsultingMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for ISLS Consulting, a company owned by Jean Louis Junien, a director of the Company", "label": "ISLS Consulting" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DescriptionOfAccountingPolicyForIssuedCapitalExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for issued capital [text block]", "terseLabel": "Share capital" } }, "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for issued capital. [Refer: Issued capital]\nEffective 2023-01-01: The description of the entity's material accounting policy information for issued capital. [Refer: Issued capital]" } } }, "auth_ref": [ "r295", "r296" ] }, "ifrs-full_ProvisionForTaxesOtherThanIncomeTaxMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ProvisionForTaxesOtherThanIncomeTaxMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Tax disputes" } }, "en": { "role": { "documentation": "This member stands for a provision for taxes other than income tax. Income taxes include all domestic and foreign taxes which are based on taxable profits. Income taxes also include taxes, such as withholding taxes, which are payable by a subsidiary, associate or joint arrangement on distributions to the reporting entity. [Refer: Other provisions [member]]" } } }, "auth_ref": [ "r281" ] }, "ifrs-full_InitiallyAppliedIFRSsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "InitiallyAppliedIFRSsAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtMovementsInPeriodBreakDownDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Initially applied IFRSs [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r100" ] }, "ifrs-full_NumberOfSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NumberOfSharesIssued", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "label": "Number of shares issued", "terseLabel": "Number of ordinary shares issued" } }, "en": { "role": { "documentation": "The number of shares issued by the entity." } } }, "auth_ref": [ "r261" ] }, "ifrs-full_AverageForeignExchangeRate": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "AverageForeignExchangeRate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceForeignExchangeRatesDetails" ], "lang": { "en-us": { "role": { "label": "Average foreign exchange rate", "terseLabel": "Average exchange rate for the period" } }, "en": { "role": { "documentation": "The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies." } } }, "auth_ref": [ "r264" ] }, "ifrs-full_CategoriesOfFinancialAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CategoriesOfFinancialAssetsAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Categories of financial assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r166" ] }, "ifrs-full_MaturityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "MaturityAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradePayablesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Maturity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r23", "r131", "r137", "r138", "r147", "r158", "r182", "r183", "r184", "r185", "r203", "r228" ] }, "iva_FrenchResearchTaxCreditReceivableAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "FrenchResearchTaxCreditReceivableAmount", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of French Research Tax Credit (CIR) receivable by the company.", "label": "French Research Tax Credit, Receivable Amount", "terseLabel": "French Research Tax Credit (CIR), amounts receivable" } } }, "auth_ref": [] }, "iva_RevenueAndOperatingIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "RevenueAndOperatingIncomeAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Revenue And Operating Income [Abstract]", "terseLabel": "Revenues and other income" } } }, "auth_ref": [] }, "iva_AdjustmentsForTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "AdjustmentsForTaxCredits", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Adjustments for tax credit to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustments For Tax Credits", "terseLabel": "Tax credits" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfFinancialAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ClassesOfFinancialAssetsAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r159", "r160", "r181", "r186", "r187", "r188" ] }, "ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DescriptionOfAccountingPolicyForMeasuringInventories", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for measuring inventories [text block]", "terseLabel": "Inventories" } }, "en": { "role": { "documentation": "The description of the entity's accounting policy for measuring inventories. [Refer: Inventories]" } } }, "auth_ref": [ "r59" ] }, "ifrs-full_CategoriesOfFinancialLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CategoriesOfFinancialLiabilitiesAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Categories of financial liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r166" ] }, "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetIntangibleAssetsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetInventoriesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r45", "r49", "r77", "r81", "r85", "r86", "r87", "r88", "r89", "r145", "r151", "r152", "r297", "r299" ] }, "ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NumberOfInstrumentsGrantedInSharebasedPaymentArrangement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "label": "Number of instruments granted in share-based payment arrangement", "terseLabel": "Number of bonus shares granted" } }, "en": { "role": { "documentation": "The number of instruments granted in share-based payment arrangement." } } }, "auth_ref": [ "r224", "r225" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "iva_FinancingPeriodOfLoan": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "FinancingPeriodOfLoan", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the financing period of loan.", "label": "Financing Period of Loan", "terseLabel": "Financing period of loan" } } }, "auth_ref": [] }, "iva_ClinicalTrialsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ClinicalTrialsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Clinical Trials(CRO).", "label": "Clinical Trials [Member]", "terseLabel": "CRO" } } }, "auth_ref": [] }, "ifrs-full_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementFinancialIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Interest expense", "negatedLabel": "Interest cost" } }, "en": { "role": { "documentation": "The amount of expense arising from interest." } } }, "auth_ref": [ "r118", "r170", "r176" ] }, "iva_ContractManufacturingOrganizationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ContractManufacturingOrganizationsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Contract Manufacturing Organizations(CMO).", "label": "Contract Manufacturing Organizations [Member]", "terseLabel": "CMO" } } }, "auth_ref": [] }, "country_JP": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2022", "localname": "JP", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "label": "JAPAN", "terseLabel": "Japan" } } }, "auth_ref": [] }, "iva_SubcontractingAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "SubcontractingAgreementsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for subcontracting agreements.", "label": "Subcontracting Agreements [Member]", "terseLabel": "Subcontracting agreements" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareWarrantsPlansDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of other equity instruments granted in share-based payment arrangement", "terseLabel": "Exercise price per share" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r293" ] }, "ifrs-full_NoncurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NoncurrentAssetsAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current assets [abstract]", "terseLabel": "Noncurrent assets" } } }, "auth_ref": [] }, "ifrs-full_AggregatedTimeBandsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "AggregatedTimeBandsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradePayablesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Aggregated time bands [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used." } } }, "auth_ref": [ "r23", "r131", "r137", "r138", "r147", "r182", "r183", "r184", "r185", "r203", "r228", "r235" ] }, "iva_OtherFinancialInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "OtherFinancialInformationAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Other financial information" } } }, "auth_ref": [] }, "ifrs-full_OtherProvisionsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "OtherProvisionsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Other provisions [member]" } }, "en": { "role": { "documentation": "This member stands for provisions other than provisions for employee benefits. It also represents the standard value for the 'Classes of other provisions' axis if no other member is used. [Refer: Provisions]" } } }, "auth_ref": [ "r75" ] }, "iva_AmountReachedUnderConditionsPrecedentToFinancingArrangement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "AmountReachedUnderConditionsPrecedentToFinancingArrangement", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount reached by the entity under the conditions precedent to the Financing arrangement.", "label": "Amount Reached Under The Conditions Precedent To Financing Arrangement", "terseLabel": "Amount reached under the conditions precedent to the EIB Financing" } } }, "auth_ref": [] }, "ifrs-full_NotLaterThanThreeMonthsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NotLaterThanThreeMonthsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "3 months or less" } }, "en": { "role": { "documentation": "This member stands for a time band of not later than three months." } } }, "auth_ref": [ "r240", "r242", "r264" ] }, "ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ShorttermDepositsNotClassifiedAsCashEquivalents", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails" ], "lang": { "en-us": { "role": { "label": "Short-term deposits, not classified as cash equivalents", "terseLabel": "Short-term deposits" } }, "en": { "role": { "documentation": "The amount of short-term deposits held by the entity that are not classified as cash equivalents. [Refer: Cash equivalents]" } } }, "auth_ref": [ "r265" ] }, "iva_NotionalAmountPerTranche": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NotionalAmountPerTranche", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "Notional amount per tranche", "label": "Notional amount per tranche" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for trade and other payables [text block]", "terseLabel": "Trade payables and other current liabilities" } }, "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for trade and other payables. [Refer: Trade and other payables]\nEffective 2023-01-01: The description of the entity's material accounting policy information for trade and other payables. [Refer: Trade and other payables]" } } }, "auth_ref": [ "r295", "r296" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r250" ] }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) investing activities", "totalLabel": "Net cash used in investing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents." } } }, "auth_ref": [ "r90", "r99" ] }, "iva_FinanceContractWithEuropeanInvestmentBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "FinanceContractWithEuropeanInvestmentBankMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the Finance contract with the European Investment Bank", "label": "Finance contract with European Investment Bank [Member]", "terseLabel": "Finance contract with EIB" } } }, "auth_ref": [] }, "iva_MaximumPotentialAmountToBeRaised": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "MaximumPotentialAmountToBeRaised", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum potential amount to be raised under the sale of stock transaction.", "label": "Maximum Potential Amount To Be Raised", "terseLabel": "Maximum potential amount to be raised" } } }, "auth_ref": [] }, "iva_WarrantAverageLife": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "WarrantAverageLife", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Average life used to calculate fair value of warrant.", "label": "Warrant Average Life", "verboseLabel": "Maturity (years)" } } }, "auth_ref": [] }, "iva_IfrsLicenseAndCollaborationAgreementUpfrontFeeReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsLicenseAndCollaborationAgreementUpfrontFeeReceivable", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of Upfront fee receivable.", "label": "IFRS License and Collaboration Agreement Upfront Fee Receivable", "terseLabel": "Upfront payment to be received" } } }, "auth_ref": [] }, "iva_PercentageOfLoanGuaranteedByFrenchState": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "PercentageOfLoanGuaranteedByFrenchState", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of loan guaranteed by French state.", "label": "Percentage of Loan Guaranteed by French State", "terseLabel": "Percentage of loan guaranteed by French state" } } }, "auth_ref": [] }, "iva_RoyaltyCertificateIssuanceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "RoyaltyCertificateIssuanceAmount", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of Royalty certificate issuance.", "label": "Royalty Certificate Issuance Amount", "terseLabel": "Royalty certificate issuance amount" } } }, "auth_ref": [] }, "iva_ProceedsFromFinancing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ProceedsFromFinancing", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of cash proceeds from financing.", "label": "Proceeds From Financing", "terseLabel": "Gross cash proceeds" } } }, "auth_ref": [] }, "ifrs-full_CounterpartiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CounterpartiesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCashAndCashEquivalentsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "Counterparties" } }, "en": { "role": { "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used." } } }, "auth_ref": [ "r168" ] }, "ifrs-full_InterestExpenseDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "InterestExpenseDefinedBenefitPlans", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetBreakdownOfExpenseRecognizedForPeriodDetails": { "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetBreakdownOfExpenseRecognizedForPeriodDetails" ], "lang": { "en-us": { "role": { "label": "Interest expense, defined benefit plans", "negatedLabel": "Interest cost for the period" } }, "en": { "role": { "documentation": "The amount of interest expense arising from defined benefit plans. [Refer: Interest expense; Post-employment benefit expense in profit or loss, defined benefit plans] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)]" } } }, "auth_ref": [ "r276" ] }, "iva_OtherReceivablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "OtherReceivablesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for other receivables.", "label": "Other receivables" } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r258" ] }, "iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for indication of continuation of recruitment for Phase III trial NATiV3 of lanifibranor in non-cirrhotic NASH.", "label": "Indication Of Continuation Of Recruitment For Phase Iii Trial Nativ3 Of Lanifibranor In Non-Cirrhotic NashASH [Member]", "terseLabel": "Indication of continuation of recruitment for Phase III trial NATiV3 of lanifibranor in non-cirrhotic NASH" } } }, "auth_ref": [] }, "iva_ServiceAgreementWithSummitClinicalServicesLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ServiceAgreementWithSummitClinicalServicesLlcMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Service agreement with Summit Clinical Services LLC.", "label": "Service Agreement With Summit Clinical Services LLC [member]", "terseLabel": "Service agreement with Summit Clinical Services LLC" } } }, "auth_ref": [] }, "iva_DisclosureOfValuationApproachForBsaShareBasedPaymentArrangementTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DisclosureOfValuationApproachForBsaShareBasedPaymentArrangementTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of valuation approach for BSA share-based payment arrangement", "label": "Disclosure of valuation approach for BSA share-based payment arrangement [table text block]", "terseLabel": "Schedule of valuation approach for BSA arrangement" } } }, "auth_ref": [] }, "iva_TresoPlusMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "TresoPlusMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Treso plus.", "label": "Treso plus [Member]", "terseLabel": "Treso plus" } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "iva_LicensingAgreementWithHepalysMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LicensingAgreementWithHepalysMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Licensing agreement with Hepalys.", "label": "Licensing Agreement With Hepalys [Member]", "terseLabel": "Licensing agreement with Hepalys" } } }, "auth_ref": [] }, "iva_CommitmentsAmountPayableForServicesReceivedUnderContractMaximumBonusOrMalusAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "CommitmentsAmountPayableForServicesReceivedUnderContractMaximumBonusOrMalusAmount", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum amount of bonus or malus payable on amount committed by the company to pay for services received under contract.", "label": "Commitments, Amount Payable For Services Received Under Contract, Maximum Bonus Or Malus Amount", "terseLabel": "Bonus or malus maximum amount" } } }, "auth_ref": [] }, "iva_ReceiptOfPaymentsUnderLicensingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ReceiptOfPaymentsUnderLicensingArrangementsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for receipt of payments under Licensing arrangements.", "label": "Receipt Of Payments Under Licensing Arrangements [Member]", "terseLabel": "Receipt of payments under Licensing arrangements" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of fair value of financial instruments [text block]", "terseLabel": "Schedule of financial assets and liabilities measured at fair value" } }, "en": { "role": { "documentation": "The disclosure of the fair value of financial instruments. [Refer: Financial instruments, class [member]; At fair value [member]]" } } }, "auth_ref": [ "r259" ] }, "iva_LicensingAndCollaborationAgreementWithCttqMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LicensingAndCollaborationAgreementWithCttqMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Licensing and collaboration agreement with CTTQ.", "label": "Licensing and collaboration agreement with CTTQ [Member]", "terseLabel": "Licensing and collaboration agreement with CTTQ" } } }, "auth_ref": [] }, "iva_HepalysPharmaIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "HepalysPharmaIncMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Hepalys Pharma, Inc.", "label": "Hepalys Pharma, Inc [Member]", "terseLabel": "Hepalys Pharma, Inc" } } }, "auth_ref": [] }, "iva_LicensingAndCollaborationAgreementGrossAmountReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LicensingAndCollaborationAgreementGrossAmountReceived", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "Gross amount received by the entity from licensing and collaborative arrangements.", "label": "Licensing And Collaboration Agreement, Gross Amount Received", "terseLabel": "Amount received" } } }, "auth_ref": [] }, "iva_LicensingAndCollaborationAgreementAmountReceivedAttributableToWithholdingTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LicensingAndCollaborationAgreementAmountReceivedAttributableToWithholdingTaxes", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount received by the entity from licensing and collaborative arrangements, attributable to withholding taxes.", "label": "Licensing And Collaboration Agreement, Amount Received Attributable To Withholding Taxes", "terseLabel": "Amount received attributable to withholding taxes" } } }, "auth_ref": [] }, "iva_ContractCroWithPharmaceuticalResearchAssociatesB.vMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ContractCroWithPharmaceuticalResearchAssociatesB.vMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Contract CRO with PRA.", "label": "Contract CRO With Pharmaceutical Research Associates B.V [Member]", "terseLabel": "Contract CRO with Pharmaceutical Research Associates B.V." } } }, "auth_ref": [] }, "ifrs-full_DilutedEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DilutedEarningsLossPerShare", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementBasicAndDilutedLossPerShareDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Diluted earnings (loss) per share", "terseLabel": "Diluted loss per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r70", "r71" ] }, "iva_Bsa20231ShareWarrantPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "Bsa20231ShareWarrantPlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA 2023-1 share warrants plan.", "label": "BSA 2023-1 Share Warrant Plan [Member]", "terseLabel": "BSA 2023 plan", "verboseLabel": "BSA 2023-1 share warrants plan" } } }, "auth_ref": [] }, "iva_LicensingAndCollaborationAgreementNetAmountReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LicensingAndCollaborationAgreementNetAmountReceived", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "Net amount received by the entity from licensing and collaborative arrangements.", "label": "Licensing And Collaboration Agreement, Net Amount Received", "terseLabel": "Net amount received" } } }, "auth_ref": [] }, "iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "FinanceContractWithEuropeanInvestmentBankFirstTrancheMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to first tranche of the finance contract with European Investment Bank (\"EIB\").", "label": "Finance Contract With European Investment Bank, First Tranche [Member]", "terseLabel": "Finance contract with EIB, first tranche" } } }, "auth_ref": [] }, "iva_LongTermIncentivePlanInPerformanceUnits2023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LongTermIncentivePlanInPerformanceUnits2023Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "documentation": "This member stands for 2023 long-term incentive plan in performance units or \"PAGUP 2023\".", "label": "Long-Term Incentive Plan In Performance Units, 2023 [Member]", "terseLabel": "PAGUP 2023" } } }, "auth_ref": [] }, "iva_WarrantAgreementWithEuropeanInvestmentBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "WarrantAgreementWithEuropeanInvestmentBankMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Warrant agreement with the European Investment Bank.", "label": "Warrant Agreement With The European Investment Bank [Member]", "terseLabel": "Warrant agreement with the European Investment Bank" } } }, "auth_ref": [] }, "iva_PercentageOfDiscountToVolumeWeightedAverageTradingPrice": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "PercentageOfDiscountToVolumeWeightedAverageTradingPrice", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of discount to volume weighted average trading price of shares applied to the price of the stock offering.", "label": "Percentage Of Discount To Volume Weighted Average Trading Price", "verboseLabel": "Percentage of discount to volume weighted average trading price" } } }, "auth_ref": [] }, "iva_NewBonusShareAwardPlan20231Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NewBonusShareAwardPlan20231Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2023-1).", "label": "New Bonus Share Award Plan 2023-1 [Member]", "terseLabel": "AGA Plan 2023-1" } } }, "auth_ref": [] }, "iva_IfrsDebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsDebtInstrumentTerm", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Ifrs Debt Instrument, Term", "verboseLabel": "Maturity term after the disbursement of the tranche" } } }, "auth_ref": [] }, "iva_MaximumDurationOfClinicalTrial": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "MaximumDurationOfClinicalTrial", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum duration of the clinical trial of the entity.", "label": "Maximum Duration Of The Clinical Trial", "verboseLabel": "Maximum duration of Phase III trial" } } }, "auth_ref": [] }, "iva_NumberOfWeeksUnderActiveTreatmentExtensionStudy": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NumberOfWeeksUnderActiveTreatmentExtensionStudy", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of weeks under the active treatment extension study of the entity.", "label": "Number Of Weeks Under The Active Treatment Extension Study", "verboseLabel": "Number of weeks under the active treatment extension study" } } }, "auth_ref": [] }, "iva_PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of Company's share capital outstanding, issued as warrants by the entity.", "label": "Percentage Of Company's Share Capital Outstanding, Issued As Warrants", "terseLabel": "Percentage of Company's share capital outstanding, issued as warrants" } } }, "auth_ref": [] }, "ifrs-full_LaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "LaterThanFiveYearsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "More than 5 years" } }, "en": { "role": { "documentation": "This member stands for a time band of later than five years." } } }, "auth_ref": [ "r137", "r138", "r185", "r228", "r234", "r237" ] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2022", "localname": "StatementScenarioAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": [] }, "iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOfCompanyOrThroughReceiptOfUpfrontOrMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "AggregateAmountToBeReceivedEitherInExchangeForNewSharesOfCompanyOrThroughReceiptOfUpfrontOrMilestonePayments", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "Aggregate amount to be received by the company, either in exchange for new shares of the Company or through the receipt of upfront or milestone payments, pursuant to the debt arrangement.", "label": "Aggregate Amount To Be Received Either In Exchange For New Shares Of The Company Or Through The Receipt Of Upfront Or Milestone Payments", "verboseLabel": "Aggregate amount to be received under the conditions precedent to the EIB Financing" } } }, "auth_ref": [] }, "iva_NumberOfBiopsiesUnderClinicalTrial": { "xbrltype": "intItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NumberOfBiopsiesUnderClinicalTrial", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2023-1).", "label": "Number Of Biopsies Under The Clinical Trial", "verboseLabel": "Number of biopsies under the Phase III trial" } } }, "auth_ref": [] }, "iva_NumberOfCountriesInWhichClinicalTrialHasBeenApproved": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NumberOfCountriesInWhichClinicalTrialHasBeenApproved", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of countries in which the entity's clinical trial has been approved", "label": "Number Of Countries In Which The Clinical Trial Has Been Approved", "terseLabel": "Number of countries in which the Phase III trial has been approved" } } }, "auth_ref": [] }, "iva_ClassOfWarrantOrRightExercisePriceOfWarrantsAsPercentageOfVolumeWeightedAveragePriceOfCompanySShares": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsAsPercentageOfVolumeWeightedAveragePriceOfCompanySShares", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Exercise price of warrants issued, represented as a percentage of volume-weighted average price of the Company's shares.", "label": "Class Of Warrant Or Right, Exercise Price Of Warrants As A Percentage Of Volume-Weighted Average Price Of The Company's Shares", "terseLabel": "Exercise price of warrants as a percentage of volume-weighted average price of the Company's shares" } } }, "auth_ref": [] }, "iva_PercentageOfActivatedSitesCurrentlyOperatingUnderRevisedDesignOfClinicalTrial": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "PercentageOfActivatedSitesCurrentlyOperatingUnderRevisedDesignOfClinicalTrial", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of activated sites currently operating under the revised design of the entity's clinical trial.", "label": "Percentage Of Activated Sites Currently Operating Under The Revised Design Of The Clinical Trial", "verboseLabel": "Percentage of activated sites currently operating under the revised design of Phase III trial" } } }, "auth_ref": [] }, "iva_ClassOfWarrantOrRightMaturityTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ClassOfWarrantOrRightMaturityTerm", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Maturity term of the warrants issued by the entity.", "label": "Class Of Warrant Or Right, Maturity Term", "terseLabel": "Maturity term of warrants" } } }, "auth_ref": [] }, "ifrs-full_NetDefinedBenefitLiabilityAssetMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NetDefinedBenefitLiabilityAssetMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetChangeInNetProvisionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetNetProvisionDetails" ], "lang": { "en-us": { "role": { "label": "Net defined benefit liability (asset) [member]" } }, "en": { "role": { "documentation": "This member stands for the net defined benefit liability (asset). It also represents the standard value for the 'Net defined benefit liability (asset)' axis if no other member is used. [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r55" ] }, "iva_PercentageOfOwnershipInterestHeld": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "PercentageOfOwnershipInterestHeld", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of ownership interest held by the entity.", "label": "Percentage Of Ownership Interest Held", "terseLabel": "Percentage of ownership interest" } } }, "auth_ref": [] }, "iva_StockIssuedDuringPeriodSharesExerciseOfWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrants", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued by the entity upon exercise of warrants.", "label": "Stock Issued During Period, Shares, Exercise Of Warrants", "terseLabel": "Number of shares issued upon exercise of warrants" } } }, "auth_ref": [] }, "iva_LicenseAndCollaborationAgreementMaximumAdditionalAmountReceivableUponAchievementOfCertainMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LicenseAndCollaborationAgreementMaximumAdditionalAmountReceivableUponAchievementOfCertainMilestones", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum additional amount receivable by the entity, upon the achievement of certain milestones, pursuant to licensing and collaborative arrangements.", "label": "License And Collaboration Agreement, Maximum Additional Amount Receivable Upon Achievement Of Certain Milestones", "terseLabel": "Maximum milestone payments receivable" } } }, "auth_ref": [] }, "iva_MaximumPotentialGrossProceedsFromExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "MaximumPotentialGrossProceedsFromExerciseOfWarrants", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum potential amount of gross proceeds that the company will receive from exercise of warrants.", "label": "Maximum Potential Gross Proceeds From Exercise Of Warrants", "terseLabel": "Maximum potential gross proceeds from exercise of warrants" } } }, "auth_ref": [] }, "iva_OtherComprehensiveIncomeNetOfTaxChangeInActuarialGainsAndLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "OtherComprehensiveIncomeNetOfTaxChangeInActuarialGainsAndLosses", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "The amount of other comprehensive income, net of tax, related to changes in actuarial gains and losses.", "label": "Other Comprehensive Income, Net Of Tax, Change In Actuarial Gains And Losses", "terseLabel": "Change in actuarial gains and losses" } } }, "auth_ref": [] }, "iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "FinanceContractWithEuropeanInvestmentBankSecondTrancheMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to second tranche of the finance contract with European investment bank (\"EIB\").", "label": "Finance Contract With European Investment Bank, Second Tranche [Member]", "terseLabel": "Finance contract with EIB, second tranche" } } }, "auth_ref": [] }, "iva_NetChangeInOtherNonCurrentFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NetChangeInOtherNonCurrentFinancialAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The amount represents net change in other non-current financial assets.", "label": "Net change in other non-current financial assets", "terseLabel": "Net change in other non-current financial assets" } } }, "auth_ref": [] }, "iva_NumberOfEqualTranches": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NumberOfEqualTranches", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent the information of number of equal tranches .", "label": "Number of Equal Tranches", "terseLabel": "Number of equal tranches" } } }, "auth_ref": [] }, "ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets carried at fair value through profit or loss" } }, "en": { "role": { "documentation": "This member stands for the financial assets at fair value through profit or loss category. [Refer: Financial assets at fair value through profit or loss]" } } }, "auth_ref": [ "r162" ] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements." } } }, "auth_ref": [ "r141" ] }, "iva_August2023FinancingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "August2023FinancingMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for August 2023 financing.", "label": "August 2023 financing [Member]", "terseLabel": "August 2023 financing" } } }, "auth_ref": [] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2022", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": [] }, "iva_LoanAgreementsWithSyndicateOfFrenchBanksMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LoanAgreementsWithSyndicateOfFrenchBanksMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for loan agreements with a syndicate of French banks.", "label": "Loan Agreements With Syndicate of French Banks [Member]", "verboseLabel": "Loan agreements with a syndicate of French banks" } } }, "auth_ref": [] }, "iva_DescriptionOfAccountingPolicyForSpecificDisclosureRequirementsForUnauditedInterimFinancialStatementsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DescriptionOfAccountingPolicyForSpecificDisclosureRequirementsForUnauditedInterimFinancialStatementsPolicyTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Specific disclosure requirements for unaudited interim financial statements.", "label": "Description Of Accounting Policy For Specific Disclosure Requirements For Unaudited Interim Financial Statements [Policy Text Block]", "terseLabel": "Specific disclosure requirements for unaudited interim financial statements" } } }, "auth_ref": [] }, "iva_MinimumUpfrontPaymentsForOutLicensingPartnershipOrRoyaltyTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "MinimumUpfrontPaymentsForOutLicensingPartnershipOrRoyaltyTransaction", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of minimum upfront payments for out-licensing, partnership or royalty transaction.", "label": "Minimum Upfront Payments For Out-Licensing, Partnership Or Royalty Transaction", "verboseLabel": "Minimum upfront payments for out-licensing, partnership or royalty transaction" } } }, "auth_ref": [] }, "iva_LongTermDepositForwardContractMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LongTermDepositForwardContractMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for long-term deposit forward contract.", "label": "Long-Term Deposit Forward Contract [Member]", "terseLabel": "Long-term deposit forward contract" } } }, "auth_ref": [] }, "iva_NumberOfDaysWrittenNoticeForAccessibilityOfLongTermDeposit": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NumberOfDaysWrittenNoticeForAccessibilityOfLongTermDeposit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of days written notice for long-term deposit to become accessible.", "label": "Number of days written notice for accessibility of long-term deposit", "terseLabel": "Number of days written notice for accessibility of long-term deposit" } } }, "auth_ref": [] }, "iva_EquityRecoveryLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "EquityRecoveryLoansMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for equity recovery loans.", "label": "Equity Recovery Loans [Member]", "terseLabel": "Equity recovery loans" } } }, "auth_ref": [] }, "iva_LongTermDepositsTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LongTermDepositsTerm", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Term of the long-term deposits of the entity.", "label": "Long-Term Deposits Term", "terseLabel": "Period of long-term deposit" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentDerivativeFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NoncurrentDerivativeFinancialLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 2.0 }, "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtDetails": { "parentTag": "ifrs-full_Borrowings", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current derivative financial liabilities", "terseLabel": "Long-term debt - derivatives", "verboseLabel": "Derivatives" } }, "en": { "role": { "documentation": "The amount of non-current derivative financial liabilities. [Refer: Derivative financial liabilities]" } } }, "auth_ref": [ "r265" ] }, "iva_NumberOfLoanAgreements": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NumberOfLoanAgreements", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of loan agreements.", "label": "Number of Loan Agreements", "terseLabel": "Number of loan agreements" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "StatementOfChangesInEquityLineItems", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments forfeited in share-based payment arrangement", "negatedLabel": "Forfeited/ Lapsed" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement." } } }, "auth_ref": [ "r293" ] }, "ifrs-full_StatementOfComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "StatementOfComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Unaudited interim condensed consolidated statement of comprehensive (income) loss" } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r257" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [text block]", "terseLabel": "Schedule of debt" } }, "en": { "role": { "documentation": "The disclosure of detailed information about borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r294" ] }, "ifrs-full_FinancialLiabilitiesAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "FinancialLiabilitiesAtFairValue", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities, at fair value", "verboseLabel": "Financial liabilities, at fair value" } }, "en": { "role": { "documentation": "The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]" } } }, "auth_ref": [ "r148" ] }, "ifrs-full_ClosingForeignExchangeRate": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ClosingForeignExchangeRate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceForeignExchangeRatesDetails" ], "lang": { "en-us": { "role": { "label": "Closing foreign exchange rate", "terseLabel": "Exchange rate at period end", "verboseLabel": "Exchange rate" } }, "en": { "role": { "documentation": "The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery." } } }, "auth_ref": [ "r264" ] }, "ifrs-full_ForeignExchangeLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ForeignExchangeLoss", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementFinancialIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Foreign exchange loss", "negatedLabel": "Foreign exchange losses" } }, "en": { "role": { "documentation": "The gross loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]" } } }, "auth_ref": [ "r8", "r61" ] }, "ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfOtherCurrentAssetsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of other current assets [text block]", "terseLabel": "Schedule of other current assets and receivables" } }, "en": { "role": { "documentation": "The disclosure of other current assets. [Refer: Other current assets]" } } }, "auth_ref": [ "r259" ] }, "ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CurrentAccruedIncomeIncludingCurrentContractAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Current accrued income including current contract assets", "terseLabel": "Current accrued income" } }, "en": { "role": { "documentation": "The amount of current accrued income including current contract assets. [Refer: Accrued income including contract assets]" } } }, "auth_ref": [ "r265", "r268" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r250" ] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for increase (decrease) in trade and other payables", "verboseLabel": "Increase / (decrease) in operating and other payables" } }, "en": { "role": { "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]" } } }, "auth_ref": [ "r289" ] }, "ifrs-full_CurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CurrentLiabilitiesAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current liabilities [abstract]", "terseLabel": "Current liabilities" } } }, "auth_ref": [] }, "ifrs-full_FinancialLiabilitiesAtAmortisedCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "FinancialLiabilitiesAtAmortisedCost", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities at amortised cost", "terseLabel": "Amortized cost of loan" } }, "en": { "role": { "documentation": "The amount of financial liabilities at amortised cost. The amortised cost is the amount at which financial liabilities are measured at initial recognition minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r165", "r192" ] }, "ifrs-full_DisclosureOfGoingConcernExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfGoingConcernExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Disclosure of going concern [text block]", "terseLabel": "Going concern" } }, "en": { "role": { "documentation": "The disclosure of the entity's ability to continue as a going concern." } } }, "auth_ref": [ "r259" ] }, "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Current tax expense (income) and adjustments for current tax of prior periods", "terseLabel": "Current taxes" } }, "en": { "role": { "documentation": "The amount of current tax expense (income) and adjustments for the current tax of prior periods. [Refer: Current tax expense (income); Adjustments for current tax of prior periods]" } } }, "auth_ref": [ "r271" ] }, "ifrs-full_OtherFinanceCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "OtherFinanceCost", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementFinancialIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Other finance cost", "negatedLabel": "Other financial expenses" } }, "en": { "role": { "documentation": "The amount of finance costs that the entity does not separately disclose in the same statement or note. [Refer: Finance costs]" } } }, "auth_ref": [ "r264" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityRegistrantName", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r250" ] }, "ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "FinancialAssetsAtAmortisedCostCategoryMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets carried at amortized cost" } }, "en": { "role": { "documentation": "This member stands for the financial assets at amortised cost category. [Refer: Financial assets at amortised cost]" } } }, "auth_ref": [ "r164" ] }, "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for unrealised foreign exchange losses (gains)", "terseLabel": "Exchange (gains) / losses" } }, "en": { "role": { "documentation": "Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r216", "r288" ] }, "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for recognition of revenue [text block]", "terseLabel": "Revenue" } }, "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for recognising revenue. [Refer: Revenue]\nEffective 2023-01-01: The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]" } } }, "auth_ref": [ "r295", "r296" ] }, "ifrs-full_BasicEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "BasicEarningsLossPerShare", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementBasicAndDilutedLossPerShareDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Basic earnings (loss) per share", "terseLabel": "Basic loss per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } } }, "auth_ref": [ "r70", "r71" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityFileNumber", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "ifrs-full_RelatedPartiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "RelatedPartiesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareWarrantsPlansDetails" ], "lang": { "en-us": { "role": { "label": "Related parties" } }, "en": { "role": { "documentation": "This member stands for related parties. Related parties are persons or entities that are related to the entity that is preparing its financial statements (the reporting entity). (a) A person or a close member of that person\u2019s family is related to a reporting entity if that person: (i) has control or joint control over the reporting entity; (ii) has significant influence over the reporting entity; or (iii) is a member of the key management personnel of the reporting entity or of a parent of the reporting entity. (b) An entity is related to a reporting entity if any of the following conditions applies: (i) The entity and the reporting entity are members of the same group (which means that each parent, subsidiary and fellow subsidiary is related to the others). (ii) One entity is an associate or joint venture of the other entity (or an associate or joint venture of a member of a group of which the other entity is a member). (iii) Both entities are joint ventures of the same third party. (iv) One entity is a joint venture of a third entity and the other entity is an associate of the third entity. (v) The entity is a post-employment benefit plan for the benefit of employees of either the reporting entity or an entity related to the reporting entity. If the reporting entity is itself such a plan, the sponsoring employers are also related to the reporting entity. (vi) The entity is controlled or jointly controlled by a person identified in (a). (vii) A person identified in (a)(i) has significant influence over the entity or is a member of the key management personnel of the entity (or of a parent of the entity). (viii) The entity, or any member of a group of which it is a part, provides key management personnel services to the reporting entity or to the parent of the reporting entity. [Refer: Joint ventures [member]; Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r64" ] }, "ifrs-full_DefinedBenefitObligationAtPresentValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DefinedBenefitObligationAtPresentValue", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetNetProvisionDetails": { "parentTag": "ifrs-full_LiabilityAssetOfDefinedBenefitPlans", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetNetProvisionDetails" ], "lang": { "en-us": { "role": { "label": "Defined benefit obligation, at present value", "verboseLabel": "Retirement benefit obligations" } }, "en": { "role": { "documentation": "The present value, without deducting any plan assets, of expected future payments required to settle the obligation resulting from employee service in the current and prior periods. [Refer: Plan assets, at fair value]" } } }, "auth_ref": [ "r279" ] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement", "terseLabel": "Exercise price (in euros)" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r293" ] }, "ifrs-full_OtherAdjustmentsForNoncashItems": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "OtherAdjustmentsForNoncashItems", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Other adjustments for non-cash items", "terseLabel": "Other" } }, "en": { "role": { "documentation": "Adjustments for non-cash items to reconcile profit (loss) to net cash flow from (used in) operating activities that the entity does not separately disclose in the same statement or note. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r288" ] }, "ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "PostemploymentBenefitExpenseDefinedContributionPlans", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Post-employment benefit expense, defined contribution plans", "terseLabel": "Post-employment benefit plans" } }, "en": { "role": { "documentation": "The amount of post-employment benefit expense relating to defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods." } } }, "auth_ref": [ "r58" ] }, "srt_CurrencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2022", "localname": "CurrencyAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Currency [Axis]" } } }, "auth_ref": [] }, "ifrs-full_FinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "FinanceCosts", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": -1.0, "order": 1.0 }, "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementFinancialIncomeAndExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Finance costs", "negatedTerseLabel": "Financial expenses", "negatedTotalLabel": "Total financial expenses" } }, "en": { "role": { "documentation": "The amount of costs associated with financing activities of the entity." } } }, "auth_ref": [ "r36" ] }, "ifrs-full_GrossCarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "GrossCarryingAmountMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetIntangibleAssetsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetInventoriesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Gross", "terseLabel": "Laboratory inventories" } }, "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]" } } }, "auth_ref": [ "r45", "r77", "r86", "r89", "r145", "r152", "r155", "r226", "r297", "r299" ] }, "ifrs-full_FinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "FinancialAssets", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets", "terseLabel": "Financial assets" } }, "en": { "role": { "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]" } } }, "auth_ref": [ "r148", "r151", "r152", "r155", "r226" ] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]", "verboseLabel": "Notes to the consolidated balance sheet" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for leases [text block]", "terseLabel": "Lease contracts" } }, "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.\nEffective 2023-01-01: The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time." } } }, "auth_ref": [ "r295", "r296" ] }, "ifrs-full_DisclosureOfIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfIntangibleAssetsLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [line items]", "verboseLabel": "Intangible Assets" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_OtherContingentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "OtherContingentLiabilitiesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "Other contingent liabilities [member]", "terseLabel": "Other" } }, "en": { "role": { "documentation": "This member stands for contingent liabilities that the entity does not separately disclose in the same statement or note. [Refer: Contingent liabilities [member]]" } } }, "auth_ref": [ "r207" ] }, "ifrs-full_OtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "OtherCurrentAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "iva_OtherCurrentAssetsAndReceivables", "weight": 1.0, "order": 2.0 }, "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Other current assets", "terseLabel": "Other current assets", "totalLabel": "Other current assets" } }, "en": { "role": { "documentation": "The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]" } } }, "auth_ref": [ "r265" ] }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivities", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) operating activities", "totalLabel": "Net cash used in operating activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]" } } }, "auth_ref": [ "r90", "r99" ] }, "ifrs-full_PropertyPlantAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "PropertyPlantAndEquipmentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, plant and equipment [member]" } }, "en": { "role": { "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r50", "r205", "r223" ] }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Expense from share-based payment transactions with employees", "negatedLabel": "Share-based payments" } }, "en": { "role": { "documentation": "The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]" } } }, "auth_ref": [ "r264" ] }, "ifrs-full_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Unaudited interim condensed consolidated statement of (income) loss" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NoncurrentAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current assets", "totalLabel": "Total non-current assets" } }, "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } } }, "auth_ref": [ "r24", "r110", "r218" ] }, "ifrs-full_Level3OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "Level3OfFairValueHierarchyMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "Level 3" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability." } } }, "auth_ref": [ "r123" ] }, "iva_IfrsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsCashAndCashEquivalentsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for cash and cash equivalents.", "label": "Cash and cash equivalents" } } }, "auth_ref": [] }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Effect of exchange rate changes on cash and cash equivalents", "terseLabel": "Exchange gains / (losses)" } }, "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r94", "r95" ] }, "ifrs-full_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ConstructionInProgressMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, plant and equipment in progress" } }, "en": { "role": { "documentation": "This member stands for expenditure capitalised during the construction of items of property, plant and equipment that are not yet available for use (ie not yet in the location and condition necessary for it to be capable of operating in the manner intended by the management). [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r273" ] }, "ifrs-full_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "General and administrative expense", "negatedLabel": "General and administrative expenses" } }, "en": { "role": { "documentation": "The amount of expense relating to general and administrative activities of the entity." } } }, "auth_ref": [ "r264" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "ifrs-full_EarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "EarningsPerShareExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementTables" ], "lang": { "en-us": { "role": { "label": "Earnings per share [text block]", "terseLabel": "Schedule of basic and diluted loss per share" } }, "en": { "role": { "documentation": "The disclosure of earnings per share." } } }, "auth_ref": [ "r70" ] }, "ifrs-full_PresentValueOfDefinedBenefitObligationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "PresentValueOfDefinedBenefitObligationMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetChangeInNetProvisionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetNetProvisionDetails" ], "lang": { "en-us": { "role": { "label": "Present value of defined benefit obligation [member]", "terseLabel": "Provision for defined benefit schemes" } }, "en": { "role": { "documentation": "This member stands for the present value of a defined benefit obligation. The present value of a defined benefit obligation is the present value, without deducting any plan assets, of expected future payments required to settle the obligation resulting from employee service in the current and prior periods." } } }, "auth_ref": [ "r54" ] }, "iva_NumberSitesRandomized": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NumberSitesRandomized", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "It represents the number of sites randomized", "label": "Number Sites Randomized" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressCountry", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Reconciliation of changes in intangible assets other than goodwill" } } }, "auth_ref": [] }, "ifrs-full_ShorttermBorrowingsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ShorttermBorrowingsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Short-term debt" } }, "en": { "role": { "documentation": "This member stands for short-term borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r215", "r217" ] }, "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "AdjustmentsForReconcileProfitLossAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile profit (loss) [abstract]", "terseLabel": "Elimination of non-cash or non-operating income and expenses" } } }, "auth_ref": [] }, "ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "IncomeTaxesPaidRefundClassifiedAsOperatingActivities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Income taxes paid (refund), classified as operating activities", "negatedLabel": "Tax credit received" } }, "en": { "role": { "documentation": "The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]" } } }, "auth_ref": [ "r96", "r210" ] }, "ifrs-full_LegalProceedingsProvisionMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "LegalProceedingsProvisionMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "AMR penalties" } }, "en": { "role": { "documentation": "This member stands for a provision for legal proceedings. [Refer: Other provisions [member]]" } } }, "auth_ref": [ "r206", "r208" ] }, "iva_AccruedPayrollAndOtherEmployeesRelatedTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "AccruedPayrollAndOtherEmployeesRelatedTaxes", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherCurrentLiabilitiesDetails": { "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount pertaining to accrued payroll and other employee related taxes.", "label": "Accrued Payroll And Other Employees Related Taxes", "verboseLabel": "Accrued payroll and other employeerelated taxes" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through other changes, property, plant and equipment", "terseLabel": "Others" } }, "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r47" ] }, "iva_FairValueVariationLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "FairValueVariationLosses", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementFinancialIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of fair value variation losses.", "label": "Fair Value Variation Losses", "negatedLabel": "Losses on fair value variation" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfGeographicalAreasExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfGeographicalAreasExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of geographical areas [text block]", "terseLabel": "Summary of entity's geographical split" } }, "en": { "role": { "documentation": "The disclosure of geographical information." } } }, "auth_ref": [ "r179" ] }, "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails" ], "lang": { "en-us": { "role": { "label": "Expected volatility, share options granted", "terseLabel": "Expected volatility" } }, "en": { "role": { "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time." } } }, "auth_ref": [ "r142" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [text block]", "terseLabel": "Schedule of financial assets and liabilities" } }, "en": { "role": { "documentation": "The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]" } } }, "auth_ref": [ "r149", "r153", "r161" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "iva_PercentageOfCurrentlyOperatingClinicalSites": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "PercentageOfCurrentlyOperatingClinicalSites", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of currently operating clinical sites", "label": "Percentage of currently operating clinical sites", "terseLabel": "Percentage of currently operating clinical sites" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialInstrumentsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of financial instruments." } } }, "auth_ref": [ "r149", "r153", "r161" ] }, "iva_NumberOfCountryInvolvedInClinicalStudiesAvailable": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NumberOfCountryInvolvedInClinicalStudiesAvailable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "It represents the number of countries involved in clinical studies.", "label": "Number of Country Involved in Clinical Studies Available", "terseLabel": "Number of extension countries involved in Phase III studies" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfFinancialAssetsTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of financial assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to financial assets." } } }, "auth_ref": [ "r161" ] }, "ifrs-full_LeaseLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "LeaseLiabilitiesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lease liabilities [member]", "terseLabel": "Lease liabilities", "verboseLabel": "Lease" } }, "en": { "role": { "documentation": "This member stands for lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r215", "r217" ] }, "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of subsidiaries [line items]", "terseLabel": "General principles and statement of compliance" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOtherProvisionsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfOtherProvisionsLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of other provisions [line items]", "terseLabel": "Other operating income and expenses" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "iva_LicensingAndCollaborationAgreementAmountInvoicedToCounterpartyNetOfWithholdingTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LicensingAndCollaborationAgreementAmountInvoicedToCounterpartyNetOfWithholdingTaxes", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount received by the entity from licensing and collaborative agreement counterparty, net of withholding taxes.", "label": "Licensing And Collaboration Agreement, Amount Invoiced To Counterparty, Net Of Withholding Taxes", "terseLabel": "Net amount" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails" ], "lang": { "en-us": { "role": { "label": "Risk free interest rate, share options granted", "terseLabel": "Risk free rate" } }, "en": { "role": { "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]" } } }, "auth_ref": [ "r142" ] }, "iva_DisclosureOfNotesToConsolidatedBalanceSheetTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DisclosureOfNotesToConsolidatedBalanceSheetTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for notes to the consolidated balance sheet.", "label": "Disclosure Of Notes To The Consolidated Balance Sheet [Text Block].", "terseLabel": "Notes to the consolidated balance sheet" } } }, "auth_ref": [] }, "iva_TradeReceivablesRelatingToReinvoicingOfShareOfCostsUnderLicensingAndCollaborationAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "TradeReceivablesRelatingToReinvoicingOfShareOfCostsUnderLicensingAndCollaborationAgreement", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of trade receivables related to reinvoicing of share of costs incurred under the licensing and collaboration agreements.", "label": "Trade Receivables Relating To Reinvoicing Of Share Of Costs Under Licensing And Collaboration Agreement", "terseLabel": "Reinvoicing of share of costs incurred included in trade receivables" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseInShortTermDepositAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IncreaseDecreaseInShortTermDepositAccounts", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in short-term deposit accounts.", "label": "Increase (Decrease) In Short-Term Deposit Accounts", "negatedLabel": "Decrease in short-term deposit accounts" } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DeferredTaxAssets", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDeferredTaxAssetDetails" ], "lang": { "en-us": { "role": { "label": "Deferred tax assets", "terseLabel": "Deferred tax asset" } }, "en": { "role": { "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } } }, "auth_ref": [ "r17", "r20", "r44" ] }, "ifrs-full_BuildingsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "BuildingsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Buildings" } }, "en": { "role": { "documentation": "This member stands for a class of plant, property and equipment representing depreciable buildings and similar structures for use in operations. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r273" ] }, "iva_AmountOfDepositsWhichHadChangeInMaturityTerm": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "AmountOfDepositsWhichHadChangeInMaturityTerm", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of deposits of the entity, which had change in maturity term.", "label": "Amount Of Deposits Which Had Change In Maturity Term", "terseLabel": "Amount of deposits with change in maturity term" } } }, "auth_ref": [] }, "iva_AmountOfDepositsClosed": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "AmountOfDepositsClosed", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of deposits of the entity closed during the period.", "label": "Amount Of Deposits Closed", "terseLabel": "Amount of deposits closed" } } }, "auth_ref": [] }, "ifrs-full_TradeAndOtherCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "TradeAndOtherCurrentPayables", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradePayablesDetails" ], "lang": { "en-us": { "role": { "label": "Trade and other current payables", "terseLabel": "Trade payables" } }, "en": { "role": { "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]" } } }, "auth_ref": [ "r13" ] }, "iva_NumberOfSitesRandom": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NumberOfSitesRandom", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of sites randomized", "label": "Number of Sites Random" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CityAreaCode", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "iva_NumberOfBiopsiesUnderClinicalTrials": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NumberOfBiopsiesUnderClinicalTrials", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "It represents the number of clinical trial.", "label": "Number Of Biopsies Under Clinical Trials", "terseLabel": "Number of Biopsies Under the Phase III trial" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [text block]", "terseLabel": "Schedule of changes in share capital" } }, "en": { "role": { "documentation": "The disclosure of classes of share capital. [Refer: Share capital [member]]" } } }, "auth_ref": [ "r31" ] }, "ifrs-full_FinancialAssetsAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "FinancialAssetsAtFairValue", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets, at fair value", "terseLabel": "Financial assets, at fair value" } }, "en": { "role": { "documentation": "The fair value of financial assets. [Refer: At fair value [member]; Financial assets]" } } }, "auth_ref": [ "r148" ] }, "ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ShorttermDepositsClassifiedAsCashEquivalents", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCashAndCashEquivalentsDetails": { "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCashAndCashEquivalentsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Short-term deposits, classified as cash equivalents", "terseLabel": "Short-term deposits", "verboseLabel": "Other cash equivalents" } }, "en": { "role": { "documentation": "A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]" } } }, "auth_ref": [ "r290" ] }, "ifrs-full_ClassesOfAssetsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ClassesOfAssetsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "Assets [member]" } }, "en": { "role": { "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used." } } }, "auth_ref": [ "r73", "r126", "r136" ] }, "iva_NumberOfBiopsiesUnderPhaseIiiTrial": { "xbrltype": "intItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NumberOfBiopsiesUnderPhaseIiiTrial", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "It represents the New bonus share award plans (AGA 2023-1).", "label": "Number of Biopsies Under the Phase III trial" } } }, "auth_ref": [] }, "ifrs-full_AtFairValueMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "AtFairValueMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "At fair value" } }, "en": { "role": { "documentation": "This member stands for measurement based on fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date." } } }, "auth_ref": [ "r84", "r88", "r122" ] }, "ifrs-full_NoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NoncurrentLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current liabilities", "totalLabel": "Total non-current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } } }, "auth_ref": [ "r25", "r112", "r218" ] }, "iva_CommitmentsAmountPayableForServicesReceivedUnderContracts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "CommitmentsAmountPayableForServicesReceivedUnderContracts", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum amount of bonus or malus payable on amount committed by the company to pay for services received under contract.", "label": "Commitments amount payable for services received under contracts" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "LocalPhoneNumber", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "iva_CommitmentAmountsPayablesForServicesReceivedUnderContracts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "CommitmentAmountsPayablesForServicesReceivedUnderContracts", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum amount of bonus or malus payable on amount committed by the company to pay for services received under contract.", "label": "Commitment Amounts Payables for Services Received Under Contracts", "terseLabel": "Commitments amount payable for services received under contracts" } } }, "auth_ref": [] }, "iva_LongtermDepositAccountsAndSecurityDepositsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LongtermDepositAccountsAndSecurityDepositsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for long term deposit accounts and security deposits.", "label": "Long-term deposit accounts and security deposits" } } }, "auth_ref": [] }, "iva_LicenseAndCollaborationAgreementShortTermPotentialMilestonePaymentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LicenseAndCollaborationAgreementShortTermPotentialMilestonePaymentReceivables", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of short-term potential milestone payment receivable by the entity under the license and collaboration agreement.", "label": "License And Collaboration Agreement, Short-Term Potential Milestone Payment Receivables", "verboseLabel": "Short-term potential milestone payment receivable" } } }, "auth_ref": [] }, "iva_NumberOfSiteRandomized": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NumberOfSiteRandomized", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails" ], "lang": { "en-us": { "role": { "documentation": "It represents the number of sites randomized", "label": "Number of Site Randomized", "terseLabel": "Number of site randomized" } } }, "auth_ref": [] }, "ifrs-full_LineItemsByFunctionMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "LineItemsByFunctionMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Line items by function [member]" } }, "en": { "role": { "documentation": "This member stands for the standard value of the \u2018Attribution of expenses by nature to their function' axis if no other member is used." } } }, "auth_ref": [ "r260", "r264" ] }, "ifrs-full_Inventories": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "Inventories", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetInventoriesDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current inventories", "terseLabel": "Inventories" } }, "en": { "role": { "documentation": "The amount of current inventories. [Refer: Inventories]" } } }, "auth_ref": [ "r11", "r60", "r196" ] }, "iva_ExpirationNoticePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ExpirationNoticePeriod", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The expiration of the term with a notice period.", "label": "Expiration Notice Period", "terseLabel": "Expiration term of notice period" } } }, "auth_ref": [] }, "iva_OtherIncomeReinvoicingOfSpecificCostsUnderServiceAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "OtherIncomeReinvoicingOfSpecificCostsUnderServiceAgreement", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount related to reinvoicing of specific costs incurred on services with customer research organization accrued liabilities included in other income.", "label": "Other Income, Reinvoicing Of Specific Costs Under Service Agreement", "terseLabel": "Reinvoicing of specific costs related to CRO accrued liabilities included in other income" } } }, "auth_ref": [] }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments exercisable in share-based payment arrangement", "terseLabel": "Number of exercisable shares" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement." } } }, "auth_ref": [ "r293" ] }, "iva_OtherIncomeRelatingToReinvoicingOfShareOfCostsUnderLicensingAndCollaborationAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "OtherIncomeRelatingToReinvoicingOfShareOfCostsUnderLicensingAndCollaborationAgreement", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount related to reinvoicing of share of costs incurred under the licensing and collaboration agreements included in other income.", "label": "Other Income, Relating To Reinvoicing Of Share Of Costs Under Licensing And Collaboration Agreement", "terseLabel": "Reinvoicing of share of costs incurred included in other income" } } }, "auth_ref": [] }, "ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CurrentReceivablesFromTaxesOtherThanIncomeTax", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "iva_OtherCurrentAssetsAndReceivables", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Current receivables from taxes other than income tax", "totalLabel": "Tax receivables" } }, "en": { "role": { "documentation": "The amount of current receivables from taxes other than income tax. [Refer: Receivables from taxes other than income tax]" } } }, "auth_ref": [ "r266" ] }, "iva_PercentageOfSeverancePaymentSubjectToPerformanceCondition": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "PercentageOfSeverancePaymentSubjectToPerformanceCondition", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of discount to percentage of severance payment subject to performance condition.", "label": "Percentage Of Severance Payment Subject To Performance Condition", "terseLabel": "Percentage of severance payment subject to performance condition" } } }, "auth_ref": [] }, "iva_SeverancePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "SeverancePayment", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of severance payment accrued.", "label": "Severance Payment", "terseLabel": "Severance payment" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtMovementsInPeriodBreakDownDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of borrowings." } } }, "auth_ref": [ "r294" ] }, "iva_CirAndOtherResearchTaxCreditsReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "CirAndOtherResearchTaxCreditsReceived", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of CIR and other research tax credits received during the period.", "label": "CIR and Other Research Tax Credits Received", "terseLabel": "CIR and other research tax credits received" } } }, "auth_ref": [] }, "iva_PeriodToBecomeEligibleForFreeAllotmentOfShares": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "PeriodToBecomeEligibleForFreeAllotmentOfShares", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails" ], "lang": { "en-us": { "role": { "documentation": "Period to become eligible for free allotment of shares .", "label": "Period To Become Eligible For Free Allotment Of Shares", "terseLabel": "Period to become eligible for free allotment of shares" } } }, "auth_ref": [] }, "ifrs-full_LaterThanOneYearMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "LaterThanOneYearMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "More than 12 months" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one year." } } }, "auth_ref": [ "r22", "r240", "r245" ] }, "iva_NumberOfDaysExercisedWithInEffectiveDateOfLicensingAgreement.": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NumberOfDaysExercisedWithInEffectiveDateOfLicensingAgreement.", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of days can be exercised within the effective date of the licensing agreement in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Number Of Days Exercised With In The Effective Date Of The Licensing Agreement.", "verboseLabel": "Number of days exercised within the effective date of the licensing agreement" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "Security12bTitle", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r249" ] }, "ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "IncreaseDecreaseInNumberOfSharesOutstanding", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in number of shares outstanding", "terseLabel": "Increase in liquidity agreement" } }, "en": { "role": { "documentation": "The increase (decrease) in the number of shares outstanding. [Refer: Number of shares outstanding]" } } }, "auth_ref": [ "r30" ] }, "iva_SubscriptionOfLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "SubscriptionOfLeaseLiabilities", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of subscription of lease liabilities.", "label": "Subscription Of Lease Liabilities", "terseLabel": "Subscription of lease liabilities" } } }, "auth_ref": [] }, "ifrs-full_DepreciationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DepreciationPropertyPlantAndEquipment", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Depreciation, property, plant and equipment", "terseLabel": "Depreciation charges" } }, "en": { "role": { "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]" } } }, "auth_ref": [ "r48", "r51" ] }, "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income that will be reclassified to profit or loss, net of tax", "verboseLabel": "Items recycled to income" } }, "en": { "role": { "documentation": "The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r200", "r201" ] }, "iva_LongTermIncentivePlanInPerformanceUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LongTermIncentivePlanInPerformanceUnitsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for long-term incentive plan in performance units or \"PAGUP\".", "label": "Long-Term Incentive Plan In Performance Units [Member]", "terseLabel": "PAGUP" } } }, "auth_ref": [] }, "ifrs-full_IssuedCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "IssuedCapital", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Issued capital", "terseLabel": "Share capital" } }, "en": { "role": { "documentation": "The nominal value of capital issued." } } }, "auth_ref": [ "r199" ] }, "ifrs-full_EquityAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "EquityAndLiabilitiesAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Equity and liabilities [abstract]", "terseLabel": "LIABILITIES AND SHAREHOLDERS' EQUITY" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfOptionLifeShareOptionsGranted": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DescriptionOfOptionLifeShareOptionsGranted", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails" ], "lang": { "en-us": { "role": { "label": "Option life, share options granted", "terseLabel": "Average life (years)" } }, "en": { "role": { "documentation": "The option life of share options granted." } } }, "auth_ref": [ "r142" ] }, "ifrs-full_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Unaudited interim condensed consolidated statement of financial position" } } }, "auth_ref": [] }, "ifrs-full_OtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "OtherCurrentLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradePayablesAndOtherCurrentLiabilitiesDetails": { "parentTag": "iva_TradePayablesAndOtherCurrentLiabilities", "weight": 1.0, "order": 1.0 }, "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 5.0 }, "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherCurrentLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherCurrentLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradePayablesAndOtherCurrentLiabilitiesDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Other current liabilities", "terseLabel": "Other current liabilities", "totalLabel": "Other current liabilities" } }, "en": { "role": { "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]" } } }, "auth_ref": [ "r265" ] }, "ifrs-full_ClassesOfFinancialInstrumentsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ClassesOfFinancialInstrumentsAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial instruments [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r151", "r153", "r155", "r156" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentAccountingStandard", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r253" ] }, "ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average fair value at measurement date, other equity instruments granted", "verboseLabel": "Fair value per AGA at grant date" } }, "en": { "role": { "documentation": "The weighted average fair value at the measurement date of granted equity instruments other than share options. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r143" ] }, "ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DescriptionOfAccountingPolicyForProvisionsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for provisions [text block]", "terseLabel": "Other provisions" } }, "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for provisions. [Refer: Provisions]\nEffective 2023-01-01: The description of the entity's material accounting policy information for provisions. [Refer: Provisions]" } } }, "auth_ref": [ "r295", "r296" ] }, "ifrs-full_Assets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets" } }, "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r19", "r122", "r123", "r125", "r172", "r175" ] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [line items]", "verboseLabel": "Property, Plant and Equipment" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "LaterThanOneMonthAndNotLaterThanTwoMonthsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradePayablesDetails" ], "lang": { "en-us": { "role": { "label": "Due in 30 60 days" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one month and not later than two months." } } }, "auth_ref": [ "r226", "r236", "r264", "r298" ] }, "ifrs-full_IncreaseDecreaseThroughOtherChangesNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "IncreaseDecreaseThroughOtherChangesNetDefinedBenefitLiabilityAsset", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetChangeInNetProvisionDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in net defined benefit liability (asset) resulting from other changes", "terseLabel": "Other changes" } }, "en": { "role": { "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r277" ] }, "ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DescriptionOfAccountingPolicyForSegmentReportingExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for segment reporting [text block]", "terseLabel": "Segment information" } }, "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for segment reporting.\nEffective 2023-01-01: The description of the entity's material accounting policy information for segment reporting." } } }, "auth_ref": [ "r295", "r296" ] }, "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfTradeAndOtherPayablesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of trade and other payables [text block]", "terseLabel": "Schedule of trade payables break down by payment" } }, "en": { "role": { "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]" } } }, "auth_ref": [ "r259" ] }, "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from borrowings, classified as financing activities", "terseLabel": "Subscription of borrowings", "verboseLabel": "Loan obtained" } }, "en": { "role": { "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]" } } }, "auth_ref": [ "r212" ] }, "ifrs-full_CurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CurrentAssetsAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current assets [abstract]", "terseLabel": "Current assets" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForTradingIncomeAndExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DescriptionOfAccountingPolicyForTradingIncomeAndExpenseExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for trading income and expense [text block]", "terseLabel": "Other operating income and expenses" } }, "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for trading income and expense. [Refer: Trading income (expense)]\nEffective 2023-01-01: The description of the entity's material accounting policy information for trading income and expense. [Refer: Trading income (expense)]" } } }, "auth_ref": [ "r295", "r296" ] }, "ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfOtherCurrentLiabilitiesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of other current liabilities [text block]", "terseLabel": "Schedule of other current liabilities" } }, "en": { "role": { "documentation": "The disclosure of other current liabilities. [Refer: Other current liabilities]" } } }, "auth_ref": [ "r259" ] }, "ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CumulativeEffectAtDateOfInitialApplicationAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "label": "Cumulative effect at date of initial application [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r262" ] }, "ifrs-full_Level2OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "Level2OfFairValueHierarchyMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "Level 2" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly." } } }, "auth_ref": [ "r123" ] }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Additions other than through business combinations, intangible assets other than goodwill", "terseLabel": "Increases" } }, "en": { "role": { "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r78" ] }, "ifrs-full_EquityAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "EquityAndLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Equity and liabilities", "totalLabel": "Total equity and liabilities" } }, "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } } }, "auth_ref": [ "r19" ] }, "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments granted in share-based payment arrangement", "terseLabel": "Issued", "verboseLabel": "Number of BSA issued" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement." } } }, "auth_ref": [ "r143", "r293" ] }, "ifrs-full_ShareIssueRelatedCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ShareIssueRelatedCost", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Share issue related cost", "negatedTerseLabel": "Transaction costs" } }, "en": { "role": { "documentation": "The amount of cost related to the issuance of shares." } } }, "auth_ref": [ "r261" ] }, "ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfInterestsInSubsidiariesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of interests in subsidiaries [text block]", "terseLabel": "Schedule of subsidiaries" } }, "en": { "role": { "documentation": "The disclosure of interests in subsidiaries. [Refer: Subsidiaries [member]]" } } }, "auth_ref": [ "r108" ] }, "ifrs-full_AdjustmentsForFinanceIncomeCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "AdjustmentsForFinanceIncomeCost", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for finance income (cost)", "negatedLabel": "Cost of net debt" } }, "en": { "role": { "documentation": "Adjustments for net finance income or cost to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income (cost); Profit (loss)]" } } }, "auth_ref": [ "r289" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [line items]", "terseLabel": "Shareholders' equity" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_RepaymentsOfCurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "RepaymentsOfCurrentBorrowings", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Repayments of current borrowings", "terseLabel": "Repayments of borrowings" } }, "en": { "role": { "documentation": "The cash outflow for repayments of current borrowings. [Refer: Current borrowings]" } } }, "auth_ref": [ "r286" ] }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NoncurrentLiabilitiesAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current liabilities [abstract]", "terseLabel": "Noncurrent liabilities" } } }, "auth_ref": [] }, "ifrs-full_FinanceIncomeCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "FinanceIncomeCost", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Finance income (cost)", "totalLabel": "Net financial income" } }, "en": { "role": { "documentation": "The amount of income or cost associated with interest and other financing activities of the entity." } } }, "auth_ref": [ "r270" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2022", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Disclosure of accounting judgements and estimates [text block]", "terseLabel": "Use of estimates and judgment" } }, "en": { "role": { "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]" } } }, "auth_ref": [ "r259" ] }, "ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "LaterThanThreeMonthsAndNotLaterThanSixMonthsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Between 3 and 6 months" } }, "en": { "role": { "documentation": "This member stands for a time band of later than three months and not later than six months." } } }, "auth_ref": [ "r228", "r230", "r237", "r240", "r243" ] }, "ifrs-full_OtherOperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "OtherOperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0, "order": 7.0 }, "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOtherOperatingIncomeAndExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOtherOperatingIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other operating income (expense)", "terseLabel": "Other operating income (expenses)", "totalLabel": "Other operating income (expenses)" } }, "en": { "role": { "documentation": "The amount of operating income (expense) that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r270" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2022", "localname": "MinimumMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails" ], "lang": { "en-us": { "role": { "label": "Minimum." } } }, "auth_ref": [] }, "ifrs-full_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "AssetsAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Assets [abstract]", "terseLabel": "ASSETS" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for trade and other receivables [text block]", "terseLabel": "Trade receivables" } }, "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for trade and other receivables. [Refer: Trade and other receivables]\nEffective 2023-01-01: The description of the entity's material accounting policy information for trade and other receivables. [Refer: Trade and other receivables]" } } }, "auth_ref": [ "r295", "r296" ] }, "ifrs-full_LossesOnDisposalsOfNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "LossesOnDisposalsOfNoncurrentAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOtherOperatingIncomeAndExpensesDetails": { "parentTag": "ifrs-full_MiscellaneousOtherOperatingExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Losses on disposals of non-current assets", "negatedLabel": "Disposals of assets" } }, "en": { "role": { "documentation": "The losses on disposals of non-current assets. [Refer: Non-current assets]" } } }, "auth_ref": [ "r264" ] }, "ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "AmortisationIntangibleAssetsOtherThanGoodwill", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Amortisation, intangible assets other than goodwill", "terseLabel": "Depreciation expenses" } }, "en": { "role": { "documentation": "The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r80" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "ifrs-full_CarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CarryingAmountMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetIntangibleAssetsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetInventoriesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Carrying amount [member]" } }, "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]" } } }, "auth_ref": [ "r49", "r81", "r85", "r87", "r88", "r145", "r151", "r152", "r241", "r246" ] }, "ifrs-full_NoncurrentDepositsFromCustomers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NoncurrentDepositsFromCustomers", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsDetails": { "parentTag": "ifrs-full_OtherNoncurrentAssets", "weight": -1.0, "order": 6.0 } }, "lang": { "en-us": { "role": { "label": "Non-current deposits from customers" } }, "en": { "role": { "documentation": "The amount of non-current deposits from customers. [Refer: Deposits from customers]" } } }, "auth_ref": [ "r265" ] }, "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ProportionOfOwnershipInterestInSubsidiary", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Proportion of ownership interest in subsidiary", "terseLabel": "Percent of ownership interest" } }, "en": { "role": { "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]" } } }, "auth_ref": [ "r66", "r68", "r107" ] }, "ifrs-full_CurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CurrentLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current liabilities", "totalLabel": "Total current liabilities" } }, "en": { "role": { "documentation": "Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.\nEffective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } } }, "auth_ref": [ "r25", "r111", "r218" ] }, "ifrs-full_DisclosureOfDefinedBenefitPlansLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfDefinedBenefitPlansLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetChangeInNetProvisionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetNetProvisionDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of defined benefit plans [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_CommunicationAndNetworkEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CommunicationAndNetworkEquipmentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Technical facilities, equipment and tooling" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing communications and network equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r273" ] }, "ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Reconciliation of changes in property, plant and equipment [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Research and development expense", "negatedLabel": "Research and development costs" } }, "en": { "role": { "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss." } } }, "auth_ref": [ "r83" ] }, "ifrs-full_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "EquityAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Equity [abstract]", "terseLabel": "Shareholders' equity" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [line items]", "terseLabel": "Foreign currency forwards contract", "verboseLabel": "Licensing agreement with Hepalys" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "iva_BorrowingsEffectiveInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "BorrowingsEffectiveInterestRate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "The effective interest rate on borrowings.", "label": "Borrowings, effective interest rate" } } }, "auth_ref": [] }, "ifrs-full_PastServiceCostAndLossesGainsArisingFromSettlementsDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "PastServiceCostAndLossesGainsArisingFromSettlementsDefinedBenefitPlans", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetBreakdownOfExpenseRecognizedForPeriodDetails": { "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetBreakdownOfExpenseRecognizedForPeriodDetails" ], "lang": { "en-us": { "role": { "label": "Past service cost and losses (gains) arising from settlements, defined benefit plans", "negatedLabel": "Benefits for the period" } }, "en": { "role": { "documentation": "The amount of expense (income) resulting from past service cost and losses (gains) arising from settlements. [Refer: Post-employment benefit expense in profit or loss, defined benefit plans; Past service cost, defined benefit plans] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from past service cost and losses (gains) arising from settlements]" } } }, "auth_ref": [ "r276" ] }, "ifrs-full_TradeReceivablesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "TradeReceivablesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Trade receivables" } }, "en": { "role": { "documentation": "This member stands for trade receivables. [Refer: Trade receivables]" } } }, "auth_ref": [ "r150", "r154", "r226", "r264" ] }, "iva_WarrantsUnitFairValue": { "xbrltype": "decimalItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "WarrantsUnitFairValue", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Unit fair value used to calculate fair value of warrants.", "label": "Warrants, Unit Fair Value", "terseLabel": "Unit fair value (\u20ac)" } } }, "auth_ref": [] }, "ifrs-full_MiscellaneousOtherOperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "MiscellaneousOtherOperatingIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOtherOperatingIncomeAndExpensesDetails": { "parentTag": "ifrs-full_OtherOperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Miscellaneous other operating income", "totalLabel": "Total other operating income" } }, "en": { "role": { "documentation": "The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]" } } }, "auth_ref": [ "r264" ] }, "iva_IfrsScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "IFRS Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of inventories" } } }, "auth_ref": [] }, "ifrs-full_SignificantInvestmentsInAssociatesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "SignificantInvestmentsInAssociatesAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "Associates [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r67", "r69", "r121", "r189", "r191" ] }, "ifrs-full_FinancialLiabilitiesCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "FinancialLiabilitiesCategoryMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities, category [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated categories of financial liabilities. It also represents the standard value for the 'Categories of financial liabilities' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r166" ] }, "iva_ScheduleOfInventoryDisclosureTable": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ScheduleOfInventoryDisclosureTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetInventoriesDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule disclosing information related to inventories.", "label": "Schedule of Inventory Disclosure [Table]" } } }, "auth_ref": [] }, "iva_DisclosureOfTradeReceivablesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DisclosureOfTradeReceivablesTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of trade receivables.", "label": "Disclosure of Trade Receivables [Table Text Block]", "terseLabel": "Schedule of trade receivables" } } }, "auth_ref": [] }, "ifrs-full_NotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NotionalAmount", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "label": "Notional amount", "verboseLabel": "Total amount of loan" } }, "en": { "role": { "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument." } } }, "auth_ref": [ "r264" ] }, "iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.", "label": "Trade Receivables and Other Current Assets and Receivables [Line Items]", "terseLabel": "Trade receivables, tax receivables and other current assets" } } }, "auth_ref": [] }, "iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "TradeReceivablesAndOtherCurrentAssetsAndReceivablesTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule disclosing information related to trade receivables and other current assets and receivables.", "label": "Trade Receivables and Other Current Assets and Receivables [Table]" } } }, "auth_ref": [] }, "iva_WarrantsCapOfPutOption": { "xbrltype": "decimalItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "WarrantsCapOfPutOption", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Cap of the put option used to calculate fair value of warrants.", "label": "Warrants, Cap of Put Option", "terseLabel": "Cap of the put option (m\u20ac)" } } }, "auth_ref": [] }, "iva_ScheduleOfInventoryDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ScheduleOfInventoryDisclosureLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetInventoriesDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.", "label": "Schedule of Inventory Disclosure [Line Items]", "terseLabel": "Inventories" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromIssuingShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ProceedsFromIssuingShares", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from issuing shares", "terseLabel": "Capital increase", "verboseLabel": "Proceeds from issuance of shares" } }, "en": { "role": { "documentation": "The cash inflow from issuing shares." } } }, "auth_ref": [ "r211" ] }, "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "AttributionOfExpensesByNatureToTheirFunctionAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Attribution of expenses by nature to their function [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r260", "r264" ] }, "iva_SocieteGeneraleMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "SocieteGeneraleMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCashAndCashEquivalentsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Societe Generale.", "label": "Societe Generale" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows used in operations before tax, interest and changes in working capital", "totalLabel": "Cash flows used in operations before tax, interest and changes in working capital" } }, "en": { "role": { "documentation": "The cash inflow (outflow) from the entity's operations before changes in working capital." } } }, "auth_ref": [ "r216", "r289" ] }, "iva_IncreaseDecreaseInTradeAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IncreaseDecreaseInTradeAccountsPayable", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradePayablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in trade accounts payable", "label": "Increase (decrease) in trade accounts payable", "terseLabel": "Increase in trade accounts payable" } } }, "auth_ref": [] }, "iva_StatementOfComplianceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "StatementOfComplianceAbstract", "lang": { "en-us": { "role": { "documentation": "N/A", "label": "Basis of preparation and statement of compliance" } } }, "auth_ref": [] }, "iva_LeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LeaseTerm", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Lease term", "label": "Lease term" } } }, "auth_ref": [] }, "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "PostemploymentBenefitExpenseDefinedBenefitPlans", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetBreakdownOfExpenseRecognizedForPeriodDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetBreakdownOfExpenseRecognizedForPeriodDetails" ], "lang": { "en-us": { "role": { "label": "Post-employment benefit expense, defined benefit plans", "negatedTotalLabel": "Total" } }, "en": { "role": { "documentation": "The amount of post-employment benefit expense included in profit or loss relating to defined benefit plans. [Refer: Profit (loss); Defined benefit plans [member]] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from expense (income) in profit or loss]" } } }, "auth_ref": [ "r276", "r278" ] }, "iva_AccountingPrinciplesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "AccountingPrinciplesAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Accounting Principles" } } }, "auth_ref": [] }, "ifrs-full_AllLevelsOfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "AllLevelsOfFairValueHierarchyMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "All levels of fair value hierarchy [member]" } }, "en": { "role": { "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used." } } }, "auth_ref": [ "r57", "r123" ] }, "ifrs-full_UnobservableInputsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "UnobservableInputsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "label": "Unobservable inputs [member]" } }, "en": { "role": { "documentation": "This member stands for all the unobservable inputs. It also represents the standard value for the 'Unobservable inputs' axis if no other member is used." } } }, "auth_ref": [ "r124", "r292" ] }, "iva_ReversalOfOtherProvisionsIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ReversalOfOtherProvisionsIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOtherOperatingIncomeAndExpensesDetails": { "parentTag": "ifrs-full_MiscellaneousOtherOperatingIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Reversal of other provisions, income", "label": "Reversal of other provisions, income", "terseLabel": "Reversal of provision" } } }, "auth_ref": [] }, "iva_Ifrs16Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "Ifrs16Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for IFRS 16.", "label": "IFRS 16" } } }, "auth_ref": [] }, "iva_ExchangeRateOnInvoice": { "xbrltype": "pureItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ExchangeRateOnInvoice", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "This amount represents the information of exchange rate on ratio of invoice.", "label": "Exchange Rate On Invoice", "terseLabel": "Exchange rate on invoice" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for intangible assets other than goodwill [text block]", "terseLabel": "Intangible assets" } }, "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]\nEffective 2023-01-01: The description of the entity's material accounting policy information for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r295", "r296" ] }, "iva_ProceedsFromLicensingArrangements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ProceedsFromLicensingArrangements", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount paid on licensing arrangements.", "label": "Proceeds From Licensing Arrangements", "terseLabel": "Amount received on licensing arrangements" } } }, "auth_ref": [] }, "ifrs-full_CurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CurrentContractLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current contract liabilities", "terseLabel": "Short-term contract liabilities" } }, "en": { "role": { "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]" } } }, "auth_ref": [ "r128" ] }, "ifrs-full_MeasurementAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "MeasurementAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "Measurement [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r84", "r88", "r122" ] }, "iva_DescriptionOfAccountingPolicyForOtherIncomePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DescriptionOfAccountingPolicyForOtherIncomePolicyTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "documentation": "The description of the entity's accounting policy for other income.", "label": "Description Of Accounting Policy For Other Income [Policy Text Block]", "terseLabel": "Other income" } } }, "auth_ref": [] }, "ifrs-full_UnderlyingEquityInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "UnderlyingEquityInstrumentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "label": "Underlying equity instrument [member]" } }, "en": { "role": { "documentation": "This member represents the standard value for the \u2018Underlying equity instrument and depositary receipts\u2019 axis if no other member is used." } } }, "auth_ref": [ "r264" ] }, "iva_DescriptionOfAccountingPolicyForNonCurrentAssetsOtherThanPropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DescriptionOfAccountingPolicyForNonCurrentAssetsOtherThanPropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "documentation": "The description of the entity's accounting policy for non-current assets other than property, plant and equipment.", "label": "Description Of Accounting Policy For Non Current Assets Other Than Property, Plant And Equipment [Policy Text Block]", "terseLabel": "Other non-current assets" } } }, "auth_ref": [] }, "iva_WarrantsStockPrice": { "xbrltype": "decimalItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "WarrantsStockPrice", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Stock price used to calculate fair value of warrants.", "label": "Warrants, Stock Price", "terseLabel": "Stock price (\u20ac)" } } }, "auth_ref": [] }, "ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Other inflows (outflows) of cash, classified as investing activities", "verboseLabel": "Decrease / (Increase) in other noncurrent financial assets" } }, "en": { "role": { "documentation": "Inflows (outflows) of cash, classified as investing activities, that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r93" ] }, "iva_DerivativeInstrumentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DerivativeInstrumentsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for derivative instruments.", "label": "Derivative instruments" } } }, "auth_ref": [] }, "iva_LibraryOfCompoundsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LibraryOfCompoundsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for library of compounds.", "label": "Library of compounds" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ClassesOfPropertyPlantAndEquipmentAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Classes of property, plant and equipment [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r50" ] }, "iva_RateOfContractsInProgressOnLeaseLiabilities": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "RateOfContractsInProgressOnLeaseLiabilities", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the rate of percentage in contract progress.", "label": "Rate Of Contracts In Progress On Lease Liabilities", "terseLabel": "Rates of contracts in progress" } } }, "auth_ref": [] }, "ifrs-full_FinancialLiabilitiesAtAmortisedCostMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "FinancialLiabilitiesAtAmortisedCostMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities at amortised cost, class [member]", "terseLabel": "Financial liabilities at amortized cost" } }, "en": { "role": { "documentation": "This member stands for the financial liabilities measured at amortised cost class. [Refer: Financial liabilities at amortised cost]" } } }, "auth_ref": [ "r167" ] }, "ifrs-full_LongtermBorrowingsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "LongtermBorrowingsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Long-term debt" } }, "en": { "role": { "documentation": "This member stands for long-term borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r215", "r217" ] }, "iva_MonetaryUcitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "MonetaryUcitsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Monetary UCITS.", "label": "Monetary UCITS" } } }, "auth_ref": [] }, "iva_CreditAgricoleBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "CreditAgricoleBankMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Credit Agricole Bank.", "label": "Crdit Agricole bank [Member]" } } }, "auth_ref": [] }, "iva_AmountInvoicedToCounterparty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "AmountInvoicedToCounterparty", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "This amount represents the information of invoiced to counterparty.", "label": "Amount Invoiced To Counterparty", "terseLabel": "Milestone payment received", "verboseLabel": "Amount invoiced to counterparty" } } }, "auth_ref": [] }, "iva_AmountInvoicedToCounterpartyForAdditionalPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "AmountInvoicedToCounterpartyForAdditionalPayment", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "This amount represents the information of invoiced to counterparty for additional payment.", "label": "Amount Invoiced To Counterparty For Additional Payment", "terseLabel": "Amount invoiced to counterparty for additional payment" } } }, "auth_ref": [] }, "iva_LongTermDepositAccountsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LongTermDepositAccountsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for long term deposit accounts.", "label": "Long-term deposit accounts" } } }, "auth_ref": [] }, "iva_AmountInvoicedToCounterpartyForInitialPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "AmountInvoicedToCounterpartyForInitialPayment", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "This amount represents the information of invoiced to counterparty for initial payment.", "label": "Amount Invoiced To Counterparty For Initial Payment", "terseLabel": "Amount invoiced to counterparty for milestone payment" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseThroughShareWarrantsSubscriptionPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IncreaseDecreaseThroughShareWarrantsSubscriptionPremium", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "The increase decrease in reserves resulting from BSA share warrants subscription premium.", "label": "Increase (Decrease) Through Share Warrants Subscription Premium", "terseLabel": "BSA share warrants subscription premium" } } }, "auth_ref": [] }, "ifrs-full_Equity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "Equity", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareCapitalDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Equity", "periodEndLabel": "Balance at the end", "periodStartLabel": "Balance at the beginning", "totalLabel": "Shareholders' equity", "verboseLabel": "Shareholders' equity" } }, "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } } }, "auth_ref": [ "r19", "r28", "r101", "r103", "r122", "r123", "r125" ] }, "iva_WarrantsThresholdTradingDays": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "WarrantsThresholdTradingDays", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Threshold number of specified trading days that common stock price to conversion price of warrants must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.", "label": "Warrants, Threshold Trading Days", "terseLabel": "Threshold trading days of warrants" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfProvisionsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ClassesOfProvisionsAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Classes of other provisions [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r75" ] }, "iva_DisclosureOfOtherNoncurrentAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DisclosureOfOtherNoncurrentAssetsTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of other non current assets.", "label": "Disclosure Of Other Noncurrent Assets [Table Text Block]", "terseLabel": "Schedule of other non current assets" } } }, "auth_ref": [] }, "iva_AmendedReimbursementPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "AmendedReimbursementPeriod", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amended reimbursement period", "label": "Amended reimbursement period" } } }, "auth_ref": [] }, "ifrs-full_RetainedEarningsProfitLossForReportingPeriod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "RetainedEarningsProfitLossForReportingPeriod", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Retained earnings, profit (loss) for reporting period", "terseLabel": "Net loss for the period" } }, "en": { "role": { "documentation": "A component of equity representing the entity\u2019s undistributed profit or loss for the reporting period. [Refer: Retained earnings; Profit (loss)]" } } }, "auth_ref": [ "r267" ] }, "iva_TransactionsCostsIncurredFromWarrantsExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "TransactionsCostsIncurredFromWarrantsExercises", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of transactions costs incurred from warrants exercises.", "label": "Transactions Costs Incurred From Warrants Exercises", "terseLabel": "Transactions costs" } } }, "auth_ref": [] }, "iva_NonCurrentSecurityDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NonCurrentSecurityDeposits", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsDetails": { "parentTag": "ifrs-full_OtherNoncurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "The non-current amount of security deposits.", "label": "Non-current Security Deposits", "terseLabel": "Security deposits" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) decrease (increase) in short-term deposits and investments", "terseLabel": "Decrease / (Increase) in short-term deposit accounts" } }, "en": { "role": { "documentation": "The cash inflow (outflow) due to a decrease (increase) in short-term deposits and investments." } } }, "auth_ref": [ "r285" ] }, "ifrs-full_ShorttermContractsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ShorttermContractsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Short-term contract liabilities" } }, "en": { "role": { "documentation": "This member stands for short-term contracts with customers." } } }, "auth_ref": [ "r222" ] }, "iva_ServiceContractWithAvantSanteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ServiceContractWithAvantSanteMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for service contract with Avant Sante.", "label": "Service contract with Avant Sante [Member]", "terseLabel": "Service contract with Avant Sante" } } }, "auth_ref": [] }, "iva_IncreaseOrDecreaseInBorrowingsDueToChangeInFairValueOfDerivativesInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IncreaseOrDecreaseInBorrowingsDueToChangeInFairValueOfDerivativesInstruments", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase or decrease in borrowings due to change in fair value of derivatives instruments.", "label": "Increase Or Decrease In Borrowings Due To Change in Fair Value of Derivatives Instruments", "terseLabel": "Change in fair value of derivatives instruments" } } }, "auth_ref": [] }, "ifrs-full_IssuedCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "IssuedCapitalMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareCapitalDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Share capital" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } } }, "auth_ref": [ "r6" ] }, "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInAssociatesLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "Other financial information [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "WeightedAverageShares", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementBasicAndDilutedLossPerShareDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Weighted average number of ordinary shares used in calculating basic earnings per share", "terseLabel": "Weighted average number of shares outstanding used to calculate basic loss per share" } }, "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } } }, "auth_ref": [ "r72" ] }, "ifrs-full_EntitysTotalForRelatedPartiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "EntitysTotalForRelatedPartiesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareWarrantsPlansDetails" ], "lang": { "en-us": { "role": { "label": "Entity's total for related parties [member]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } } }, "auth_ref": [ "r64" ] }, "ifrs-full_CurrentTaxAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CurrentTaxAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsDetails": { "parentTag": "ifrs-full_OtherNoncurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Current tax assets, non-current", "terseLabel": "Tax loss carry back" } }, "en": { "role": { "documentation": "The non-current amount of current tax assets. [Refer: Current tax assets]" } } }, "auth_ref": [ "r16" ] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss": { "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans", "terseLabel": "Actuarial gains and losses on retirement benefit obligations (IAS 19)", "verboseLabel": "Actuarial gains and losses, net of deferred tax" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [member]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]" } } }, "auth_ref": [ "r26", "r38", "r276" ] }, "iva_EstimatedAmountPayableUnderAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "EstimatedAmountPayableUnderAgreement", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the estimated amount payable under the agreement.", "label": "Estimated Amount Payable Under Agreement", "terseLabel": "Estimated amount payable" } } }, "auth_ref": [] }, "ifrs-full_SharePremiumMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "SharePremiumMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareCapitalDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Premiums related to share capital" } }, "en": { "role": { "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r6" ] }, "iva_OtherNonCurrentAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "OtherNonCurrentAssetsTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule disclosing information related to other non-current assets.", "label": "Other Non Current Assets [Table]" } } }, "auth_ref": [] }, "iva_NumberOfSubjectsRandomized": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NumberOfSubjectsRandomized", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of subjects randomized.", "label": "Number of Subjects Randomized", "terseLabel": "Number of subjects randomized" } } }, "auth_ref": [] }, "ifrs-full_LongtermContractsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "LongtermContractsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Long-term contract liabilities" } }, "en": { "role": { "documentation": "This member stands for long-term contracts with customers." } } }, "auth_ref": [ "r222" ] }, "ifrs-full_UnobservableInputsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "UnobservableInputsAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "label": "Unobservable inputs [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r124", "r292" ] }, "iva_OtherNonCurrentAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "OtherNonCurrentAssetsLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.", "label": "Other Non Current Assets [Line Items]", "verboseLabel": "Other Non Current Assets" } } }, "auth_ref": [] }, "ifrs-full_RightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "RightofuseAssets", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Right-of-use assets", "verboseLabel": "Leased equipment" } }, "en": { "role": { "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee." } } }, "auth_ref": [ "r135" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "iva_Fees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "Fees", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to fees.", "label": "Fees", "negatedLabel": "Fees" } } }, "auth_ref": [] }, "iva_SupportCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "SupportCosts", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to support costs.", "label": "Support costs", "negatedLabel": "Support costs (including taxes)" } } }, "auth_ref": [] }, "iva_OtherOperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "OtherOperatingExpenses", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to other operating expenses.", "label": "Other operating expenses", "negatedLabel": "Other operating expenses" } } }, "auth_ref": [] }, "iva_CurrentTaxCreditResearchIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "CurrentTaxCreditResearchIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementRevenuesAndOtherIncomeDetails": { "parentTag": "iva_OtherIncomeFromOrdinaryActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementRevenuesAndOtherIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of income from tax credit research.", "label": "Current Tax Credit Research Income", "terseLabel": "Tax credits" } } }, "auth_ref": [] }, "iva_DepreciationAmortizationAndProvisions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DepreciationAmortizationAndProvisions", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to depreciation, amortization and provisions.", "label": "Depreciation, amortization and provisions", "negatedLabel": "Depreciation, amortization and provisions" } } }, "auth_ref": [] }, "ifrs-full_SharebasedPaymentArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "SharebasedPaymentArrangementsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetNetProvisionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "label": "Sharebased compensation expense" } }, "en": { "role": { "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used." } } }, "auth_ref": [ "r141" ] }, "ifrs-full_ComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ComprehensiveIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive income", "totalLabel": "Total comprehensive loss" } }, "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } } }, "auth_ref": [ "r1", "r34", "r102", "r104", "r113", "r218" ] }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Expense from share-based payment transactions in which goods or services received did not qualify for recognition as assets", "terseLabel": "Share based payment expense" } }, "en": { "role": { "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets." } } }, "auth_ref": [ "r144" ] }, "iva_ItSystems": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ItSystems", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to it systems.", "label": "IT Systems", "negatedLabel": "IT systems" } } }, "auth_ref": [] }, "iva_Studies": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "Studies", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to studies.", "label": "Studies", "negatedLabel": "Studies" } } }, "auth_ref": [] }, "ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "label": "Opening balance before adjustment, cumulative effect at date of initial application [member]" } }, "en": { "role": { "documentation": "This member indicates the opening balance before the cumulative effect adjustment in the financial statements at the date of initial application of a new or amended IFRS Standard. It also represents the standard value for the \u2018Cumulative effect at date of initial application\u2019 axis if no other member is used." } } }, "auth_ref": [ "r262" ] }, "iva_Patents": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "Patents", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to patents.", "label": "Patents", "negatedLabel": "Patents" } } }, "auth_ref": [] }, "ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "RetainedEarningsProfitLossForReportingPeriodMember", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Retained earnings, profit (loss) for reporting period [member]", "terseLabel": "Net income (loss) for the period" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing the entity\u2019s undistributed profit or loss for the reporting period. [Refer: Retained earnings [member]; Profit (loss)]" } } }, "auth_ref": [ "r263" ] }, "ifrs-full_Borrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "Borrowings", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtMovementsInPeriodBreakDownDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Borrowings", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total debt", "verboseLabel": "Total debt" } }, "en": { "role": { "documentation": "The amount of outstanding funds that the entity is obligated to repay." } } }, "auth_ref": [ "r265" ] }, "iva_Bsa2017PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "Bsa2017PlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA - 2017 plan.", "label": "BSA - 2017 plan" } } }, "auth_ref": [] }, "iva_BsaPlansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "BsaPlansMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA plans.", "label": "BSA plans" } } }, "auth_ref": [] }, "ifrs-full_ExpectedDividendShareOptionsGranted": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ExpectedDividendShareOptionsGranted", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails" ], "lang": { "en-us": { "role": { "label": "Expected dividend, share options granted", "terseLabel": "Expected dividends" } }, "en": { "role": { "documentation": "The amount of an expected dividend used to calculate the fair value of share options granted." } } }, "auth_ref": [ "r142" ] }, "ifrs-full_ProfitLossFromOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ProfitLossFromOperatingActivities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Profit (loss) from operating activities", "totalLabel": "Net operating loss" } }, "en": { "role": { "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r204", "r270" ] }, "ifrs-full_NotLaterThanOneYearMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NotLaterThanOneYearMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Less than 1 year" } }, "en": { "role": { "documentation": "This member stands for a time band of not later than one year." } } }, "auth_ref": [ "r21", "r137", "r138", "r185", "r228", "r237" ] }, "ifrs-full_NonadjustingEventsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NonadjustingEventsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "label": "Non-adjusting events after reporting period [member]", "terseLabel": "Non-adjusting events after reporting period [member]" } }, "en": { "role": { "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used." } } }, "auth_ref": [ "r40" ] }, "iva_Bsa2018PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "Bsa2018PlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA - 2018 plan.", "label": "BSA - 2018 plan" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information", "documentation": "Cover page." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of effect of changes in foreign exchange rates [text block]", "terseLabel": "Schedule of exchange rates" } }, "en": { "role": { "documentation": "The entire disclosure for the effect of changes in foreign exchange rates." } } }, "auth_ref": [ "r63" ] }, "iva_Bsa2019PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "Bsa2019PlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA - 2019 plan.", "label": "BSA - 2019 plan [Member]" } } }, "auth_ref": [] }, "iva_EnergyAndLiquids": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "EnergyAndLiquids", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to energy and liquids.", "label": "Energy and liquids", "negatedLabel": "Energy and liquids" } } }, "auth_ref": [] }, "iva_Disposables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "Disposables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to disposables.", "label": "Disposables", "negatedLabel": "Disposables" } } }, "auth_ref": [] }, "ifrs-full_EntitysTotalForSubsidiariesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "EntitysTotalForSubsidiariesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Entity's total for subsidiaries [member]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Subsidiaries' axis if no other member is used." } } }, "auth_ref": [ "r67", "r69", "r120" ] }, "iva_NumberOfCorporateOfficersWhoCancelledTheirShareWarrants": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NumberOfCorporateOfficersWhoCancelledTheirShareWarrants", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of corporate officers who cancelled their share warrants under the share-based payment arrangement.", "label": "Number Of Corporate Officers Who Cancelled Their Share Warrants", "terseLabel": "Number of corporate officers who cancelled their share warrants" } } }, "auth_ref": [] }, "ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities at fair value through profit or loss, category [member]", "terseLabel": "Financial liabilities carried at fair value through profit or loss" } }, "en": { "role": { "documentation": "This member stands for the financial liabilities at fair value through profit or loss category. [Refer: Financial liabilities at fair value through profit or loss]" } } }, "auth_ref": [ "r163" ] }, "iva_ClassOfWarrantOrRightExercisedDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ClassOfWarrantOrRightExercisedDuringPeriod", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights exercised during the period.", "label": "Class Of Warrant Or Right, Exercised During Period", "terseLabel": "Number of warrants exercised" } } }, "auth_ref": [] }, "iva_TradePayablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "TradePayablesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for trade payables.", "label": "Trade payables" } } }, "auth_ref": [] }, "ifrs-full_BorrowingCostsIncurred": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "BorrowingCostsIncurred", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "label": "Borrowing costs incurred", "terseLabel": "Borrowing costs" } }, "en": { "role": { "documentation": "The amount of interest and other costs that an entity incurs in connection with the borrowing of funds." } } }, "auth_ref": [ "r264" ] }, "iva_NumberOfExternalAdvisersToWhomShareWarrantsWereAllocated": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NumberOfExternalAdvisersToWhomShareWarrantsWereAllocated", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of Company's external advisers to whom share warrants were allocated under the share-based payment arrangement.", "label": "Number Of External Advisers To Whom Share Warrants Were Allocated", "terseLabel": "Number of Company's external advisers to whom share warrants were allocated" } } }, "auth_ref": [] }, "iva_NewBonusShareAwardPlan20172Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NewBonusShareAwardPlan20172Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2017-1).", "label": "AGA 2017-2" } } }, "auth_ref": [] }, "iva_NonCurrentLongTermDepositsFromCustomers": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NonCurrentLongTermDepositsFromCustomers", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsDetails": { "parentTag": "ifrs-full_OtherNoncurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "It represents information about non current long term deposits from customers.", "label": "Non Current Long Term Deposits From Customers", "terseLabel": "Longterm deposit accounts" } } }, "auth_ref": [] }, "iva_PersonnelCostsAndHeadcount": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "PersonnelCostsAndHeadcount", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementTables" ], "lang": { "en-us": { "role": { "documentation": "Personnel costs and headcount", "label": "Personnel costs and headcount", "terseLabel": "Schedule of personnel costs and headcount" } } }, "auth_ref": [] }, "iva_SharesIssuedPricePerShare1": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "SharesIssuedPricePerShare1", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Per share price of equity shares issued.", "label": "Shares Issued Price Per Share 1", "terseLabel": "Issue price" } } }, "auth_ref": [] }, "ifrs-full_ProductsAndServicesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ProductsAndServicesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "label": "Products and services [member]" } }, "en": { "role": { "documentation": "This member stands for the entity's products and services. It also represents the standard value for the 'Products and services' axis if no other member is used." } } }, "auth_ref": [ "r177", "r221" ] }, "iva_AdjustmentsForDepreciationAmortisationAndProvisions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "AdjustmentsForDepreciationAmortisationAndProvisions", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Adjustments for depreciation, amortisation expense and provisions to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustments for Depreciation, Amortisation and Provisions", "terseLabel": "Depreciation, amortization and provisions" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for income tax [text block]", "terseLabel": "Current and deferred tax" } }, "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for income tax.\nEffective 2023-01-01: The description of the entity's material accounting policy information for income tax." } } }, "auth_ref": [ "r295", "r296" ] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentInformationTable", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "ifrs-full_ClassesOfShareCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ClassesOfShareCapitalMember", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Share capital [member]" } }, "en": { "role": { "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used." } } }, "auth_ref": [ "r31" ] }, "iva_SalesTaxReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "SalesTaxReceivableCurrent", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of sales tax receivables, classified as current.", "label": "Sales Tax Receivable, Current", "terseLabel": "Sales tax receivable" } } }, "auth_ref": [] }, "ifrs-full_RangesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "RangesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "label": "Ranges [member]" } }, "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } } }, "auth_ref": [ "r127", "r140", "r184", "r219", "r220", "r294" ] }, "iva_EmployeeRelatedPayables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "EmployeeRelatedPayables", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherCurrentLiabilitiesDetails": { "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount pertaining to employee related payables.", "label": "Employee related payables", "verboseLabel": "Employee-related payables" } } }, "auth_ref": [] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss": { "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations", "terseLabel": "Currency translation differences" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r26", "r38" ] }, "iva_BorrowingsNumberOfLoansObtained": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "BorrowingsNumberOfLoansObtained", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of loans obtained by the company.", "label": "Borrowings, Number Of Loans Obtained", "terseLabel": "Number of loans obtained" } } }, "auth_ref": [] }, "iva_NewBonusShareAwardPlan20183Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NewBonusShareAwardPlan20183Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2018-3).", "label": "AGA 2018-3 [Member]" } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "NoTradingSymbolFlag", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "iva_CashUnderLiquidityAgreementCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "CashUnderLiquidityAgreementCurrent", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of cash under liquidity agreement, classified as current.", "label": "Cash Under Liquidity Agreement, Current", "terseLabel": "Liquidity agreement - Cash" } } }, "auth_ref": [] }, "ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetChangeInNetProvisionDetails" ], "lang": { "en-us": { "role": { "label": "Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income", "terseLabel": "Actuarial gains or losses recognized in other comprehensive income" } }, "en": { "role": { "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r56" ] }, "ifrs-full_ProductsAndServicesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ProductsAndServicesAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "label": "Products and services [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r177", "r221" ] }, "iva_FinancialInstrumentsNumberOfContracts": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "FinancialInstrumentsNumberOfContracts", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of contracts entered under financial instruments.", "label": "Financial Instruments, Number of Contracts", "terseLabel": "Number of contracts under foreign currency forward" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "TradingSymbol", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "iva_NewEnterpriseAssociatesNeaBvfPartnersL.p.SofinnovaPartnersAndNovoHoldingsSMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NewEnterpriseAssociatesNeaBvfPartnersL.p.SofinnovaPartnersAndNovoHoldingsSMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for New Enterprise Associates (NEA), as well as BVF Partners L.P., Sofinnova Partners and Novo Holdings A/S.", "label": "New Enterprise Associates (NEA), as well as BVF Partners L.P., Sofinnova Partners and Novo Holdings A/S" } } }, "auth_ref": [] }, "iva_SubscriptionPremiumPricePerShareOfOtherEquityInstrumentsGranted": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "SubscriptionPremiumPricePerShareOfOtherEquityInstrumentsGranted", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Subscription premium price per share of other equity instruments granted in share-based payment arrangement.", "label": "Subscription Premium Price Per Share Of Other Equity Instruments Granted", "terseLabel": "Subscription premium price per share (\u20ac)" } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SecurityExchangeName", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r251" ] }, "ifrs-full_DisclosureOfFinancialAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfFinancialAssetsLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of financial assets [line items]", "terseLabel": "Cash and Cash Equivalents" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "iva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfTranches": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfTranches", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of tranches in which award under share-based payment arrangement will vest.", "label": "Share-based Compensation Arrangement By Share-based Payment Award, Award Vesting, Number Of Tranches", "terseLabel": "Vesting period, number of tranches" } } }, "auth_ref": [] }, "iva_PrepaymentsOfInsuranceCostsDeferredCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "PrepaymentsOfInsuranceCostsDeferredCurrent", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of prepayment of insurance costs deferred as on carrying date, classified as current.", "label": "Prepayments of Insurance Costs, Deferred, Current", "terseLabel": "Deferral of insurance costs" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "IncreaseDecreaseThroughTreasuryShareTransactions", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through treasury share transactions, equity", "terseLabel": "Treasury shares" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from treasury share transactions. [Refer: Equity; Treasury shares]" } } }, "auth_ref": [ "r5" ] }, "ifrs-full_CurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CurrentAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current assets", "totalLabel": "Total current assets" } }, "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } } }, "auth_ref": [ "r24", "r109", "r218" ] }, "iva_RevenueAndOtherIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "RevenueAndOtherIncomeTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of revenue and other income.", "label": "Revenue and Other Income [Table Text Block]", "terseLabel": "Schedule of revenue and other income" } } }, "auth_ref": [] }, "iva_ShortTermDepositAccountsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ShortTermDepositAccountsCurrent", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of short term deposits accounts, classified as current.", "label": "Short-Term Deposit Accounts, Current", "terseLabel": "Short-term deposit accounts" } } }, "auth_ref": [] }, "ifrs-full_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "RangeAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "label": "Range [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r127", "r140", "r184", "r219", "r220", "r294" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) financing activities [abstract]", "terseLabel": "Cash flows used in financing activities" } } }, "auth_ref": [] }, "iva_JeremyGoldbergMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "JeremyGoldbergMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Jeremy Goldberg.", "label": "Jeremy Goldberg" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtMovementsInPeriodBreakDownDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [line items]", "terseLabel": "Guarantee Details", "verboseLabel": "Financial debt" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "iva_ShortTermDepositAccountsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ShortTermDepositAccountsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for short-term deposit accounts.", "label": "Shortterm deposit accounts" } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "ifrs-full_FinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "FinancialLiabilities", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities", "terseLabel": "Financial liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]" } } }, "auth_ref": [ "r148" ] }, "iva_TermAccountsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "TermAccountsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for term accounts.", "label": "Comptes termes courants" } } }, "auth_ref": [] }, "ifrs-full_SalesAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "SalesAndMarketingExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Sales and marketing expense", "negatedLabel": "Marketing - Business development expenses" } }, "en": { "role": { "documentation": "The amount of expense relating to the marketing and selling of goods or services." } } }, "auth_ref": [ "r270" ] }, "iva_FairValueVariationGains": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "FairValueVariationGains", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementFinancialIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of gains recognized for variation in fair value.", "label": "Fair Value Variation Gains", "terseLabel": "Fair value variation gains / losses" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) financing activities", "totalLabel": "Net cash from (used in) financing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity." } } }, "auth_ref": [ "r90", "r99" ] }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ReserveOfExchangeDifferencesOnTranslation", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Reserve of exchange differences on translation", "terseLabel": "Translation reserve" } }, "en": { "role": { "documentation": "A component of equity representing exchange differences on translation of financial statements recognised in other comprehensive income and accumulated in equity. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r62" ] }, "iva_IfrsOtherOperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsOtherOperatingIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementRevenuesAndOtherIncomeDetails": { "parentTag": "iva_OtherIncomeFromOrdinaryActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementRevenuesAndOtherIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.", "label": "Ifrs Other Operating Income", "terseLabel": "Other" } } }, "auth_ref": [] }, "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "TypesOfSharebasedPaymentArrangementsAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetNetProvisionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "label": "Types of share-based payment arrangements [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r141" ] }, "iva_IndemnificationAmountReceivableUnderGuaranteeMaximum": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IndemnificationAmountReceivableUnderGuaranteeMaximum", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of maximum indemnification under guarantee , classified as non-current receivable.", "label": "Indemnification Amount Receivable Under Guarantee, Maximum", "terseLabel": "Maximum indemnification amount" } } }, "auth_ref": [] }, "ifrs-full_StatementOfIFRSCompliance": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "StatementOfIFRSCompliance", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfCompliance" ], "lang": { "en-us": { "role": { "label": "Statement of IFRS compliance [text block]", "terseLabel": "Basis of preparation and statement of compliance" } }, "en": { "role": { "documentation": "An explicit and unreserved statement of compliance with all the requirements of IFRSs." } } }, "auth_ref": [ "r7" ] }, "ifrs-full_IncreaseDecreaseInWorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "IncreaseDecreaseInWorkingCapital", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in working capital", "negatedTotalLabel": "Tax, interest and changes in operating working capital" } }, "en": { "role": { "documentation": "The increase (decrease) in working capital." } } }, "auth_ref": [ "r289" ] }, "ifrs-full_EmployeeBenefitsExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "EmployeeBenefitsExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 3.0 }, "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Employee benefits expense", "negatedTerseLabel": "Personnel costs", "negatedTotalLabel": "Total personnel costs" } }, "en": { "role": { "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment." } } }, "auth_ref": [ "r0", "r39", "r193" ] }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } }, "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } } }, "auth_ref": [ "r97" ] }, "ifrs-full_ClassesOfShareCapitalAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ClassesOfShareCapitalAxis", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Classes of share capital [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r31" ] }, "iva_NewBonusShareAwardPlan20192Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NewBonusShareAwardPlan20192Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2019-2).", "label": "AGA 2019-2 [Member]" } } }, "auth_ref": [] }, "iva_ProvisionForRetirementBenefitObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ProvisionForRetirementBenefitObligations", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of provision for retirement obligations during the period.", "label": "Provision For Retirement Benefit Obligations", "negatedLabel": "Provisions for retirement benefit obligations" } } }, "auth_ref": [] }, "iva_FibroscanMachinesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "FibroscanMachinesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for fibroscan machines.", "label": "Fibroscan machines" } } }, "auth_ref": [] }, "ifrs-full_LoansReceived": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "LoansReceived", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtDetails": { "parentTag": "ifrs-full_Borrowings", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Loans received", "terseLabel": "Bank borrowings" } }, "en": { "role": { "documentation": "The amount of loans received." } } }, "auth_ref": [ "r264" ] }, "ifrs-full_AdjustmentsForIncomeTaxExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "AdjustmentsForIncomeTaxExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for income tax expense", "terseLabel": "Deferred and current taxes" } }, "en": { "role": { "documentation": "Adjustments for income tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r96" ] }, "ifrs-full_ClassesOfOrdinarySharesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ClassesOfOrdinarySharesAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "label": "Classes of ordinary shares [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r70" ] }, "iva_DescriptionOfAccountingPolicyForOtherCurrentAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DescriptionOfAccountingPolicyForOtherCurrentAssetsTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "documentation": "The description of the entity's accounting policy for other current assets.", "label": "Description Of Accounting Policy For Other Current Assets [Text Block]", "terseLabel": "Other current assets" } } }, "auth_ref": [] }, "ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherCurrentLiabilitiesDetails": { "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "lang": { "en-us": { "role": { "label": "Current payables on social security and taxes other than income tax" } }, "en": { "role": { "documentation": "The amount of current payables on social security and taxes other than incomes tax. [Refer: Payables on social security and taxes other than income tax]" } } }, "auth_ref": [ "r268" ] }, "ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "FinancialLiabilitiesAtAmortisedCostCategoryMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities carried at amortized cost", "verboseLabel": "Liabilities carried at amortized cost" } }, "en": { "role": { "documentation": "This member stands for the financial liabilities at amortised cost category. [Refer: Financial liabilities at amortised cost]" } } }, "auth_ref": [ "r165", "r192" ] }, "iva_SubsidiesIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "SubsidiesIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementRevenuesAndOtherIncomeDetails": { "parentTag": "iva_OtherIncomeFromOrdinaryActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementRevenuesAndOtherIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of income from subsidies.", "label": "Subsidies income", "terseLabel": "Subsidies" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciples" ], "lang": { "en-us": { "role": { "label": "Disclosure of significant accounting policies [text block]", "terseLabel": "Accounting Principles" } }, "en": { "role": { "documentation": "The entire disclosure for significant accounting policies applied by the entity." } } }, "auth_ref": [ "r190" ] }, "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "SignificantInvestmentsInSubsidiariesAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Subsidiaries [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r67", "r69", "r120" ] }, "iva_NonCurrentAdvancesToSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NonCurrentAdvancesToSuppliers", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsDetails": { "parentTag": "ifrs-full_OtherNoncurrentAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount represents the non current advances of suppliers.", "label": "Non Current Advances To Suppliers", "terseLabel": "Advance payments - non-current", "verboseLabel": "Non-current advances to suppliers" } } }, "auth_ref": [] }, "ifrs-full_AdditionsToRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "AdditionsToRightofuseAssets", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Additions to right-of-use assets" } }, "en": { "role": { "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]" } } }, "auth_ref": [ "r134" ] }, "ifrs-full_NoncurrentAccruedIncomeIncludingNoncurrentContractAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NoncurrentAccruedIncomeIncludingNoncurrentContractAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsDetails": { "parentTag": "ifrs-full_OtherNoncurrentAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Non-current accrued income including non-current contract assets", "terseLabel": "Accrued income" } }, "en": { "role": { "documentation": "The amount of non-current accrued income including non-current contract assets. [Refer: Accrued income including contract assets]" } } }, "auth_ref": [ "r265", "r268" ] }, "iva_IfrsResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for research and development expense member.", "label": "Ifrs Research And Development Expense [Member]", "terseLabel": "Research and development costs" } } }, "auth_ref": [] }, "iva_IfrsGeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsGeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for general and administrative expense member.", "label": "General and administrative expenses" } } }, "auth_ref": [] }, "iva_IfrsotherFinancialInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsotherFinancialInformationLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.", "label": "IFRSOther Financial Information [Line Items]", "terseLabel": "Events after the reporting date" } } }, "auth_ref": [] }, "iva_PercentageOfAnuualRoyaltiesOnFutureNetSales": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "PercentageOfAnuualRoyaltiesOnFutureNetSales", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "The percentage of annual royalties over future net sales.", "label": "Percentage Of Anuual Royalties On Future Net Sales", "terseLabel": "Percentage of annual royalties on future net sales" } } }, "auth_ref": [] }, "iva_OtherMiscellaneousPayablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "OtherMiscellaneousPayablesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for other miscellaneous payables.", "label": "Other miscellaneous payables" } } }, "auth_ref": [] }, "iva_TradePayableAndOtherCurrentLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "TradePayableAndOtherCurrentLiabilitiesTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradePayablesDetails" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Trade Payable And Other Current Liabilities [Table]" } } }, "auth_ref": [] }, "iva_TermOfRoyaltyCertificate": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "TermOfRoyaltyCertificate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Term of royalty certificate in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Term Of Royalty Certificate", "terseLabel": "Term of royalty certificate" } } }, "auth_ref": [] }, "iva_TradePayableAndOtherCurrentLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "TradePayableAndOtherCurrentLiabilitiesLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradePayablesDetails" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Trade Payable And Other Current Liabilities [Line Items]" } } }, "auth_ref": [] }, "iva_ProceedsFromSalesOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ProceedsFromSalesOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The cash inflow from the disposal of property, plant and equipment and intangible assets, classified as investing activities.", "label": "Proceeds From Sales Of Property Plant And Equipment And Intangible Assets Classified As Investing Activities", "terseLabel": "Disposals of property, plant and equipment and intangible assets" } } }, "auth_ref": [] }, "iva_TermDepositMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "TermDepositMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for term deposit.", "label": "Term Deposit [Member]", "terseLabel": "Term deposit" } } }, "auth_ref": [] }, "iva_IfrsSalesAndMarketingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsSalesAndMarketingExpenseMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for sales and marketing expense member.", "label": "Marketing - Business development expenses" } } }, "auth_ref": [] }, "iva_AccruedPayrollAndOtherEmployeeRelatedTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "AccruedPayrollAndOtherEmployeeRelatedTaxes", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherCurrentLiabilitiesDetails": { "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount pertaining to accrued payroll and other employee related taxes.", "label": "Accrued payroll and other employeerelated taxes", "terseLabel": "Accrued payroll and other employee-related taxes" } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2022", "localname": "OwnershipDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "label": "Ownership [Domain]" } } }, "auth_ref": [] }, "iva_AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "documentation": "This member stands for American Depositary Shares, each representing one ordinary share.", "label": "American Depositary Shares, each representing one ordinary share" } } }, "auth_ref": [] }, "iva_NotesToConsolidatedBalanceSheet": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NotesToConsolidatedBalanceSheet", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Notes to the consolidated balance sheet" } } }, "auth_ref": [] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2022", "localname": "OwnershipAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityShellCompany", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r250" ] }, "ifrs-full_RevenueFromContractsWithCustomers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "RevenueFromContractsWithCustomers", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementRevenuesAndOtherIncomeDetails": { "parentTag": "ifrs-full_Revenue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementRevenuesAndOtherIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Revenue from contracts with customers", "terseLabel": "Revenue" } }, "en": { "role": { "documentation": "The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity\u2019s ordinary activities in exchange for consideration." } } }, "auth_ref": [ "r129", "r130" ] }, "iva_MaximumAnnualPaymentPostMarketAuthorization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "MaximumAnnualPaymentPostMarketAuthorization", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "The maximum amount of annual payment post market authorization.", "label": "Maximum Annual Payment, Post Market Authorization", "terseLabel": "Maximum annual payment post market authorization" } } }, "auth_ref": [] }, "iva_PercentageOfDiscountToWeightedAverageTradingPrice": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "PercentageOfDiscountToWeightedAverageTradingPrice", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of discount to weighted average trading price of shares applied to the price of the stock offering.", "label": "Percentage Of Discount To Weighted Average Trading Price", "terseLabel": "Percentage of discount to weighted average trading price" } } }, "auth_ref": [] }, "iva_IfrsotherFinancialInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsotherFinancialInformationTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule disclosing information related to other financial information.", "label": "IFRSOther Financial Information [Table]" } } }, "auth_ref": [] }, "iva_ExpectedVolatility": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ExpectedVolatility", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Expected volatility used to calculate fair value of warrants.", "label": "Expected volatility", "verboseLabel": "Volatility" } } }, "auth_ref": [] }, "iva_ContractualCapitalCommitmentReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ContractualCapitalCommitmentReceived", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of contractual capital commitment received.", "label": "Contractual Capital Commitment Received", "totalLabel": "Total commitments received" } } }, "auth_ref": [] }, "iva_AgreementsConcerningProvisionOfFacilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "AgreementsConcerningProvisionOfFacilities", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails": { "parentTag": "iva_ContractualCapitalCommitmentReceived", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of agreements concerning provision of facilities.", "label": "Agreements concerning the provision of facilities", "terseLabel": "Agreements concerning the provision of facilities" } } }, "auth_ref": [] }, "iva_InventivaS.aMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "InventivaS.aMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Inventiva S.A, U.S. affiliate.", "label": "Inventiva S.A [Member]" } } }, "auth_ref": [] }, "ifrs-full_ChangesInPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ChangesInPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in property, plant and equipment", "terseLabel": "Increase in net value of property, plant and equipment" } }, "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r49" ] }, "iva_PharmaceuticalResearchAssociatesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "PharmaceuticalResearchAssociatesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Pharmaceutical Research Associates.", "label": "Pharmaceutical Research Associates [Member]", "terseLabel": "Pharmaceutical Research Associates" } } }, "auth_ref": [] }, "iva_CommitmentContractualPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "CommitmentContractualPeriod", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Commitment contractual period.", "label": "Commitment Contractual Period", "terseLabel": "Commitment contractual period" } } }, "auth_ref": [] }, "ifrs-full_ForeignExchangeRatesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ForeignExchangeRatesAbstract", "lang": { "en-us": { "role": { "label": "Exchange rate (USD per EUR)" } } }, "auth_ref": [] }, "iva_WarrantsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "WarrantsRiskFreeInterestRate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Risk free interest rate used to calculate fair value of warrants.", "label": "Warrants, Risk Free Interest Rate", "terseLabel": "Risk-free rate" } } }, "auth_ref": [] }, "iva_PercentageOfPatientsWithFibrosis": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "PercentageOfPatientsWithFibrosis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of patients with fibrosis.", "label": "Percentage Of Patients With Fibrosis", "terseLabel": "Percentage of patients with fibrosis" } } }, "auth_ref": [] }, "iva_AmendedPreviousCommitmentContractualAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "AmendedPreviousCommitmentContractualAmount", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of amended previous commitment contractual.", "label": "Amended Previous Commitment Contractual Amount", "terseLabel": "Amended previous commitment contractual amount" } } }, "auth_ref": [] }, "iva_WarrantsExpectedDividends": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "WarrantsExpectedDividends", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Expected dividends used to calculate fair value of warrants.", "label": "Warrants, Expected Dividends", "terseLabel": "Expected dividends" } } }, "auth_ref": [] }, "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 1.0 }, "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradePayablesAndOtherCurrentLiabilitiesDetails": { "parentTag": "iva_TradePayablesAndOtherCurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradePayablesAndOtherCurrentLiabilitiesDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current trade payables", "terseLabel": "Trade payables" } }, "en": { "role": { "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]" } } }, "auth_ref": [ "r197", "r268" ] }, "iva_CommitmentContractualBonusOrMalusCappedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "CommitmentContractualBonusOrMalusCappedAmount", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of commitment contractual bonus or malus capped amount.", "label": "Commitment Contractual Bonus Or Malus Capped Amount", "terseLabel": "Bonus or malus capped amount" } } }, "auth_ref": [] }, "iva_IncreasesInPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IncreasesInPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of increases in property, plant and equipment", "label": "Increases in property, plant and equipment", "terseLabel": "Increases" } } }, "auth_ref": [] }, "ifrs-full_NoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NoncontrollingInterests", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Non-controlling interests" } }, "en": { "role": { "documentation": "The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Subsidiaries [member]]" } } }, "auth_ref": [ "r18", "r105", "r106" ] }, "ifrs-full_NumberOfSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NumberOfSharesOutstanding", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Number of shares outstanding", "terseLabel": "Number of shares outstanding" } }, "en": { "role": { "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]" } } }, "auth_ref": [ "r30" ] }, "iva_AmendedPreviousCommitmentBonusOrMalusCappedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "AmendedPreviousCommitmentBonusOrMalusCappedAmount", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of amended previous commitment bonus or malus capped.", "label": "Amended Previous Commitment Bonus Or Malus Capped Amount", "terseLabel": "Amended previous commitment bonus or malus capped amount" } } }, "auth_ref": [] }, "iva_NewBonusShareAwardPlanAga2021BisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NewBonusShareAwardPlanAga2021BisMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2021-bis).", "label": "AGA 2021-bis" } } }, "auth_ref": [] }, "iva_NewBonusShareAwardPlanAga20211Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NewBonusShareAwardPlanAga20211Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2021-1)", "label": "AGA 2021-1" } } }, "auth_ref": [] }, "iva_NumberofsitesrandomizedAvailable": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NumberofsitesrandomizedAvailable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of sites randomized", "label": "NumberOfSitesRandomized (Available)", "terseLabel": "Number of sites randomized" } } }, "auth_ref": [] }, "iva_NumberofcountriesinvolvedinclinicalstudiesAvailable": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NumberofcountriesinvolvedinclinicalstudiesAvailable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of countries involvedIin clinical studies.", "label": "NumberOfCountriesInvolvedInClinicalStudies (Available)", "terseLabel": "Number of countries involved in Phase III studies" } } }, "auth_ref": [] }, "iva_NewBsa20211ShareWarrantPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NewBsa20211ShareWarrantPlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for new BSA 2021-1 share warrant plan.", "label": "BSA - Plan 2021-1" } } }, "auth_ref": [] }, "iva_NumberOfCountriesExtensionToInvolvedInClinicalStudies": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NumberOfCountriesExtensionToInvolvedInClinicalStudies", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of extension countries involved in Phase III studies.", "label": "Number Of Countries Extension To Involved In Clinical Studies", "terseLabel": "Number of extension countries involved in Phase III studies" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageSharePrice2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "WeightedAverageSharePrice2019", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average share price", "terseLabel": "Weighted average share price", "verboseLabel": "Stock price at grant date (in euros)" } }, "en": { "role": { "documentation": "The weighted average share price. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r139" ] }, "ifrs-full_OtherNoncurrentFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "OtherNoncurrentFinancialLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Other non-current financial liabilities", "terseLabel": "Long-term debt" } }, "en": { "role": { "documentation": "The amount of non-current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]" } } }, "auth_ref": [ "r15", "r117" ] }, "iva_IslsConsultingAndDavidNikademMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IslsConsultingAndDavidNikademMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for ISLS Consulting and David nikadem member.", "label": "ISLS Consulting and David Nikadem" } } }, "auth_ref": [] }, "iva_PercentageOfCurrentlyOperatingCilinicalSites": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "PercentageOfCurrentlyOperatingCilinicalSites", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of currently operating cilinical sites", "label": "Percentage Of Currently Operating Cilinical Sites", "terseLabel": "Percentage of currently operating cilinical sites" } } }, "auth_ref": [] }, "iva_SubscriptionPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "SubscriptionPricePerShare", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Subscription price per share in new issue of shares", "label": "Subscription Price Per Share", "terseLabel": "Subscription price" } } }, "auth_ref": [] }, "iva_FredericCrenAndPierreBroquaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "FredericCrenAndPierreBroquaMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Frederic Cren and Pierre Broqua.", "label": "Frederic Cren and Pierre Broqua" } } }, "auth_ref": [] }, "iva_ContractCroWithResearchAssociatesGroupeB.vMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ContractCroWithResearchAssociatesGroupeB.vMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Contract CRO with PRA.", "label": "Contract CRO with Pharmaceutical Research Associates B.V." } } }, "auth_ref": [] }, "iva_CommitmentsAmountPayableForServicesReceivedUnderContract": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "CommitmentsAmountPayableForServicesReceivedUnderContract", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Commitment amount payable for services received under contract.", "label": "Commitments Amount Payable For Services Received Under Contract", "verboseLabel": "Amount committed to pay" } } }, "auth_ref": [] }, "ifrs-full_RevenueAndOperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "RevenueAndOperatingIncome", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementRevenuesAndOtherIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Revenue and other operating income", "totalLabel": "Total revenue and other income" } }, "en": { "role": { "documentation": "The aggregate amount of the entity's revenue and other operating income. [Refer: Revenue]" } } }, "auth_ref": [ "r270" ] }, "iva_CurrentTaxCreditReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "CurrentTaxCreditReceivables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "documentation": "The amount of current tax credit receivables", "label": "Current tax credit receivables", "terseLabel": "Tax receivables" } } }, "auth_ref": [] }, "iva_ComponentsOfIncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ComponentsOfIncomeStatementAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Notes to the income statement" } } }, "auth_ref": [] }, "iva_DisclosureOfComponentsOfIncomeStatementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DisclosureOfComponentsOfIncomeStatementTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatement" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for components of income statement.", "label": "Disclosure Of Components Of Income Statement [Text Block]", "terseLabel": "Notes to the income statement" } } }, "auth_ref": [] }, "iva_DisclosureOfOtherFinancialInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DisclosureOfOtherFinancialInformationTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformation" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other financial information.", "label": "Disclosure Of Other Financial Information [Text Block]", "terseLabel": "Other financial information" } } }, "auth_ref": [] }, "iva_OtherIncomeFromOrdinaryActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "OtherIncomeFromOrdinaryActivities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementRevenuesAndOtherIncomeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementRevenuesAndOtherIncomeDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "documentation": "The amount of other income from ordinary activities.", "label": "Other income from ordinary activities", "terseLabel": "Other income", "totalLabel": "Other operating income" } } }, "auth_ref": [] }, "iva_RetainedEarningsExcludingProfitLossForReportingPeriodAndTreasuryShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "RetainedEarningsExcludingProfitLossForReportingPeriodAndTreasuryShares", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "documentation": "A component of equity representing retained earnings excluding profit (loss) for the reporting period, and treasury shares", "label": "Retained earnings excluding profit (loss) for the reporting period and treasury shares", "terseLabel": "Reserves" } } }, "auth_ref": [] }, "iva_GoingConcernTable": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "GoingConcernTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule disclosing information related to going concern.", "label": "Going Concern [Table]" } } }, "auth_ref": [] }, "iva_OtherOperatingIncomeExpenseFromNonOrdinaryActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "OtherOperatingIncomeExpenseFromNonOrdinaryActivities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "documentation": "The amount of operating income (expense) from non-ordinary activities that the entity does not separately disclose in the same statement or note.", "label": "Other operating income (expense) from non-ordinary activities", "terseLabel": "Other operating income (expenses)" } } }, "auth_ref": [] }, "ifrs-full_CurrentTradeReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CurrentTradeReceivables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current trade receivables", "terseLabel": "Trade receivables" } }, "en": { "role": { "documentation": "The amount of current trade receivables. [Refer: Trade receivables]" } } }, "auth_ref": [ "r196", "r198" ] }, "iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "This member represent a component of equity consisting of retained earnings excluding the current reporting period, and treasury shares.", "label": "Retained earnings excluding profit (loss) from current reporting period and treasury shares [Member]", "terseLabel": "Reserves" } } }, "auth_ref": [] }, "iva_GoingConcernLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "GoingConcernLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.", "label": "Going Concern [Line Items]", "terseLabel": "Going Concern" } } }, "auth_ref": [] }, "iva_TermDepositsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "TermDepositsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for term deposits.", "label": "Term deposits [Member]", "terseLabel": "Term deposits" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfContingentLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfContingentLiabilitiesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of contingent liabilities [text block]", "terseLabel": "Schedule of commitments given and received" } }, "en": { "role": { "documentation": "The disclosure of contingent liabilities. [Refer: Contingent liabilities [member]]" } } }, "auth_ref": [ "r76" ] }, "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for impairment of non-financial assets [text block]", "terseLabel": "Impairment of non-financial assets" } }, "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for the impairment of non-financial assets. [Refer: Financial assets]\nEffective 2023-01-01: The description of the entity's material accounting policy information for the impairment of non-financial assets. [Refer: Financial assets]" } } }, "auth_ref": [ "r295", "r296" ] }, "iva_DecreasesInPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DecreasesInPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of decreases in property, plant and equipment", "label": "Decreases in property, plant and equipment", "negatedLabel": "Decreases" } } }, "auth_ref": [] }, "iva_DecreasesInIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DecreasesInIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of decreases to intangible assets other than goodwill.", "label": "Decreases in intangible assets other than goodwill", "negatedLabel": "Decreases" } } }, "auth_ref": [] }, "iva_IncreasesInIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IncreasesInIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of increases to intangible assets other than goodwill.", "label": "Increases in intangible assets other than goodwill", "terseLabel": "Increases" } } }, "auth_ref": [] }, "iva_PercentageOfMajorMarkets": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "PercentageOfMajorMarkets", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of major markets.", "label": "Percentage Of Major Markets", "terseLabel": "Percentage of major markets for lanifibranor" } } }, "auth_ref": [] }, "iva_NumberOfActiveClinicalSitesInNativ3Trial": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NumberOfActiveClinicalSitesInNativ3Trial", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of active clinical sites in NATiV3 trial", "label": "Number of active clinical sites in NATiV3 trial" } } }, "auth_ref": [] }, "ifrs-full_TopOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "TopOfRangeMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "label": "Maximum", "terseLabel": "Maximum" } }, "en": { "role": { "documentation": "This member stands for top of a range." } } }, "auth_ref": [ "r127", "r140", "r184", "r219", "r220", "r294" ] }, "iva_IncreaseDecreaseInLongTermDepositAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IncreaseDecreaseInLongTermDepositAccounts", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in long-term deposit accounts", "label": "Increase (decrease) in long-term deposit accounts", "terseLabel": "Increase in long-term deposit accounts" } } }, "auth_ref": [] }, "iva_DecreaseInCirAndOtherResearchTaxCreditsThroughCorrectiveClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DecreaseInCirAndOtherResearchTaxCreditsThroughCorrectiveClaims", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Decrease in CIR and other research tax credits through corrective claims", "label": "Decrease in CIR and other research tax credits through corrective claims" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "IncreaseDecreaseThroughAppropriationOfRetainedEarnings", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through appropriation of retained earnings, equity", "terseLabel": "Appropriation of 2022 net income (loss)" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the appropriation of retained earnings. [Refer: Retained earnings]" } } }, "auth_ref": [ "r261" ] }, "iva_DecreaseInCurrentAccruedIncomeThroughPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DecreaseInCurrentAccruedIncomeThroughPayments", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Decrease in current accrued income through payments", "label": "Decrease in current accrued income through payments" } } }, "auth_ref": [] }, "iva_TotalFairValueOfAwardsGrantedAtGrantDate": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "TotalFairValueOfAwardsGrantedAtGrantDate", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Total fair value of awards granted at grant date", "label": "Total fair value of awards granted at grant date", "terseLabel": "Fair value at grant date (k\u20ac)" } } }, "auth_ref": [] }, "ifrs-full_CurrentValueAddedTaxPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CurrentValueAddedTaxPayables", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherCurrentLiabilitiesDetails": { "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Current value added tax payables", "terseLabel": "Sales tax payables" } }, "en": { "role": { "documentation": "The amount of current value added tax payables. [Refer: Value added tax payables]" } } }, "auth_ref": [ "r268" ] }, "iva_Bsa2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "Bsa2022Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the BSA 2022 share-based payment plan", "label": "BSA 2022 [Member]", "terseLabel": "BSA 2022" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for property, plant and equipment [text block]", "terseLabel": "Property, plant and equipment" } }, "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for property, plant and equipment. [Refer: Property, plant and equipment]\nEffective 2023-01-01: The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r295", "r296" ] }, "iva_IncreaseDecreaseInCurrentDepositAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IncreaseDecreaseInCurrentDepositAccounts", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in current deposit accounts", "label": "Increase (decrease) in current deposit accounts", "terseLabel": "Decrease in current deposit accounts" } } }, "auth_ref": [] }, "iva_DecreaseInCirAndOtherResearchTaxCreditsThroughPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DecreaseInCirAndOtherResearchTaxCreditsThroughPayments", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Decrease in CIR and other research tax credits through payments", "label": "Decrease in CIR and other research tax credits through payments" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [text block]", "terseLabel": "Schedule of intangible assets" } }, "en": { "role": { "documentation": "The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r82" ] }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through share-based payment transactions, equity", "terseLabel": "Share-based payment compensation expenses" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } } }, "auth_ref": [ "r4" ] }, "ifrs-full_LongtermDeposits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "LongtermDeposits", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Long-term deposits", "terseLabel": "Long-term deposit" } }, "en": { "role": { "documentation": "The amount of long-term deposits held by the entity." } } }, "auth_ref": [ "r265" ] }, "ifrs-full_CurrentServiceCostDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CurrentServiceCostDefinedBenefitPlans", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetBreakdownOfExpenseRecognizedForPeriodDetails": { "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetBreakdownOfExpenseRecognizedForPeriodDetails" ], "lang": { "en-us": { "role": { "label": "Current service cost, defined benefit plans", "negatedLabel": "Service cost for the period" } }, "en": { "role": { "documentation": "The expense of employee service in the current period arising from defined benefit plans. [Refer: Post-employment benefit expense in profit or loss, defined benefit plans] [Contrast: Increase in net defined benefit liability (asset) resulting from current service cost]" } } }, "auth_ref": [ "r276" ] }, "iva_LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for loan agreements with a syndicate of French banks, under a stimulus economic plan.", "label": "Loan agreements with syndicate of French banks, under stimulus economic plan [Member]", "terseLabel": "Loan agreements with syndicate of French banks, under stimulus economic plan" } } }, "auth_ref": [] }, "iva_CancellationTermForFundsNotDispersedAfterExecutionOfFinanceContract": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "CancellationTermForFundsNotDispersedAfterExecutionOfFinanceContract", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "Cancellation term for funds not dispersed after execution of finance contract", "label": "Cancellation term for funds not dispersed after execution of finance contract" } } }, "auth_ref": [] }, "iva_IncreaseOrDecreaseInBorrowingsDueToChangesInExchangeRates": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IncreaseOrDecreaseInBorrowingsDueToChangesInExchangeRates", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase or decrease in borrowings due to exchange rate change.", "label": "Increase or Decrease in Borrowings Due to Changes in Exchange Rates", "terseLabel": "Exchange rate change" } } }, "auth_ref": [] }, "iva_LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for loan agreements with syndicate of French banks, state guaranteed loan (Pret Garanti par l'Etat)", "label": "Loan agreements with syndicate of French banks, state guaranteed loan (Pret Garanti par l’Etat) [Member]", "terseLabel": "Loan agreements with syndicate of French banks, state guaranteed loan (Pret Garanti par l'Etat)" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInOtherCurrentAssets", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Adjustments for decrease (increase) in other current assets", "terseLabel": "Increase in other current assets" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in other current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other current assets; Profit (loss)]" } } }, "auth_ref": [ "r289" ] }, "iva_LoanAgreementsWithSyndicateOfFrenchBanksAgreementWithCreditAgricoleChampagneBourgogneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LoanAgreementsWithSyndicateOfFrenchBanksAgreementWithCreditAgricoleChampagneBourgogneMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for loan agreements with syndicate of French banks, agreement with Credit Agricole Champagne-Bourgogne", "label": "Loan agreements with syndicate of French banks, agreement with Credit Agricole Champagne-Bourgogne [Member]", "terseLabel": "Loan agreements with syndicate of French banks, agreement with Credit Agricole Champagne-Bourgogne" } } }, "auth_ref": [] }, "iva_LoanAgreementsWithSyndicateOfFrenchBanksAgreementWithSocieteGeneraleMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LoanAgreementsWithSyndicateOfFrenchBanksAgreementWithSocieteGeneraleMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for loan agreements with syndicate of French banks, agreement with Societe Generale", "label": "Loan agreements with syndicate of French banks, agreement with Societe Generale [Member]", "terseLabel": "Loan agreements with syndicate of French banks, agreement with Societe Generale" } } }, "auth_ref": [] }, "iva_NumberOfEntitiesBeingConsolidated": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NumberOfEntitiesBeingConsolidated", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of entities being consolidated", "label": "Number of entities being consolidated" } } }, "auth_ref": [] }, "country_KR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2022", "localname": "KR", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "label": "KOREA, REPUBLIC OF", "terseLabel": "South Korea" } } }, "auth_ref": [] }, "currency_USD": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2022", "localname": "USD", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "United States of America, Dollars" } } }, "auth_ref": [] }, "iva_DecreaseInBorrowingsThroughRepayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DecreaseInBorrowingsThroughRepayments", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of decrease in borrowings through repayments.", "label": "Decrease in borrowings through repayments", "negatedLabel": "Repayment of bank borrowings" } } }, "auth_ref": [] }, "iva_DecreaseInBorrowingsThroughRepaymentOfLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DecreaseInBorrowingsThroughRepaymentOfLeaseLiabilities", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of decrease in borrowings through repayment of lease liabilities.", "label": "Decrease in borrowings through repayment of lease liabilities", "negatedLabel": "Repayment of lease liabilities" } } }, "auth_ref": [] }, "ifrs-full_MiscellaneousOtherOperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "MiscellaneousOtherOperatingExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOtherOperatingIncomeAndExpensesDetails": { "parentTag": "ifrs-full_OtherOperatingIncomeExpense", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Miscellaneous other operating expense", "totalLabel": "Total other operating expenses" } }, "en": { "role": { "documentation": "The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)]" } } }, "auth_ref": [ "r264" ] }, "iva_IncreaseInBorrowingsThroughCapitalizedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IncreaseInBorrowingsThroughCapitalizedInterest", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase in borrowings through capitalized interest.", "label": "Increase in borrowings through capitalized interest", "terseLabel": "Capitalized interests" } } }, "auth_ref": [] }, "ifrs-full_CurrentPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CurrentPrepaidExpenses", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Current prepaid expenses", "terseLabel": "Prepaid expenses" } }, "en": { "role": { "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised." } } }, "auth_ref": [ "r264" ] }, "ifrs-full_IntangibleAssetsOtherThanGoodwillMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "IntangibleAssetsOtherThanGoodwillMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Intangible assets other than goodwill [member]" } }, "en": { "role": { "documentation": "This member stands for intangible assets other than goodwill. It also represents the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r82", "r205", "r223" ] }, "iva_ConditionsForFundDisbursementMetMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ConditionsForFundDisbursementMetMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to conditions for fund disbursement met.", "label": "Conditions for Fund Disbursement Met [Member]", "terseLabel": "Conditions for fund disbursement met" } } }, "auth_ref": [] }, "ifrs-full_CurrentLoansReceivedAndCurrentPortionOfNoncurrentLoansReceived": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CurrentLoansReceivedAndCurrentPortionOfNoncurrentLoansReceived", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtDetails" ], "lang": { "en-us": { "role": { "label": "Current loans received and current portion of non-current loans received", "terseLabel": "Bank borrowings, short-term" } }, "en": { "role": { "documentation": "The amount of current loans received and the current portion of non-current loans received. [Refer: Loans received]" } } }, "auth_ref": [ "r264" ] }, "ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisposalsIntangibleAssetsOtherThanGoodwill", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Disposals, intangible assets other than goodwill", "negatedLabel": "Decreases" } }, "en": { "role": { "documentation": "The decrease in intangible assets other than goodwill resulting from disposals. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r79" ] }, "iva_LongTermFinancialDebtDerivativesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LongTermFinancialDebtDerivativesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Long-term financial debt, derivatives.", "label": "Derivatives", "terseLabel": "Long-term financial debt - derivatives" } } }, "auth_ref": [] }, "iva_CirAndOtherResearchTaxCreditsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "CirAndOtherResearchTaxCreditsReceivable", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of CIR and other research tax credits receivable.", "label": "CIR and Other Research Tax Credits Receivable", "terseLabel": "CIR and other research tax credits receivable" } } }, "auth_ref": [] }, "iva_IncreaseInResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IncreaseInResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase in research and development expense.", "label": "Increase in Research and Development Expense", "terseLabel": "Increase in research and development expense" } } }, "auth_ref": [] }, "ifrs-full_OtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "OtherNoncurrentAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 3.0 }, "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Other non-current asset", "terseLabel": "Other non-current assets", "totalLabel": "Other noncurrent assets" } }, "en": { "role": { "documentation": "The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]" } } }, "auth_ref": [ "r265" ] }, "iva_Aga2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "Aga2022Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2022 Plan).", "label": "AGA 2022 [Member]", "terseLabel": "AGA 2022" } } }, "auth_ref": [] }, "ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "MaturityAnalysisForNonderivativeFinancialLiabilities", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of maturity analysis for non-derivative financial liabilities [text block]", "terseLabel": "Schedule of maturity of long-term and short-term debt" } }, "en": { "role": { "documentation": "The disclosure of a maturity analysis for non-derivative financial liabilities (including issued financial guarantee contracts) that shows the remaining contractual maturities. [Refer: Derivative financial liabilities]" } } }, "auth_ref": [ "r157" ] }, "iva_LatePaymentOfInterestOnFrenchResearchTaxCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LatePaymentOfInterestOnFrenchResearchTaxCredit", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOtherOperatingIncomeAndExpensesDetails": { "parentTag": "ifrs-full_MiscellaneousOtherOperatingExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of late payment of interest to be paid on French Research tax credit.", "label": "Late Payment of Interest on French Research Tax Credit", "negatedLabel": "Late payment interest on CIR 2013-2015" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AmendmentFlag", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "iva_TransactionsCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "TransactionsCosts", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOtherOperatingIncomeAndExpensesDetails": { "parentTag": "ifrs-full_MiscellaneousOtherOperatingExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of transactions costs incurred during the period.", "label": "Transactions Costs", "negatedLabel": "Transaction costs" } } }, "auth_ref": [] }, "ifrs-full_IssueOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "IssueOfEquity", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareCapitalDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issue of equity", "terseLabel": "Issue of ordinary shares", "verboseLabel": "Share capital" } }, "en": { "role": { "documentation": "The increase in equity through the issue of equity instruments." } } }, "auth_ref": [ "r4" ] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r252", "r253", "r254" ] }, "iva_IncreaseDecreaseInActuarialAssumptionOfDiscountRatesAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IncreaseDecreaseInActuarialAssumptionOfDiscountRatesAmount", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetNetProvisionDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the discount rate used as the significant actuarial assumption to determine the present value of a defined benefit obligation.", "label": "Increase (Decrease) In Actuarial Assumption Of Discount Rates, Amount", "terseLabel": "Increase in discount rate" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for finance income and costs [text block]", "terseLabel": "Net financial income" } }, "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for finance income and costs. [Refer: Finance income (cost)]\nEffective 2023-01-01: The description of the entity's material accounting policy information for finance income and costs. [Refer: Finance income (cost)]" } } }, "auth_ref": [ "r295", "r296" ] }, "iva_IncreaseDecreaseInActuarialAssumptionOfDiscountRatesPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IncreaseDecreaseInActuarialAssumptionOfDiscountRatesPercent", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetNetProvisionDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in the discount rate used as the significant actuarial assumption to determine the present value of a defined benefit obligation.", "label": "Increase (Decrease) In Actuarial Assumption Of Discount Rates, Percent", "terseLabel": "Increase in discount rate (as a percent)" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AmendmentDescription", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "currency_AllCurrenciesDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2022", "localname": "AllCurrenciesDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "All Currencies [Domain]" } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for determining components of cash and cash equivalents [text block]", "terseLabel": "Cash and cash equivalents" } }, "en": { "role": { "documentation": "The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r98" ] }, "ifrs-full_FinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "FinanceIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": 1.0, "order": 2.0 }, "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementFinancialIncomeAndExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Finance income", "terseLabel": "Financial income", "totalLabel": "Total financial income" } }, "en": { "role": { "documentation": "The amount of income associated with interest and other financing activities of the entity." } } }, "auth_ref": [ "r270" ] }, "iva_AdvancePaymentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "AdvancePaymentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for advance payment.", "label": "Advance payment" } } }, "auth_ref": [] }, "iva_LongTermAccruedIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LongTermAccruedIncomeMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for long term accrued income.", "label": "Long-term accrued income" } } }, "auth_ref": [] }, "iva_LicenseAndCollaborationAgreementUpfrontFeeReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LicenseAndCollaborationAgreementUpfrontFeeReceivable", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of upfront fee receivable by the entity, pursuant to licensing and collaborative arrangements.", "label": "License And Collaboration Agreement Upfront Fee Receivable", "terseLabel": "Upfront payment receivable" } } }, "auth_ref": [] }, "ifrs-full_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Unaudited interim condensed consolidated statement of cash flows" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfFinancialInstrumentsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ClassesOfFinancialInstrumentsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Financial instruments, class [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]" } } }, "auth_ref": [ "r151", "r153", "r155", "r156" ] }, "iva_DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about expense recognized in the statement of income (loss) for Retirement Benefit Obligations.", "label": "Disclosure Of Expenses Recognized In Statement Of Income (Loss) For Retirement Benefit Obligations, Explanatory", "terseLabel": "Schedule of expense recognized in the statement of income (loss)" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentProvisionsForEmployeeBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NoncurrentProvisionsForEmployeeBenefits", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current provisions for employee benefits", "terseLabel": "Provisions for retirement benefit obligations" } }, "en": { "role": { "documentation": "The amount of non-current provisions for employee benefits. [Refer: Provisions for employee benefits]" } } }, "auth_ref": [ "r27" ] }, "ifrs-full_IntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "IntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetIntangibleAssetsDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Intangible assets other than goodwill", "periodEndLabel": "Balance at the end", "periodStartLabel": "Balance at the beginning", "terseLabel": "Intangible assets" } }, "en": { "role": { "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]" } } }, "auth_ref": [ "r10", "r81" ] }, "ifrs-full_InterestIncomeOnCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "InterestIncomeOnCashAndCashEquivalents", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementFinancialIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Interest income on cash and cash equivalents", "terseLabel": "Income from cash equivalents" } }, "en": { "role": { "documentation": "The amount of interest income on cash and cash equivalents. [Refer: Interest income; Cash and cash equivalents]" } } }, "auth_ref": [ "r264" ] }, "ifrs-full_RepairsAndMaintenanceExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "RepairsAndMaintenanceExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Repairs and maintenance expense", "negatedLabel": "Maintenance" } }, "en": { "role": { "documentation": "The amount of expenses incurred for the day-to-day servicing of assets, which may include the cost of labour, consumables or small parts." } } }, "auth_ref": [ "r270" ] }, "iva_NewShareWarrantPlansBsa2019Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NewShareWarrantPlansBsa2019Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for new share warrant plans (\"BSA 2019\").", "label": "BSA 2019" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for derivative financial instruments [text block]", "terseLabel": "Derivatives" } }, "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for derivative financial instruments. [Refer: Financial instruments, class [member]; Derivatives [member]]\nEffective 2023-01-01: The description of the entity's material accounting policy information for derivative financial instruments. [Refer: Financial instruments, class [member]; Derivatives [member]]" } } }, "auth_ref": [ "r295", "r296" ] }, "ifrs-full_LevelsOfFairValueHierarchyAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "LevelsOfFairValueHierarchyAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "Levels of fair value hierarchy [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r57", "r123" ] }, "ifrs-full_OtherPropertyPlantAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "OtherPropertyPlantAndEquipmentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Other property, plant and equipment" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing property, plant and equipment that the entity does not separately disclose in the same statement or note. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r273" ] }, "ifrs-full_SharePremium": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "SharePremium", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Share premium", "terseLabel": "Premiums related to share capital" } }, "en": { "role": { "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r199" ] }, "ifrs-full_ComponentsOfEquityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ComponentsOfEquityAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareCapitalDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Components of equity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r6" ] }, "ifrs-full_NetDefinedBenefitLiabilityAssetAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NetDefinedBenefitLiabilityAssetAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetChangeInNetProvisionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetNetProvisionDetails" ], "lang": { "en-us": { "role": { "label": "Net defined benefit liability (asset) [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r55" ] }, "iva_DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about change in the provision recorded in respect of defined benefit schemes.", "label": "Disclosure Of Changes In Provision Recorded In Respect Of Defined Benefit Schemes, Explanatory", "terseLabel": "Schedule of change in the provision recorded in respect of defined benefit schemes" } } }, "auth_ref": [] }, "ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "AccumulatedDepreciationAmortisationAndImpairmentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetIntangibleAssetsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated depreciation, amortisation and impairment [member]", "terseLabel": "Amortization", "verboseLabel": "Depreciation and impairment" } }, "en": { "role": { "documentation": "This member stands for accumulated depreciation, amortisation and impairment. [Refer: Impairment loss; Depreciation and amortisation expense]" } } }, "auth_ref": [ "r45", "r52", "r77", "r86", "r89" ] }, "ifrs-full_UnderlyingEquityInstrumentAndDepositaryReceiptsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "UnderlyingEquityInstrumentAndDepositaryReceiptsAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "label": "Underlying equity instrument and depositary receipts [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r264" ] }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of intangible assets other than goodwill [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r82" ] }, "ifrs-full_EntitysTotalForAssociatesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "EntitysTotalForAssociatesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "Entity's total for associates [member]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Associates' axis if no other member is used." } } }, "auth_ref": [ "r67", "r69", "r121", "r189", "r191" ] }, "iva_CollaborativeArrangementMilestonePaymentsReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "CollaborativeArrangementMilestonePaymentsReceived", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the cumulative amount of research funding received in a collaborative arrangement.", "label": "Collaborative Arrangement, Milestone Payments Received", "terseLabel": "Milestone payments received" } } }, "auth_ref": [] }, "ifrs-full_LongtermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "LongtermBorrowings", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current portion of non-current borrowings", "terseLabel": "Long-term debt" } }, "en": { "role": { "documentation": "The non-current portion of non-current borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r265" ] }, "ifrs-full_OrdinarySharesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "OrdinarySharesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails", "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Ordinary shares", "terseLabel": "Ordinary shares" } }, "en": { "role": { "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used." } } }, "auth_ref": [ "r70", "r269" ] }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "IncomeTaxExpenseContinuingOperations", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Tax expense (income)", "negatedLabel": "Income tax" } }, "en": { "role": { "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]" } } }, "auth_ref": [ "r37", "r41", "r42", "r43", "r65", "r119", "r171" ] }, "iva_ProvisionForFrenchResearchTaxCreditRelatedToTaxAuditForYearsEnded2017Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ProvisionForFrenchResearchTaxCreditRelatedToTaxAuditForYearsEnded2017Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Provision For French Research Tax Credit Related To Tax Audit For Years Ended 2017", "label": "Provision For French Research Tax Credit Related To Tax Audit For Years Ended 2017 [Member]" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInInventories", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for decrease (increase) in inventories", "terseLabel": "Decrease / (increase) in inventories" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]" } } }, "auth_ref": [ "r287" ] }, "ifrs-full_OtherLongtermProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "OtherLongtermProvisions", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Other non-current provisions", "terseLabel": "Long-term provisions" } }, "en": { "role": { "documentation": "The amount of non-current provisions other than provisions for employee benefits. [Refer: Non-current provisions]" } } }, "auth_ref": [ "r27" ] }, "ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for fair value measurement [text block]", "terseLabel": "Fair value measurement" } }, "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for fair value measurement. [Refer: At fair value [member]]\nEffective 2023-01-01: The description of the entity's material accounting policy information for fair value measurement. [Refer: At fair value [member]]" } } }, "auth_ref": [ "r295", "r296" ] }, "iva_NewBonusShareAwardPlan20182Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NewBonusShareAwardPlan20182Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2018-2).", "label": "AGA 2018-2 [Member]" } } }, "auth_ref": [] }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ReserveOfExchangeDifferencesOnTranslationMember", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Reserve of exchange differences on translation [member]", "terseLabel": "Translation reserves" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r62", "r195" ] }, "ifrs-full_LeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "LeaseLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtDetails": { "parentTag": "ifrs-full_Borrowings", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lease liabilities", "terseLabel": "Lease liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration." } } }, "auth_ref": [ "r133" ] }, "ifrs-full_LiabilityAssetOfDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "LiabilityAssetOfDefinedBenefitPlans", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetNetProvisionDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetChangeInNetProvisionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetNetProvisionDetails" ], "lang": { "en-us": { "role": { "label": "Net defined benefit liability (asset)", "negatedPeriodEndLabel": "At end of period", "negatedPeriodStartLabel": "At beginning of period", "totalLabel": "Total Obligation" } }, "en": { "role": { "documentation": "The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [member]]" } } }, "auth_ref": [ "r55" ] }, "ifrs-full_Revenue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "Revenue", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0, "order": 2.0 }, "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementRevenuesAndOtherIncomeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementRevenuesAndOtherIncomeDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Revenue", "terseLabel": "Revenue", "totalLabel": "Total revenue" } }, "en": { "role": { "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims." } } }, "auth_ref": [ "r35", "r114", "r146", "r169", "r173", "r177", "r178", "r180", "r193", "r194", "r218" ] }, "ifrs-full_StatementOfChangesInEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "StatementOfChangesInEquityAbstract", "lang": { "en-us": { "role": { "label": "Unaudited interim condensed consolidated statement of changes in shareholders' equity" } } }, "auth_ref": [] }, "ifrs-full_Level1OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "Level1OfFairValueHierarchyMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "Level 1" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date." } } }, "auth_ref": [ "r57", "r123" ] }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) investing activities [abstract]", "terseLabel": "Cash flows used in investing activities" } } }, "auth_ref": [] }, "iva_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails" ], "lang": { "en-us": { "role": { "documentation": "Period which the right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "IFRS Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "verboseLabel": "Vesting and holding period (year)" } } }, "auth_ref": [] }, "ifrs-full_DiscountRateMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DiscountRateMeasurementInputMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "label": "Discount rate, measurement input [member]", "terseLabel": "Discount rate" } }, "en": { "role": { "documentation": "This member stands for a discount rate used as a measurement input used in valuation techniques based on a present value calculation." } } }, "auth_ref": [ "r291" ] }, "ifrs-full_BottomOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "BottomOfRangeMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails" ], "lang": { "en-us": { "role": { "label": "Minimum", "terseLabel": "Minimum" } }, "en": { "role": { "documentation": "This member stands for the bottom of a range." } } }, "auth_ref": [ "r127", "r140", "r184", "r219", "r220", "r294" ] }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments of lease liabilities, classified as financing activities", "negatedLabel": "Repayment of lease liabilities" } }, "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r214" ] }, "ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through transfers, property, plant and equipment", "terseLabel": "Reclassifications" } }, "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment resulting from transfers. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r275" ] }, "ifrs-full_BorrowingsByNameMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "BorrowingsByNameMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Borrowings by name [member]" } }, "en": { "role": { "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]" } } }, "auth_ref": [ "r294" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2022", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for employee benefits [text block]", "terseLabel": "Provisions for retirement benefit obligations" } }, "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment.\nEffective 2023-01-01: The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment." } } }, "auth_ref": [ "r295", "r296" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments outstanding in share-based payment arrangement", "periodEndLabel": "Outstanding, Ending balance", "periodStartLabel": "Outstanding, Beginning balance" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r293" ] }, "ifrs-full_PropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "PropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Property, plant and equipments", "periodEndLabel": "Balance at the end", "periodStartLabel": "Balance at the beginning", "terseLabel": "Property, plant and equipment" } }, "en": { "role": { "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period." } } }, "auth_ref": [ "r9", "r49" ] }, "ifrs-full_AggregatedMeasurementMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "AggregatedMeasurementMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "Aggregated measurement [member]" } }, "en": { "role": { "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used." } } }, "auth_ref": [ "r84", "r88", "r122" ] }, "ifrs-full_NoncurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NoncurrentContractLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current contract liabilities", "terseLabel": "Long-term contract liabilities" } }, "en": { "role": { "documentation": "The amount of non-current contract liabilities. [Refer: Contract liabilities]" } } }, "auth_ref": [ "r128" ] }, "iva_NewBonusShareAwardPlan20191Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NewBonusShareAwardPlan20191Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2019-1).", "label": "AGA 2019-1 [Member]" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for foreign currency translation [text block]", "terseLabel": "Foreign currency transactions" } }, "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for foreign currency translation.\nEffective 2023-01-01: The description of the entity's material accounting policy information for foreign currency translation." } } }, "auth_ref": [ "r295", "r296" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_104&doctype=Standard", "URIDate": "2022-03-24" }, "r1": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "106", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_a&doctype=Standard", "URIDate": "2022-03-24" }, "r2": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "106", "Subparagraph": "d", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_i&doctype=Standard", "URIDate": "2022-03-24" }, "r3": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "106", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_ii&doctype=Standard", "URIDate": "2022-03-24" }, "r4": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "106", "Subparagraph": "d", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2022-03-24" }, "r5": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2022-03-24" }, "r6": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106&doctype=Standard", "URIDate": "2022-03-24" }, "r7": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_16&doctype=Standard", "URIDate": "2022-03-24" }, "r8": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_35&doctype=Standard", "URIDate": "2022-03-24" }, "r9": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "54", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_a&doctype=Standard", "URIDate": "2022-03-24" }, "r10": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "54", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_c&doctype=Standard", "URIDate": "2022-03-24" }, "r11": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "54", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_g&doctype=Standard", "URIDate": "2022-03-24" }, "r12": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "54", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_i&doctype=Standard", "URIDate": "2022-03-24" }, "r13": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "54", "Subparagraph": "k", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_k&doctype=Standard", "URIDate": "2022-03-24" }, "r14": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "54", "Subparagraph": "l", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_l&doctype=Standard", "URIDate": "2022-03-24" }, "r15": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "54", "Subparagraph": "m", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_m&doctype=Standard", "URIDate": "2022-03-24" }, "r16": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "54", "Subparagraph": "n", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_n&doctype=Standard", "URIDate": "2022-03-24" }, "r17": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "54", "Subparagraph": "o", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_o&doctype=Standard", "URIDate": "2022-03-24" }, "r18": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "54", "Subparagraph": "q", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_q&doctype=Standard", "URIDate": "2022-03-24" }, "r19": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_55&doctype=Standard", "URIDate": "2022-03-24" }, "r20": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "56", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_56&doctype=Standard", "URIDate": "2022-03-24" }, "r21": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "61", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_61_a&doctype=Standard", "URIDate": "2022-03-24" }, "r22": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "61", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_61_b&doctype=Standard", "URIDate": "2022-03-24" }, "r23": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "61", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_61&doctype=Standard", "URIDate": "2022-03-24" }, "r24": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_66&doctype=Standard", "URIDate": "2022-03-24" }, "r25": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "69", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_69&doctype=Standard", "URIDate": "2022-03-24" }, "r26": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard", "URIDate": "2022-03-24" }, "r27": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "78", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_d&doctype=Standard", "URIDate": "2022-03-24" }, "r28": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2022-03-24" }, "r29": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "79", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2022-03-24" }, "r30": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "79", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a_iv&doctype=Standard", "URIDate": "2022-03-24" }, "r31": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2022-03-24" }, "r32": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "81A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_a&doctype=Standard", "URIDate": "2022-03-24" }, "r33": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "81A", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_b&doctype=Standard", "URIDate": "2022-03-24" }, "r34": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "81A", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_c&doctype=Standard", "URIDate": "2022-03-24" }, "r35": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "82", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_a&doctype=Standard", "URIDate": "2022-03-24" }, "r36": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "82", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_b&doctype=Standard", "URIDate": "2022-03-24" }, "r37": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "82", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_d&doctype=Standard", "URIDate": "2022-03-24" }, "r38": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "91", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_91_a&doctype=Standard", "URIDate": "2022-03-24" }, "r39": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "99", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_99&doctype=Standard", "URIDate": "2022-03-24" }, "r40": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2022-03-24", "Paragraph": "21", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2022-en-r&anchor=para_21&doctype=Standard", "URIDate": "2022-03-24" }, "r41": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2022-03-24", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_79&doctype=Standard", "URIDate": "2022-03-24" }, "r42": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2022-03-24", "Paragraph": "81", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2022-03-24" }, "r43": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2022-03-24", "Paragraph": "81", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2022-03-24" }, "r44": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2022-03-24", "Paragraph": "81", "Subparagraph": "g", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2022-03-24" }, "r45": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2022-03-24", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2022-03-24" }, "r46": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2022-03-24", "Paragraph": "73", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_i&doctype=Standard", "URIDate": "2022-03-24" }, "r47": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2022-03-24", "Paragraph": "73", "Subparagraph": "e", "Clause": "ix", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_ix&doctype=Standard", "URIDate": "2022-03-24" }, "r48": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2022-03-24", "Paragraph": "73", "Subparagraph": "e", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_vii&doctype=Standard", "URIDate": "2022-03-24" }, "r49": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2022-03-24", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2022-03-24" }, "r50": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2022-03-24", "Paragraph": "73", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73&doctype=Standard", "URIDate": "2022-03-24" }, "r51": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2022-03-24", "Paragraph": "75", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_75_a&doctype=Standard", "URIDate": "2022-03-24" }, "r52": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2022-03-24", "Paragraph": "75", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_75_b&doctype=Standard", "URIDate": "2022-03-24" }, "r53": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2022-03-24", "Paragraph": "138", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_138&doctype=Standard", "URIDate": "2022-03-24" }, "r54": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2022-03-24", "Paragraph": "140", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_140_a_ii&doctype=Standard", "URIDate": "2022-03-24" }, "r55": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2022-03-24", "Paragraph": "140", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_140_a&doctype=Standard", "URIDate": "2022-03-24" }, "r56": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2022-03-24", "Paragraph": "141", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_c&doctype=Standard", "URIDate": "2022-03-24" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2022-03-24", "Paragraph": "142", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_142&doctype=Standard", "URIDate": "2022-03-24" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2022-03-24", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_53&doctype=Standard", "URIDate": "2022-03-24" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "2", "IssueDate": "2022-03-24", "Paragraph": "36", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&anchor=para_36_a&doctype=Standard", "URIDate": "2022-03-24" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "2", "IssueDate": "2022-03-24", "Paragraph": "36", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&anchor=para_36_b&doctype=Standard", "URIDate": "2022-03-24" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2022-03-24", "Paragraph": "52", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2022-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2022-03-24" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2022-03-24", "Paragraph": "52", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2022-en-r&anchor=para_52_b&doctype=Standard", "URIDate": "2022-03-24" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2022-03-24", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS21_g51-57__IAS21_g51-57_TI", "URIDate": "2022-03-24" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2022-03-24", "Paragraph": "19", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_19&doctype=Standard", "URIDate": "2022-03-24" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2022-03-24", "Paragraph": "35", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2022-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2022-03-24" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2022-03-24", "Paragraph": "16", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_16_b_iii&doctype=Standard", "URIDate": "2022-03-24" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2022-03-24", "Paragraph": "16", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_16_b&doctype=Standard", "URIDate": "2022-03-24" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2022-03-24", "Paragraph": "17", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_17_b_iii&doctype=Standard", "URIDate": "2022-03-24" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2022-03-24", "Paragraph": "17", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2022-03-24" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2022-03-24", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_66&doctype=Standard", "URIDate": "2022-03-24" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2022-03-24", "Paragraph": "67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_67&doctype=Standard", "URIDate": "2022-03-24" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2022-03-24", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2022-03-24" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2022-03-24", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_126&doctype=Standard", "URIDate": "2022-03-24" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2022-03-24", "Paragraph": "130", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_130_d_ii&doctype=Standard", "URIDate": "2022-03-24" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2022-03-24", "Paragraph": "84", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_84&doctype=Standard", "URIDate": "2022-03-24" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2022-03-24", "Paragraph": "86", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_86&doctype=Standard", "URIDate": "2022-03-24" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2022-03-24", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2022-03-24" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2022-03-24", "Paragraph": "118", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_i&doctype=Standard", "URIDate": "2022-03-24" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2022-03-24", "Paragraph": "118", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_ii&doctype=Standard", "URIDate": "2022-03-24" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2022-03-24", "Paragraph": "118", "Subparagraph": "e", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_vi&doctype=Standard", "URIDate": "2022-03-24" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2022-03-24", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2022-03-24" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2022-03-24", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118&doctype=Standard", "URIDate": "2022-03-24" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2022-03-24", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_126&doctype=Standard", "URIDate": "2022-03-24" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2022-03-24", "Paragraph": "32A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_32A&doctype=Standard", "URIDate": "2022-03-24" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2022-03-24", "Paragraph": "76", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_76&doctype=Standard", "URIDate": "2022-03-24" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2022-03-24", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2022-03-24" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2022-03-24", "Paragraph": "79", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_79_d&doctype=Standard", "URIDate": "2022-03-24" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2022-03-24", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2022-en-r&anchor=para_50&doctype=Standard", "URIDate": "2022-03-24" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2022-03-24", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2022-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2022-03-24" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_10&doctype=Standard", "URIDate": "2022-03-24" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "14", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_14&doctype=Standard", "URIDate": "2022-03-24" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "18", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2022-03-24" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "21", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_21&doctype=Standard", "URIDate": "2022-03-24" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_25&doctype=Standard", "URIDate": "2022-03-24" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_28&doctype=Standard", "URIDate": "2022-03-24" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35&doctype=Standard", "URIDate": "2022-03-24" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard", "URIDate": "2022-03-24" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "46", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_46&doctype=Standard", "URIDate": "2022-03-24" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "50", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2022-03-24" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2022-03-24", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28&doctype=Standard", "URIDate": "2022-03-24" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2022-03-24" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2022-03-24" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "32", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2022-03-24" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "32", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2022-03-24" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "10", "IssueDate": "2022-03-24", "Paragraph": "22", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=10&code=ifrs-tx-2022-en-r&anchor=para_22&doctype=Standard", "URIDate": "2022-03-24" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2022-03-24", "Paragraph": "12", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_12_f&doctype=Standard", "URIDate": "2022-03-24" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2022-03-24", "Paragraph": "19B", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_19B_c&doctype=Standard", "URIDate": "2022-03-24" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2022-03-24", "Paragraph": "2", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_2_b_i&doctype=Standard", "URIDate": "2022-03-24" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2022-03-24", "Paragraph": "B12", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2022-03-24", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2022-03-24", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2022-03-24", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2022-03-24", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ix", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2022-03-24", "Paragraph": "B12", "Subparagraph": "b", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2022-03-24", "Paragraph": "B12", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2022-03-24", "Paragraph": "B13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2022-03-24", "Paragraph": "B13", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_c&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2022-03-24", "Paragraph": "B13", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_f&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2022-03-24", "Paragraph": "B13", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2022-03-24", "Paragraph": "B4", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2022-03-24", "Paragraph": "B4", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B4_d&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2022-03-24", "Paragraph": "93", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2022-03-24" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2022-03-24", "Paragraph": "93", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2022-03-24" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2022-03-24", "Paragraph": "93", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_d&doctype=Standard", "URIDate": "2022-03-24" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2022-03-24", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2022-03-24" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2022-03-24", "Paragraph": "93", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93&doctype=Standard", "URIDate": "2022-03-24" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "14", "IssueDate": "2022-03-24", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2022-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2022-03-24" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2022-03-24", "Paragraph": "105", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_105&doctype=Standard", "URIDate": "2022-03-24" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2022-03-24", "Paragraph": "113", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_113_a&doctype=Standard", "URIDate": "2022-03-24" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2022-03-24", "Paragraph": "114", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_114&doctype=Standard", "URIDate": "2022-03-24" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2022-03-24", "Paragraph": "120", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_120_b_i&doctype=Standard", "URIDate": "2022-03-24" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2022-03-24", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_33&doctype=Standard", "URIDate": "2022-03-24" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2022-03-24", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2022-03-24" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2022-03-24", "Paragraph": "53", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_h&doctype=Standard", "URIDate": "2022-03-24" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2022-03-24", "Paragraph": "53", "Subparagraph": "j", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_j&doctype=Standard", "URIDate": "2022-03-24" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2022-03-24", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53&doctype=Standard", "URIDate": "2022-03-24" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2022-03-24", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_94&doctype=Standard", "URIDate": "2022-03-24" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2022-03-24", "Paragraph": "97", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_97&doctype=Standard", "URIDate": "2022-03-24" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2022-03-24", "Paragraph": "45", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_c&doctype=Standard", "URIDate": "2022-03-24" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2022-03-24", "Paragraph": "45", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2022-03-24" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2022-03-24", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard", "URIDate": "2022-03-24" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2022-03-24", "Paragraph": "47", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_47_a_i&doctype=Standard", "URIDate": "2022-03-24" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2022-03-24", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2022-03-24" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2022-03-24", "Paragraph": "51", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_51_a&doctype=Standard", "URIDate": "2022-03-24" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2022-03-24", "Paragraph": "B67", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2022-03-24", "Paragraph": "33", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2022-03-24" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "23B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_23B_a&doctype=Standard", "URIDate": "2022-03-24" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_25&doctype=Standard", "URIDate": "2022-03-24" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_31&doctype=Standard", "URIDate": "2022-03-24" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "35H", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35H_b_iii&doctype=Standard", "URIDate": "2022-03-24" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2022-03-24" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "35I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35I&doctype=Standard", "URIDate": "2022-03-24" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "35K", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35K&doctype=Standard", "URIDate": "2022-03-24" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "35M", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35M_b_iii&doctype=Standard", "URIDate": "2022-03-24" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "35M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2022-03-24" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "36", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_36&doctype=Standard", "URIDate": "2022-03-24" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "39", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_39_a&doctype=Standard", "URIDate": "2022-03-24" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "42E", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_42E_e&doctype=Standard", "URIDate": "2022-03-24" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "42I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_42I&doctype=Standard", "URIDate": "2022-03-24" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_6&doctype=Standard", "URIDate": "2022-03-24" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard", "URIDate": "2022-03-24" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "8", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8_a&doctype=Standard", "URIDate": "2022-03-24" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "8", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8_e&doctype=Standard", "URIDate": "2022-03-24" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "8", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8_f&doctype=Standard", "URIDate": "2022-03-24" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "8", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8_g&doctype=Standard", "URIDate": "2022-03-24" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "8", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8&doctype=Standard", "URIDate": "2022-03-24" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "B2", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B2_a&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "B52", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B52&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2022-03-24", "Paragraph": "23", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_a&doctype=Standard", "URIDate": "2022-03-24" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2022-03-24", "Paragraph": "23", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_d&doctype=Standard", "URIDate": "2022-03-24" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2022-03-24", "Paragraph": "23", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2022-03-24" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2022-03-24", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23&doctype=Standard", "URIDate": "2022-03-24" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2022-03-24", "Paragraph": "28", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_a&doctype=Standard", "URIDate": "2022-03-24" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2022-03-24", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2022-03-24" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2022-03-24", "Paragraph": "28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2022-03-24" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2022-03-24", "Paragraph": "28", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_e&doctype=Standard", "URIDate": "2022-03-24" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2022-03-24", "Paragraph": "32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_32&doctype=Standard", "URIDate": "2022-03-24" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2022-03-24", "Paragraph": "33", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_33_a&doctype=Standard", "URIDate": "2022-03-24" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2022-03-24", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_33&doctype=Standard", "URIDate": "2022-03-24" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2022-03-24", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_34&doctype=Standard", "URIDate": "2022-03-24" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2022-03-24", "Paragraph": "7.2.34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2022-en-r&anchor=para_7.2.34&doctype=Standard", "URIDate": "2022-03-24" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2023-01-01", "Name": "IFRS", "Number": "17", "IssueDate": "2022-03-24", "Paragraph": "109", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_109&doctype=Standard", "URIDate": "2022-03-24" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2023-01-01", "Name": "IFRS", "Number": "17", "IssueDate": "2022-03-24", "Paragraph": "109A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_109A&doctype=Standard", "URIDate": "2022-03-24" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2023-01-01", "Name": "IFRS", "Number": "17", "IssueDate": "2022-03-24", "Paragraph": "120", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_120&doctype=Standard", "URIDate": "2022-03-24" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2023-01-01", "Name": "IFRS", "Number": "17", "IssueDate": "2022-03-24", "Paragraph": "132", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_132_b&doctype=Standard", "URIDate": "2022-03-24" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2023-01-01", "Name": "IFRS", "Number": "17", "IssueDate": "2022-03-24", "Paragraph": "C32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_C32&doctype=Appendix&subtype=C", "URIDate": "2022-03-24" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2023-01-01", "Name": "IFRS", "Number": "9", "IssueDate": "2022-03-24", "Paragraph": "7.2.42", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2022-en-r&anchor=para_7.2.42&doctype=Standard", "URIDate": "2022-03-24" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective on first application of IFRS 9", "Name": "IFRS", "Number": "4", "IssueDate": "2022-03-24", "Paragraph": "39L", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39L_b&doctype=Standard", "URIDate": "2022-03-24" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective on first application of IFRS 9", "Name": "IFRS", "Number": "4", "IssueDate": "2022-03-24", "Paragraph": "39M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39M&doctype=Standard", "URIDate": "2022-03-24" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2023-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_117&doctype=Standard", "URIDate": "2022-03-24" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2023-01-01", "Name": "IFRS", "Number": "4", "IssueDate": "2022-03-24", "Paragraph": "39J", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39J&doctype=Standard&book=b", "URIDate": "2022-03-24" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2023-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "8", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_8_f&doctype=Standard&book=b", "URIDate": "2022-03-24" }, "r193": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_102&doctype=Standard", "URIDate": "2022-03-24" }, "r194": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_103&doctype=Standard", "URIDate": "2022-03-24" }, "r195": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_108&doctype=Standard", "URIDate": "2022-03-24" }, "r196": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "68", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_68&doctype=Standard", "URIDate": "2022-03-24" }, "r197": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_70&doctype=Standard", "URIDate": "2022-03-24" }, "r198": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2022-03-24" }, "r199": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2022-03-24" }, "r200": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "82A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82A&doctype=Standard", "URIDate": "2022-03-24" }, "r201": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "IG6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2022-03-24" }, "r202": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "16", "IssueDate": "2022-03-24", "Paragraph": "37", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_37_a&doctype=Standard", "URIDate": "2022-03-24" }, "r203": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2022-03-24", "Paragraph": "147", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2022-03-24" }, "r204": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "32", "IssueDate": "2022-03-24", "Paragraph": "IE33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2022-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2022-03-24" }, "r205": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "36", "IssueDate": "2022-03-24", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_127&doctype=Standard", "URIDate": "2022-03-24" }, "r206": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "37", "IssueDate": "2022-03-24", "Paragraph": "87", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_87&doctype=Standard", "URIDate": "2022-03-24" }, "r207": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "37", "IssueDate": "2022-03-24", "Paragraph": "88", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_88&doctype=Standard", "URIDate": "2022-03-24" }, "r208": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "37", "IssueDate": "2022-03-24", "Section": "Example 10 A court case", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&doctype=Illustrative%20Examples&dita_xref=IAS37_IE_C_ex10__IAS37_IE_C_ex10_TI", "URIDate": "2022-03-24" }, "r209": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "38", "IssueDate": "2022-03-24", "Paragraph": "119", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_119_c&doctype=Standard", "URIDate": "2022-03-24" }, "r210": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "14", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_14_f&doctype=Standard", "URIDate": "2022-03-24" }, "r211": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2022-03-24" }, "r212": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "17", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_c&doctype=Standard", "URIDate": "2022-03-24" }, "r213": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "17", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_d&doctype=Standard", "URIDate": "2022-03-24" }, "r214": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2022-03-24" }, "r215": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "44C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_44C&doctype=Standard", "URIDate": "2022-03-24" }, "r216": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2022-03-24", "Section": "A Statement of cash flows for an entity other than a financial institution", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A__IAS07_IE_A_TI", "URIDate": "2022-03-24" }, "r217": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2022-03-24", "Section": "C Reconciliation of liabilities arising from financing activities", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C__IAS07_IE_C_TI", "URIDate": "2022-03-24" }, "r218": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "12", "IssueDate": "2022-03-24", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r219": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2022-03-24", "Paragraph": "B6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r220": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2022-03-24", "Paragraph": "IE63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2022-03-24" }, "r221": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2022-03-24", "Paragraph": "B89", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_B89_a&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r222": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2022-03-24", "Paragraph": "B89", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_B89_e&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r223": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "16", "IssueDate": "2022-03-24", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53&doctype=Standard", "URIDate": "2022-03-24" }, "r224": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "2", "IssueDate": "2022-03-24", "Paragraph": "45", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_a&doctype=Standard", "URIDate": "2022-03-24" }, "r225": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "2", "IssueDate": "2022-03-24", "Paragraph": "IG23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_IG23&doctype=Implementation%20Guidance", "URIDate": "2022-03-24" }, "r226": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "35N", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35N&doctype=Standard", "URIDate": "2022-03-24" }, "r227": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "B11", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B11_a&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r228": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "B11", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B11&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r229": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "B35", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35_a&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r230": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "B35", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35_c&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r231": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "B35", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35_d&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r232": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "B35", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35_e&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r233": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "B35", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35_f&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r234": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "B35", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r235": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "B35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r236": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "IG20D", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_IG20D&doctype=Implementation%20Guidance", "URIDate": "2022-03-24" }, "r237": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "IG31A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance", "URIDate": "2022-03-24" }, "r238": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2023-01-01", "Name": "IFRS", "Number": "17", "IssueDate": "2022-03-24", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2022-03-24" }, "r239": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective on first application of IFRS 9", "Name": "IFRS", "Number": "4", "IssueDate": "2022-03-24", "Paragraph": "39L", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39L_e&doctype=Standard", "URIDate": "2022-03-24" }, "r240": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2023-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "37", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_a&doctype=Standard&book=b", "URIDate": "2022-03-24" }, "r241": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2023-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "37", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_b&doctype=Standard&book=b", "URIDate": "2022-03-24" }, "r242": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2023-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "IG28", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG28_a&doctype=Implementation%20Guidance&book=b", "URIDate": "2022-03-24" }, "r243": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2023-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "IG28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG28_b&doctype=Implementation%20Guidance&book=b", "URIDate": "2022-03-24" }, "r244": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2023-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "IG28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG28_c&doctype=Implementation%20Guidance&book=b", "URIDate": "2022-03-24" }, "r245": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2023-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "IG28", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG28_d&doctype=Implementation%20Guidance&book=b", "URIDate": "2022-03-24" }, "r246": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2023-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "IG29", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29_a&doctype=Implementation%20Guidance&book=b", "URIDate": "2022-03-24" }, "r247": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2023-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "IG29", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29_b&doctype=Implementation%20Guidance&book=b", "URIDate": "2022-03-24" }, "r248": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r249": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r250": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r251": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r253": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r254": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r255": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r257": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r258": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r259": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_10_e&doctype=Standard", "URIDate": "2022-03-24" }, "r260": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_104&doctype=Standard", "URIDate": "2022-03-24" }, "r261": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2022-03-24" }, "r262": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106&doctype=Standard", "URIDate": "2022-03-24" }, "r263": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_108&doctype=Standard", "URIDate": "2022-03-24" }, "r264": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_112_c&doctype=Standard", "URIDate": "2022-03-24" }, "r265": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_55&doctype=Standard", "URIDate": "2022-03-24" }, "r266": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2022-03-24" }, "r267": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2022-03-24" }, "r268": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "78", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78&doctype=Standard", "URIDate": "2022-03-24" }, "r269": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2022-03-24" }, "r270": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "85", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_85&doctype=Standard", "URIDate": "2022-03-24" }, "r271": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "12", "IssueDate": "2022-03-24", "Paragraph": "80", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_80&doctype=Standard", "URIDate": "2022-03-24" }, "r272": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "12", "IssueDate": "2022-03-24", "Paragraph": "81", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2022-03-24" }, "r273": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2022-03-24", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_37&doctype=Standard", "URIDate": "2022-03-24" }, "r274": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2022-03-24", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2022-03-24" }, "r275": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2022-03-24", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2022-03-24" }, "r276": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2022-03-24", "Paragraph": "135", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_135_b&doctype=Standard", "URIDate": "2022-03-24" }, "r277": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2022-03-24", "Paragraph": "141", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141&doctype=Standard", "URIDate": "2022-03-24" }, "r278": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2022-03-24", "Paragraph": "5", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_5&doctype=Standard", "URIDate": "2022-03-24" }, "r279": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2022-03-24", "Paragraph": "57", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_57_a&doctype=Standard", "URIDate": "2022-03-24" }, "r280": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2022-03-24", "Paragraph": "9", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_9&doctype=Standard", "URIDate": "2022-03-24" }, "r281": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "37", "IssueDate": "2022-03-24", "Paragraph": "84", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_84&doctype=Standard", "URIDate": "2022-03-24" }, "r282": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2022-03-24", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2022-03-24" }, "r283": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "40", "IssueDate": "2022-03-24", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2022-03-24" }, "r284": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "41", "IssueDate": "2022-03-24", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2022-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2022-03-24" }, "r285": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_16&doctype=Standard", "URIDate": "2022-03-24" }, "r286": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17&doctype=Standard", "URIDate": "2022-03-24" }, "r287": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "20", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_a&doctype=Standard", "URIDate": "2022-03-24" }, "r288": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2022-03-24" }, "r289": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20&doctype=Standard", "URIDate": "2022-03-24" }, "r290": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard", "URIDate": "2022-03-24" }, "r291": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "13", "IssueDate": "2022-03-24", "Paragraph": "93", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_d&doctype=Standard", "URIDate": "2022-03-24" }, "r292": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "13", "IssueDate": "2022-03-24", "Paragraph": "93", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_h&doctype=Standard", "URIDate": "2022-03-24" }, "r293": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "2", "IssueDate": "2022-03-24", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard", "URIDate": "2022-03-24" }, "r294": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard", "URIDate": "2022-03-24" }, "r295": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Effective 2023-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_117&doctype=Standard", "URIDate": "2022-03-24" }, "r296": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2023-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "117", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-b&anchor=para_117_b&doctype=Standard&forcepdf=true", "URIDate": "2022-03-24" }, "r297": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2023-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "37", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_b&doctype=Standard&book=b", "URIDate": "2022-03-24" }, "r298": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2023-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37&doctype=Standard&book=b", "URIDate": "2022-03-24" }, "r299": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2023-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "IG29", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29&doctype=Implementation%20Guidance&book=b", "URIDate": "2022-03-24" } } }